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Resumen 
El objeto de estudio de esta Tesis son dos enfermedades quísticas renales hereditarias: 
Poliquistosis Renal Autosómica Dominante, siglas en inglés ADPKD (Autosomal Dominant Polycystic 
Kidney Disease); y Poliquistosis Renal Autosómica Recesiva, corresponde al acrónimo inglés ARPKD 
(Autosomal Recessive Polycystic Kidney Disease). En ambas se ha establecido la existencia de un 
componente genético, sin embargo, el estudio molecular se encuentra en diferentes fases en cada una 
de ellas. Mientras en ADPKD se conocen los genes implicados, su ubicación y anatomía molecular, 
ARPKD todavía se encuentra en la primera fase de estudio ya que sólo recientemente se ha localizado 
el gen responsable de la enfermedad. En esta tesis se ha establecido una estrategia racional de 
búsqueda de mutaciones en los genes responsables de la Poliquistosis Renal y su aplicación en el 
desarrollo de un test clínico/genético de la enfermedad. En colaboración con Athena Diagnostics, Inc.; 
dicha estrategia ha sido testada en 82 familias con Poliquistosis Renal con un excelente porcentaje de 
detección  del 83%. Meticulosamente, se ha examinado la predicción patogénica de las sustituciones 
aminoacídicas y alteraciones en el lugar de expansión (splice site) para cada probando. Una fracción 
sustancial de variantes encontradas en el gen PKD1 también se ha encontrado en sus genes homólogos, 
posiblemente debido a una conversión génica entre ellos. Evidencias experimentales de esta tesis dan 
soporte a la idea de que PKD1 es un gen altamente mutable. Se ha observado la existencia de 
individuos con una gran cantidad de sustituciones aminoacídicas, mientras que otros sólo poseen una 
pequeña cantidad, sugiriendo que ciertos haplotipos podrían ser más mutables que otros. También, 
dichos resultados remarcan la precaución que se debe tomar, desde un punto de vista clínico, a la hora 
de distinguir entre una variante con sentido perdido (missense) pero dentro de la normalidad y aquellas 
que son probables de causar la enfermedad. Se ha identificado un número de individuos con múltiples 
cambios pero sin que ninguno de ellos pueda ser clasificado como definitivamente patogénico 
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(definidos como codones de parada prematura, deleciones, inserciones,...). Se presenta la hipótesis de 
que en algunos casos, a pesar de no tener una única mutación patogénica, el efecto combinado de 
varias substituciones con sentido alterado no-patogénicas pueden producir un alelo hipomórfico. Por 
ejemplo, varias variaciones con sentido alterado o cambios “silenciosos” pueden resultar en una 
función reducida e inadecuada debido a la alteración de la eficiencia translacional, ya sea por su efecto 
aditivo en el mismo alelo o en combinación con una mutación en el otro alelo. Nuestros 
descubrimientos tienen distintas implicaciones: 1) Las muestras utilizadas como controles deben de ser 
étnicamente iguales para evaluar las variantes raras, 2) El análisis del DNA no es suficiente para 
aportar un diagnóstico definitivo en aquellas variantes con sentido alterado  “particulares”, 3) Se 
necesitan mejores herramientas para evaluar las consecuencias de dichos cambios. 
Así pues, este manuscrito propone que los sistemas in vitro pueden ser utilizados para 
determinar la función de la Poliquistina y además analizar si está alterada por la presencia de las 
variantes asociadas a la enfermedad. Esta parte de la Tesis no había sido contemplada inicialmente en 
los objetivos, pero debido al significado incierto de un número elevado número de variantes con 
sentido alterado, se ha planteado la necesidad de buscar un sistema que determinara la patogenicidad 
de dichas variantes. Se partía de la hipótesis que algunos de los cambios con sentido alterado  serían 
patogénicos (habían sido encontrados apareciendo de novo). En algunos casos, se encontró evidencia 
directa que muestra su patogenicidad, sin embargo en otros resultó indeterminada la manera en que la 
función de la proteína podría estar alterada. En éstos, se barajó la posibilidad de utilizar sistemas in 
vitro para evaluar mutaciones putativas y polimorfismos. Estos resultados tienen varias implicaciones 
importantes: 1) Se ha demostrado que los sistemas in vitro pueden ser utilizados para distinguir entre 
polimorfismos y mutaciones, 2) Estos sistemas pueden ser utilizados para determinar los efectos de las 
variaciones de la secuencia en los genes candidatos. 
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Los datos proporcionados por la secuenciación directa de la totalidad de la región codificadora 
de PKD1 y PKD2 son una valiosa herramienta para el análisis y un mejor conocimiento de la 
enfermedad. Se han testado las distintas hipótesis propuestas por la comunidad científica como 
causantes de la alta mutabilidad de PKD1. Así pues, se ha concluido que las causas principales de la 
alta mutabilidad del gen PKD1 se deben al efecto de la conversión génica con sus genes homólogos, a 
su alto % en GC y a la presencia de un tracto de polipirimidina en el intrón 21. Por el contrario, no se 
ha encontrado evidencias que soporten la hipótesis propuesta por el grupo del Dr. Harris, implicando a 
los dinucleótidos CpG como responsables directos de la alta mutabilidad en PKD1.  
Puesto que todavía se conoce relativamente poco sobre las vías de señalización en PKD, se ha 
invertido mucho esfuerzo en el desarrollo modelos de ratón ADPKD que puedan ser utilizados en el 
estudio de la biología de las Poliquistinas.  Hasta el momento, un número de laboratorios (hasta 10 
líneas mutantes diferentes publicadas) han generado ratones portando alelos mutados tanto para Pkd1 
(Pkd1-/-) como para Pkd2 (Pkd2-/-). Puesto que los quistes se desarrollan a través del mecanismo “two 
hit”, no fue una sorpresa que los heterocigotos sean uniformemente viables y con escasas 
manifestaciones renales y hepáticas. Por el contrario, el estado homocigoto resulta en una elevada 
mortandad embrionaria mediano/tardía, dependiendo del modelo. Esta temprana mortandad en estado 
homocigoto limita los tipos de preguntas que pueden ser contestadas con estos modelos de ratón. Wu y 
col. han generado un alelo instable de Pkd2 con una duplicación que genera mutaciones somáticas al 
azar. Este es el único modelo que se acerca al comportamiento de la enfermedad en humanos, pero  sin 
embargo, no permite una perdida génica regulada. El Dr. Piontek, ha generado un alelo floxeado 
(flanqueado por dos secuencias lox-p) que puede ser utilizado controlando el momento y el lugar de la 
mutación en Pkd1. Dicho modelo no existe para Pkd2. Dado que el comportamiento en PKD1 y PKD2 
podría diferir, creemos que ambos modelos son necesarios para el mejor conocimiento de la biología 
de las Poliquistinas y de la enfermedad. En esta Tesis se presenta el primer alelo floxeado de Pkd2 
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(Pkd2cond) con el fin de estudiar las consecuencias de la perdida de la Poliquistina-2 en un determinado 
tejido y en un momento puntual, y cuyo objetivo es la caracterización de dicho modelo. En el 
momento de la muerte, los ratones homocigotos presentan Poliquistosis renal y pancreática, edema 
severo, anormalidades cardiacas, hemorragias espontáneas y polihidramnios. De modo interesante, el 
modelo knock-out de ratón Pkd2 presenta similitudes al de Pkd1 pero no son totalmente iguales.  Los 
ratones Pkd2-/- presentan anormalidades en la determinación axial derecha/izquierda (isomerismo 
pulmonar derecho, cambio embrionario, colocación del corazón y localización abdominal al azar). 
Esto sugiere que la función de PKD1 y PKD2 podrían no superponerse en todos los tipos celulares.  
Con el mismo fin y puesto que hasta el momento no ha sido descrito ningún modelo de ratón 
que represente en su totalidad la ARPKD, también se ha desarrollado un modelo floxeado de Pkhd1. 
Varios grupos han intentado modelar la enfermedad en ratones alterando el Pkhd1 murino, pero 
ninguno ha conseguido representar todas las manifestaciones clínicas. Así pues, se presenta un alelo 
funcional de Pkhd1 (Pkhd1flox3-4) el cual, después de una recombinación mediada por Cre, genera un 
alelo mutante putativo (Pkhd1del3-4) con los exones 3 y 4 eliminados. Al igual que en humanos, una 
fracción sustancial de Pkhd1del3-4/del3-4 murieron en fase perinatal, y los sobrevivientes, todos ellos 
presentaban una variedad de anormalidades hepatobiliares que incluía la fibrosis hepática congénita, 
quistes coledocales y colangitis ascendente. Representando el fenotipo humano, muchos de ellos 
mostraron un crecimiento retardado, enfermedad quística pancreática severa y diferentes grados de 
afectación renal.  
Así pues, en esta Tesis ha sido desarrollada una estrategia para la búsqueda de mutaciones en 
los genes causantes de ADPKD, y testado la eficacia de la misma en un grupo de 82 pacientes. Con un 
85% de detección de las mutaciones causantes de la enfermedad, es la estrategia más eficaz descrita 
hasta el momento, la cual esta siendo aplicada por Athena Diagnostics como único test de aplicación 
en la clínica para la Poliquistosis Renal Autosómica Dominante (PKDx). La información 
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proporcionada por este trabajo ha sido utilizada para el desarrollo de un método novedoso en el 
análisis del comportamiento génico de PKD1. También han sido generados satisfactoriamente los dos 
primeros modelos condicionales de ratón de los genes causantes de ADPKD y ARPKD. El 
entendimiento de los genes y el estudio en los modelos animales experimentales, proporcionará una 
base sólida para un mejor conocimiento de la biología de las enfermedades y su aplicación para la 
búsqueda de posibles terapias. 
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1. Introduction. 
1.1. Autosomal Polycystic Kidney Disease (ADPKD). 
1.1.1. Clinical Manifestations of ADPKD. 
Autosomal dominant polycystic kidney disease (ADPKD) is one of the most common inherited 
disorders in humans (Gabow, 1985), affecting ~1/600-1/1000 individuals, and which the main clinical 
manifestation is the formation of bilateral fluid-filled renal cysts, leading to gross enlargement of the 
kidneys (Figure 1).Cysts are thought to form in utero and 
increase in size and number throughout life. This 
typically results in end-stage renal failure (ESRD) in 50% 
of patients by the age of 60, where men manifest ERSD 
in average 6 years earlier than women. Around 90% of 
the patients that live into their 70´s develop the disease. 
Kidney transplantation is required in 30-35% of ADPKD 
patients by the age of 52, increasing to 60-85% by the age 
of 70 (Germino et al., 2001).  
Until now, genetic testing has not been used as a diagnostic method. Three major reasons explain 
this: a) the main gene responsible for ADPKD (PKD1) is very large; b) mutations have been found 
throughout its entirety; and c) at least 5 confounding pseudo-genes have been described proximally on 
the same chromosome. Instead, the major mode 
of clinical diagnosis is via ultrasound, 
considering ADPKD when multiple bilateral 
renal are present in the kidney. Also, as shown 
in table 1, the number of cyst required for a 
Figure 1. End-stage ADPKD kidney shown 
on left, same scale normal kidney on right. 
Picture taken form www.nhpress.com
Table 1. Number of cysts required for the diagnosis of 
ADPKD, dependent on age. Reproduced from Germino and 
Chapman, 2001. 
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correct ADPKD diagnosis is age-dependent. Those individuals with mutations in the PKD1 gene and 
less that 30 years old that do not present any detectable cyst in their kidneys, were found to have less 
than 5% chance of developing ADPKD (Germino, 2001). 
 
 
ADPKD is not solely a disease of the kidneys, however, it is a systemic disorder. Patients often 
develop extrarenal manifestations like polycystic liver and pancreas, intracranial aneurysms, hernias 
and valve abnormalities, many of which have been responsible for a significant fraction of morbidity. 
The high frequency of these clinical manifestations has confused ADPKD with other diseases over the 
time. Gabow et al (1990) have shown that, liver (Figure 2A) and pancreatic cysts are two extrarenal 
cystic manifestations found in ~10% ADPKD patients. Other than cystic phenotypes, ADPKD patients 
have also been associated to a number of vascular and cardiac abnormalities, including intracranial 
aneurysms (~5%), aortic insufficiency (~12%) and mitral valve prolapse (~26%). Intracranial 
aneurysms (Figure 2B) have also been leading to subarachnoid hemorrhage and are becoming an 
important factor in morbidity and mortality of ADPKD patients. Even these are not the most common 
cause of cerebrovascular death in ADPKD patients. One of the early manifestations of the disease is 
hypertension (10-15% of affected children), which becomes more common in adult ADPKD patients 
close to the age of 30 with normal renal function (Pirson et al.., 1998).  
Figure 2. ADPKD phenotypes. ADPKD patient which MRI (A) shows polycystic kidneys 
(PK) and polycystic liver (PL), and which angiography (B) shows an intracranial 
aneurysm (IA). Pictures donated by Dr. Watnick. 
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Also, it has been shown that ADPKD patients from the same family manifest a great variation 
in the severity and progression of the disease. This interfamilial variability could be due to the 
different manifestations of PKD1 and PKD2, the mutational spread across these genes, the influence of 
modifier genes and the second-hit nature of ADPKD. PKD2 presents a milder form of the disease than 
PKD1, but in general terms, mutations of PKD1 and PKD2 show similar clinical phenotypes. Also, 
alterations in certain regions could result in variation of the protein function, driving to different levels 
of severity (Torra et al., 1997). The role of genes acting as modifiers, like eNOS and CFTR, has been 
studied which, (Persu et al., 2002, Osullivan et al., 1998) depending of their splice pattern, act in a 
beneficial or unhelpful manner in disease progression. The third 
possibility of a potential influence on intrafamilial variability is the 
recessive nature of ADPKD at the cellular level. This phenomenon 
is called second-hit, because even having an autosomal dominant 
transmission, the cyst formation requires a second somatic 
mutation at the cellular level and a monoclonal growth for its 
expansion (Figure 3). Qian et al (1999) review that only 2% of the 
nephrons acquire a second somatic mutation to form a cyst and 
suggested that the number of second-hits could be affected either by environmental or genetic factors, 
giving the phenotypic variability within a family with the same genomic mutation. 
Up to this moment, there is no effective therapy for ADPKD other than treatment for 
hypertension, tract infections, dialysis or kidney transplantation. Several treatment theories have been 
tested in mouse and rat cystic models for PKD with a different outcome. Restrictive protein diets and 
vasopressin V2 receptor antagonists have been shown to be beneficial for the disease progression in 
these models (Gattone et al., 2003, Torres et al., 2004), but there is still not a truly effective therapy 
that could be applied in humans. Antimutagens or antioxidants (for reducing the number of second-
Figure 3. Knudson’s “two-hit” 
model is the likely explanation for 
the focal cyst formation seen in 
ADPKD. Reproduced from Qian and 
Watnick, 1999. 
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hits), cAMP (which promotes cell proliferation and secretion into the cyst) antagonists and retinoids 
and vitamin D (modulators of proliferation, apoptosis and cell growth) are other modulators 
hypothesized to be possibly effective targets for therapies. 
1.1.2. ADPKD Genes: PKD1 and PKD2. 
As previously mentioned, PKD1 and PKD2 are the genes link to ADPKD. PKD1 is a 53 kb 
gene mapped into the chromosome 16p13.3 (Reeders et al., 1985) which consists of 46 exons yielding 
a predicted transcript of 14 kb in length with a 228 nucleotides 5´ untranslated region (UTR) and a 
1019 nucleotides in the 3´UTR (European Polycystic Kidney Disease Consortium, 1994; Burn et al., 
1995; International Polycystic Kidney Disease Consortium, 1995; Hughes et al., 1995) Its genomic 
structure has a number of features that complicate its evaluation and likely contribute to its frequent 
mutation rate (Burn et al., 1995) such as: 
• It is highly GC-rich with a large number of CpG dinucleotides –known hot spots for C-
T transitions. 
• ~70% of the gene’s length is replicated multiple times elsewhere on chromosome 16 
with high sequence fidelity (95% identity) (European Polycystic Kidney Disease 
Consortium, 1994; Burn et al., 1995; Bogdanova et al., 2001; Watnick et al., 1998).  
Figure 4. Genomic structure of PKD1. PKD1 extends approximately 50 kb and contains 46 exons. It is 
bisected by two large polypyrimidine tracts, of approximately 2.5 and 0.5 kb, in introns 21 and 22, respectively 
(...CCTCCTCCT...). The replicated portion of the gene begins before the 5' untranslated region and is thought to 
end in exon 34 (stippled rectangle). LRR, leucine-rich repeats; LDL-A, low-density lipoprotein type A; REJ, 
receptor for egg jelly motif; TM, transmembrane domain. J Am Soc Nephrol. 2001 May;12(5):955-63. 
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• PKD1 contains a 2.5 kb polypyrimidine tract (largest in the human genome) in intron 
21, possibly able to form a triple-helical structure which may play a role in the 
mutability of neighboring areas (Figure 4, Patel et al., 2004). 
These structures may regulate DNA replication, RNA transcription and processing, induce 
mutations in neighboring sequences and enhance recombination between homologous sequences 
(Wang et al., 1996; Faruqi et al., 2000).  
The search for mutations in PKD1 has been difficult; they have been found spread across the 
gene, there is no a major recurrence of a particular mutation in the ADPKD population and PKD1 is a 
big gene with 5 pseudogenes. These pseudogenes make very difficult to differentiate between the 
sequence of PKD1 and its homologues (European Polycystic Disease Consortium, 1994). In 1997, 
Watnick et al. published a strategy avoiding this problem, using a long-range PCR based on specific 
primers for PKD1, diluting it 1x104 and performing nested PCRs to analyze the exonic sequences. This 
new technique has allowed for additional advances in mutational screening; however it has still not 
become practical for diagnostic purposes.  
Mutations in PKD1 account for approximately 85% of ADPKD cases, and the remaining have 
been found in PKD2. In 1996, Mochizuki et al. mapped PKD2 in chromosome 4q21-23 showing that 
three non-related families contained nonsense mutations in a gene with homology to PKD1 (~25% 
identity and ~50% similarity). The genomic DNA of PKD2 spans over 68 kb and contains 15 exons 
and mRNA is 5.4 kb with an open reading frame of 968 amino acids predicted to have a molecular 
weight of 110 kDa (Figure 5). 
A small number of families have another form that has not yet been mapped (Daoust et al., 1995; 
Bogdanove et al., 1995; de Almeida et al., 1995; Ariza et al., 1997., McConnell et al., 2001). These 
unlinked families may be the result of methodological errors or complicated bilineal inherence 
(Paterson et al., 1998A; Paterson et al., 1998B; Pei et al., 2001).  
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1.1.3. PKD1 and PKD2 protein products: Polycystin-1 and Polycystin-2. 
The protein product of PKD1, polycystin-1 (PC1), is 4302 amino acids in length with a predicted 
molecular weight of 462 kDa (International Polycystic Kidney Disease Consortium, 1995). Hughes et 
al. (1995) predicted polycystin-1 to be an 11-transmembrane protein with a large extracellular domain 
of approximately 2550 amino acids, and a short intracellular C-terminal domain of approximately 225 
amino acids (Figure 6). In the large N-terminal extracellular domain there are multiple motifs that 
could suggest a role for polycystin-1 in cell-cell and cell-matrix interactions:  
• two leucine-rich repeats (LRR), probably associated in protein-protein interactions, flanked 
by cysteine-rich repeats (exons 2 and 3), 
• a C-type lectin domain, which is thought to be involved in the extracellular binding of 
carbohydrates, and possibly play a role in cell adhesion,  
• a LDL-A domain usually found in tandem arrays on lipoprotein receptors, and are 
possibly involved in ligand-binding (exon 10), 
• 16 PKD domains, similar to the Immunoglobulin domains, a ligand-binding sites in cell-
surface proteins (one copy is in exon 5 and the others are in tandem from exons 11 to 15),  
• a receptor for egg jelly (REJ) domain initially described in sea urchin, with unknown function 
(Moy et al., 1996), 
• a G protein-coupled receptor proteolytic site (GPS), previously described as a cleavage site in 
the neuronal G protein-coupled receptor latrophilin, has been confirm to be present in PD1 
Figure 5. Genomic structure of PKD2. PKD2 extends over 68Kb and contains 15 exons. Exon1 is 
highly rich in GC% 
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(Qian et al., 2002). Cleavage of PD1 has recently been shown to be essential for proper 
biological function, with cleavage-deficient knock-in mice developing massively cystic 
kidneys (FASEB meeting, 2005). 
In addition to the N-terminal extracellular motifs, there are two notable intracellular motifs: 
• the lipoxygenase homology 2 (LH2) domain (a noncatalytic domain thought to facilitate 
binding), 
• an intracellular α-helical coiled-coil domain known to form multimeric complexes with 
proteins with and without similar coiled-coil domains.  
 
Mochizuki et al. also predicted that the protein product of PKD2, polycystin-2 (PC2), has (Figure 
6): 
• 6 transmembrane domains with the C- and N-terminus in the cytoplasm: 
• a large extracellular loop between the 
1st and 2nd transmembrane domains 
• and in its c-terminus, a α-helical 
coiled-coil domain necessary for 
PC1/PC2 and PC2/PC2 interaction and 
a Ca2+-binding EF-hand motif 
associated to Ca2+-binding activity.  
Polycystin-2 has been shown to function 
as a non-specific cation channel with highest 
permeability for calcium and identified as the 
founding member of the TrpP (transient 
Figure 6. PKD1 and PKD2 protein products: Polycystin-
1 and Polycystin-2. 
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receptor potential) channel family.  
1.1.4. Polycystin-1 and –2 localization and expression. 
Polycystin-1 and polycystin-2 are integral membrane proteins, but their subcellular localization 
is still controversial, because they can change their localization dependent of the cell culture model 
that has been used: 
• Using a 3-D model of MDCK cells, Scheffers et al. (2000) found that PC1 was present in the 
cytoplasm, co-localized in desmosomes in cells and localizes in the membrane only after 
incorporation of desmoplakin into these desmosomes. On the other hand, Bukanov et al. 
(2002) showed that PC1 localizes to the basolateral membrane when the MDCK cells form 
tubules and in cytoplasm when cysts were formed. 
• Several studies suggest that the use of overexpression models may lead to different 
localization patterns than would be seen in the endogenous state. For example, Scheffers et 
al. found expression of endogenous PC2 in the Golgi apparatus and plasma membrane of 
MDCK cells, but focally in the ER (Endoplasmic Reticulum) when PC2 was over-expressed 
(Scheffers et al., 2002). These overexpressed results also were found by Koulen et al. (2002). 
• It has also been suggested that, the subcellular localization of these proteins can change in 
response to the presence or absence of the other protein. Grimm et al. showed that PC1, in the 
presence of polycystin-2, both localize to the ER, and in the absence of PC2, to the plasma 
membrane and ER (Grimm et al., 2003). In contrast, mouse and human kidney cells 
expressing a transgenic human PKD1 showed that only a small percentage of PC2 
colocalized in the plasma membrane with PC-1 (Newby et al., 2002).  
• Recently, the community has been interested in the localization to the renal primary cilia of 
the gene products that are mutated in cystic kidney diseases (Yoder et al., 2002) like PC1 and 
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PC2 (Nauli et al., 2003), polaris, cystin, nephrocystin, inversin and fibrocystin/polyductin 
proteins (Morgan, 2002, Wang, 2004) suggesting a potential role of ciliary function and renal 
flow in the progression of cystic kidney diseases. It has since been suggested that PC1 and 
PC2 function as flow sensors on renal cilia and control a mechanotransduction pathway. 
Recently, a publication by Kottgen et al. suggested that PC2 goes to the membrane, 
independently of PC1. They showed that PC2 contains a phosphofurin acidic cluster sorting (PACS) 
protein-interacting binding motif that may play an important role in its trafficking and cellular 
localization. PACS-1 and PACS-2, through protein casein kinase-2-dependent phosphorylation, 
obligates PC2 to be retain into the ER. In the absence of phosphorylation or in the absence of the 
PACS proteins, PC2 would be trafficked to the plasma membrane (Kottgen et al., 2005). 
The published data of PC1 and PC2 tissue distribution is less controversial. PC1 appears to have 
low-level expression in most adult and fetal tissues, with the highest expression level in hepatocytes, 
fetal kidney, in cystic liver and in cystic kidney (Geng et al., 1997; Peters et al., 1999; Chauvet et al., 
2002, Ward et al., 1996). A PC2 expression level seems to be higher than PC1 with similar 
localization, and is expressed in most adult and fetal tissues (Ong et al., 1999).  
 
1.1.5. Polycystin-1’s interacting partners and signaling pathways.  
Similarities in the disease progression of patients, coiled-coil domains in both C-termini and 
similar localization would lead to hypothesized PC1/PC2 physical interaction or its involvement in 
some common signaling pathways. Qian et al. (1997) showed that PC1 and PC2 interact through their 
coiled-coil domain in the C-terminus (Figure 6), and naturally occurring mutations in these C-terminal 
domains disrupted this association. Hanaoka et al. demonstrated that the interaction between PC1 and 
PC2 create a new calcium-permeable nonselective cation current, and this interaction is necessary for 
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the regulation of PC2’s channel activity and other signaling properties of both proteins (Hanaoka et al., 
2000). 
PC1’s protein structure would suggest that it plays a role in cell-cell interactions and intracellular 
signaling cascades. Several proteins have been associated PC-1: 
• Cell Matrix proteins. PC1 co-localizes and co-precipitates with E-cadherin, and α-, β-, and 
γ-catenin, and is also capable of co-immunoprecipitating them (Huan et al., 1999).  
• Proteins involved in the intermediate filament network. C-terminal tail of polycystin-1 was 
able to bind to vimentin, as well as to cytokeratins K8 and K18 (Xu et al., 2001). 
• β-catenin and Wnt signaling. An integral membrane protein containing the PC1 terminal 
tail, an extracellular domain of CD16 and a transmembrane domain of CD7 cause elevated 
levels of β-catenin in Hek293 cells and defects in dorsalization when injected in zebra fish, 
a phenomenon linked to alterations in Wnt signaling (Kim et al., 1999).  
• G-protein coupled signaling. Several studies have suggested that polycystin-1 initiates 
heterotrimeric G-protein coupled signal transduction. A 20 amino acid heterotrimeric G-
protein activation sequence in the C-terminus of PC1, a 74-amino acid G-protein binding 
region that contains the G-protein activation peptide, flanking tyrosine and serine 
phosphorylation motifs were found by Parnell et al. Polycystin-1 lacks most of the other 
characteristic of a GPCR, which could suggest to be the founding member of a new GPCRs 
family (Parnell et al., 1998). Kim et al showed an interaction of PC1 C-terminus with a 
family member of the G-protein signaling regulators, RGS7, accelerator of the of the Gαi 
and Gαq subunits intrinsic activity (Kim et al., 1999). More recently, Puri et al. showed that 
c-terminus PC1 was able to activate NFAT, increased by the inhibition of GSK-3β or by 
Gαq co-expression (Puri et al., 2004). 
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• Activation of JNK kinase and AP-1. Overexpression of the PC1 C-terminus in 
mammalian cell lines increase JNK kinase activity leading to the activation of the 
transcription factor AP-1. This activation was abolished when cells were transfected with 
dominant negative mutants of GTP-binding proteins Rac-1 and Cdc42, suggesting a role 
for the Rho family of GTP-binding proteins in polycystin-1 signaling pathways, as well 
as possible downstream transcriptional alterations in the absence of PC-1 expression 
(Arnould et al., 1998).  
• Activate JAK/STAT signaling. Bhunia et al. showed that PC1 up regulates p21waf1 and 
induces cell cycle arrest in G0/G1 phase dependent of the PC-2 co-expression (Figure 6). 
Also, they showed that Pkd1
-/-
embryos had decreased STAT1 phosphorylation and 
p21
waf1 
induction (Bhunia et al., 2002).  
 
Most of these models used parts of PC1 because it is very difficult to manipulate the full-
length in cell culture systems. However, Boletta et al. developed a stably transfected MDCK cell 
line expressing the full-length human polycystin-1 protein, slowing the growth rate and protecting 
them from apoptosis. Additionally these cells were capable of forming spontaneous branching 
tubules when grown in a collagen matrix, whereas control cells formed cystic structures. They 
proposed that PC1 play a potential role in cellular differentiation, in the regulation of proliferation 
and apoptosis, both implicated in cyst formation (Boletta et al., 2000). 
The function and signaling pathways of PC1 are still very poorly understood, but we can say 
that the loss of polycystins results in a detrimental dysregulation of cell proliferation and apoptosis, 
as well as altered fluid secretion and a disruption of cell-cell and cell-matrix interactions 
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1.1.6. Murine models of ADPKD. 
PKD1 and PKD2 homologues have been discovered in a variety of organisms, including mouse. 
Numerous murine models have been created disrupting either Pkd1 or Pkd2, exhibiting similar 
phenotypes to those found in patients which make them very useful models. The mouse Pkd1 gene is 
localized to chromosome 17 with a 79% identity to human PKD1 at the amino acid level. The cloned 
cDNA contains 14141 bp and is predicted to have a protein product of 4293 amino acids in length 
(Olsson et al., 1996). The gene is pretty similar to human PKD1 and has been shown to contain many 
of the same protein domains. Several models have been developed for Pkd1: 
• Knockout models for Pkd1. These models try to disrupt PC1 by introducing mutations or 
cassettes of DNA (LacZ, PgkNeo …) with several Stop codons or deleting critical coding 
regions. Basically, all of them manifest same phenotypes: Heterozygous mice are basically 
normal developing few, if any, polycystic kidneys (Figure 7) and liver disease. Homozygous 
mice die in utero around day e12.5-e18-5, developing kidney 
cysts at day e15.5, and develop pancreatic cysts as early as 
day e13.5. A few die shortly after birth with massively cystic 
kidneys and hypoplastic lungs. This finding suggested that 
PC1 is not necessary in the early stages of tubule 
development, but rather plays a role in the establishment and 
maintenance of normal tubular architecture. (Lu et al., 1997, 
Guay-Woodford et al., 2003).  
• Pkd1-/- embryos also presented other extrarenal manifestations, defects in skeletal development 
(Lu et al., 2001), cardiac and vascular defects (Boulter et al., 2001), vascular leakiness, 
polyhydramnios, hydrops fetalis (systemic edema of the entire embryo), and hemorrhages (Kim 
Figure 7. Pkd1-/+ mice 
occasionally develop cystic 
kidneys when they are more than 
1 year of age. Donated by Dr. 
Germino’s group. 
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et al., 2000) in a variety of 
different locations (including 
but not limited to the skin, 
neck and brain, Figure 8). 
• Piontek et al., (2004) has 
recently developed a 
conditional Pkd1 mouse line 
that allows inactivating Pkd1 
gene in a tissue and time 
specific manner, using the 
Cre/lox system. This line contains an FRT-flanked neomycin cassette inserted into intron 1 of 
Pkd1 and loxP sites inserted into introns 1 and 4. The loxP sites are specific 34 base pairs 
sequence originally from bacteriophage that, in presence of Cre (cyclization recombination), 
catalyze the deletion of 
the sequence between 
them by reciprocal 
recombination. Using cell 
type specific promoter for 
Cre, the deletion can be 
controlled whenever 
wanted in a specific cell 
type or tissue (Figure 9). 
These Pkd1del2-4/Cond mice 
Figure 8: Representative phenotypes seen in Pkd null animals. A) 
Cyst formation in 15.5dpc embryonic kidneys, B) Disorganized 
myocardium of embryonic hearts C) Edema D) Hemorrhage. Figure 
8, A, C and D where donated by Dr. Germino’s group 
Figure 9. Cre/lox Mouse Breeding. Mice with the Cre protein 
expressing in a specific cell type are bred with mice that contain a target 
gene surrounded by loxP sites. When the mice are bred, the cells carrying 
Cre will cause those cells to lose the target gene. www.bioteach.ubc.ca 
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(completed normal before Cre-mediated deletion) crossed to an MMTV-Cre transgenic, where 
Cre is expressed in a mosaic pattern at low levels in tissues including the kidney and liver, it is 
the first model that mimics the human disease having a germline and a somatic mutation. 
Additionally, Piontek et al. conditionally inactivate Pkd1 in epiblast-derived tissues using Cre 
recombinase regulated by the Meox2 promoter (Meox2-Cre), thus sparing the placenta. 66% of 
Pkd1 mutants survive to birth dying shortly after birth of respiratory failure with massive PKD, 
edema and hemorrhage. This model showed that placental abnormalities play a significant role 
in fetal demise and collectively these animal models have demonstrated an essential 
developmental role for both polycystin genes. 
• New insights in renal cystogenesis in Pkd1-/- mice were generated by Nishio et al. (2005). 
Using Pkd1-/-ES cells and Pkd1+/+
 
morulae they generate a chimeric mouse which developed 
cystic kidneys containing both Pkd1-/- and Pkd1+/+
 
cells, liver and pancreas similar to 
previously established models. The progression of cyst formation was driven by a shift of the 
Pkd1-/-cells from a cuboidal shape to a flat cell shape, proliferating and replacing the Pkd1+/+
 
cells through JNK-mediated apoptosis to form larger endstage cysts.  
The mouse Pkd2 gene is been mapped on chromosome 5 with a 91% identity and 98% similarity 
to the human PC2. The cloned cDNA contains 5134 bp and is predicted to have a protein product of 
966 amino acids, forming a similar 6 transmembrane-domain protein with both N- and C-termini in the 
cytoplasm (Wu et al., 1997). Several Pkd2 animal models have also been created showing similar 
phenotype to the Pkd1 animals (Wu et al., 2000), and an interesting left/right axis lateralization defect 
associated with the dysregulated expression of genes involved in laterality, LeftB, nodal, Ebaf, and 
Pitx2 (Pennekamp et al., 2002). Wu et al. created another interesting PKD2 model generating an 
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unstable PKD2 allele which generates both a mutant and a wild-type exon 1, which then undergoes a 
somatic conversion in vivo, causing eventually a second-hit similar to human disease. When both 
alleles in these mice become null, they saw the development of clonally expanded cysts, supporting the 
idea of a two-hit model of ADPKD cyst formation (Wu et al., 1998).  
Up to this moment, no Pkd2 conditional knockout mouse has been described, like in Pkd1, which 
helps to study ADPKD in a time and tissue specific manner. In this thesis, we describe the first 
conditional Pkd2 model that, using a Cre/lox system, will help to find different aspects of the disease 
pathogenesis. This model has an additional aspect to Pkd1Cond model, which makes it more interesting. 
The conditional allele, with a Pgk-Neomycin cassette in intro 13, works as a hypomorphic allele 
associated with a severe vascular phenotype. Pkd2flox11-13 is a powerful tool not only for studying 
ADPKD, but also to define the biology and the implicated aspects responsible of the vascular 
phenotype in humans. 
 
1.2. Autosomal Recessive Polycystic kidney Disease (ARPKD). 
1.2.1. Clinical Manifestations of ADPKD. 
ARPKD is a hereditary cystic disease is a significant cause of pediatric morbidity and mortality 
affecting the kidneys and the biliary tract (Osathanondh et al., 1963; Osathanondh et al., 1964) with an 
estimated incidence of 1 in 20,000 live births (Zerres et al., 1998). 50% of the affected neonates die 
shortly after birth by respiratory insufficiency with a critical degree of pulmonary hypoplasia, enlarged 
echogenic kidneys and oligohydramnios due to poor renal output. The oligohydramnios cause the 
Potter sequence with pulmonary hypoplasia, characteristic facies, and deformities of the spine and 
limbs (Reuss et al., 1990). The other half, survive to adulthood with chronic lung disease (12%), 
hypertension, progressive renal insufficiency with 50% of them developing ESRD in the first decade, 
and portal tract fibrosis (Guay-Woodford et al., 1996; Roy et al., 1997, Fonck et al, 2001, Guay-
.          Polycystic Kidney Disease. From the clinical/genetic test, through in vitro and in vivo analysis, and back to humans 
   21 
Woodford et al., 2003)  
The kidney phenotype of affected neonates consists in a symmetric enlargement of both kidneys 
with dilated collecting ducts extended radially from the renal pelvis to the cortex (Holthofer et al., 
1990). In less severely affected children, the collecting duct dilation is less prominent and the course is 
more chronic with loss of glomeruli, tubular atrophy and interstitial fibrosis (Fonck et al., 2001). The 
number and distribution of collecting ducts and nephrons are appropriate (Osathanondh et al., 1964) 
and there is no evidence of either tubular obstruction or dysplastic elements (Kissane et al., 1990). 
Hypertension occurs in 75-100% of patients which is typically quite severe and develops in the context 
of a normal GFR (Guay-Woodford et al., 2003; Zerres et al., 1996).  
ARPKD livers showed congenital hepatic fibrosis. This consisted of abnormal development of 
biliary tree, increasing the number of tortuous interlobular bile ducts located in the periphery of the 
portal tract. Only a few, if any, normal bile ducts are evident. There are varying degrees of portal 
fibrosis, hypoplasia of the small portal vein branches, and hepatic arteriolar prominence (Bernstein et 
al., 1992; Desmet et al., 1992). The degree of portal tract fibrosis defines the clinical manifestations 
which it is quite variable (D’Agati et al., 1994). 
1.2.2.. ARPKD gene: PKHD1. 
Initial molecular genetic studies had shown that all typical ARPKD manifestations, including 
perinatal and late onset, result from mutations at a single locus (Zerres et al., 1994; Guay-Woodford et 
al., 1995). At the time that this disease started to be seriously considered, Lens et al. (1997) suggested 
that the PKHD1 gene was localized in a critical region of < 3.1 Mb (Figure 10). As a continuation of 
Lens results, Dr. Onuchic used recombination-mapping studies to reduced candidate region into a large 
region (~500kb) of chromosome 6p12 (Figure 11). PKHD1 is predicted to have a minimum of 86 
exons assembled in a complicated pattern of alternative splice variants which transcribes a large full-
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length mRNA of ~13kb and encodes a full-length protein of 4074aa.  
The protein, polyductin-1 (PD-1) is predicted to be a type I membrane protein that with multiple 
IPT and PbH1 repeats in the extracellular N-terminus and a short cytoplasmic C-terminus of ~200aa. 
PD1 function is still unknown, but based on its structure is predicted to function as either a receptor or 
Figure 10. STS contig map of the PKHD1 interval and flanking region. At the top, the 5-cM segment defined 
by the markers D6S1253 and D6S295, which includes the PKHD1 interval, is indicated by a horizontal arrow. 
The markers are listed in physical order across the top and the corresponding YACs are shown below. The 
markers presented in boldface were isolated in the current study. A more detailed map of the minimal PKHD1 
interval is presented at the bottom. The CEPH identification number of each YAC is listed on the left, and its 
size as listed in the database is shown in parentheses on the right. Solid dots indicate confirmed marker content. 
YAC ends are identified by a single asterisk. GATA11E02 maps to two unique positions within the contig 
(double asterisk). The three ESTs in the interval are italicized. Solid brackets define sets of markers within 
which individual STSs cannot be physically ordered. Dotted brackets identify sets of markers whose relative 
order has been determined based upon evidence from a single YAC. YAC 961c3 is prone to acquiring an 
internal deletion that removes markers LBS1, 802L, and 693R. The deletion allows ordering of the markers 
LBS1 and LBS2. The position of markers has been evenly spaced in the region and does not reflect true 
physical distances. Genomics 1;41(3):463-6(1997). 
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ligand. 
Ward et al, 
2002, using a 
comparative 
genomic approach, 
identified the gene 
at the same time as 
Onuchic using a 
mutation detection 
strategy in both the 
PCK rat and human 
ARPKD. They 
named the protein 
product of PKHD1 
as fibrocystin, 
generating a controversy about the right way to call this protein. To avoid any conflict, many groups in 
the community decided to name it as Polyductin/Fibrocystin-1. Because the ARPKD work of this 
thesis is been develop based on Lens and Onuchic previous results and interaction with them, we will 
use Polyductin-1 as the term to define the PKHD1 product. The two groups independently identified 
essentially identical sequences for the transcript that encodes the longest open reading frame. Both 
groups equally concluded that Northern blots of kidney tissue for PKHD1 showed a high molecular 
weight smear, but their interpretation of the significance and cause of the smear was different. Ward et 
al. suggested that this smear was likely the result of specific properties of the PKHD1 transcript that 
made it unstable and prone to rapid degradation. On the other hand, Onuchic et al. postulated that the 
Figure 11. Chromosomal localization 
and genomic organization of 
PKHD1.  
A, Schematic representation of 
chromosome 6p12. Currently known 
genes are identified on the far left 
(italics), and STSs/polymorphic 
markers are on the right. The closest 
flanking genetic markers that define 
the minimal PKHD1 interval are 
indicated (boldface). Not all of the 35 
overlapping sets of expressed 
sequences described in the text are 
shown. B, Genomic organization of 
PKHD1. Exons identified by numbers 
have been shown to be part of PKHD1 
transcripts. Letters indicate exons that 
belong to either hCT1642763 or 
hCT1646988 and that have not been 
confirmed by our analyses. The black 
diamond identifies, in hCT1642763 
and hCT1646988, overlapping exons 
whose boundaries differ from those 
used in the present study. Arrows 
indicate the positions of the Gene Unit 
6 and Gene Unit 442L12 transcripts 
described in the text. C, BACs and 
PACs sequenced by the Sanger Centre 
that cover the interval. 
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smear might be the result of the gene’s complicated pattern of splicing. 
Since PKHD1 undergoes a very complicated splice pattern it was very difficult to predict the 
exonic/intronic structure of the gene. Onuchic et al. (2002) discovered that the amplification of two 
long RT-PCR products containing the longest open reading frame (ORF) predicted that PKHD1 
contained 67 exons transcribing a 12.6 kb full-length cDNA (Figure 12B). But this is not the total exon 
number of PKHD1; they found a substantial number of additional exons that were variably present in 
PKHD1 transcripts, predicting a conservative estimation of at least 86 exons (Figure 12A). A large 
number of distinct transcripts were found as the result of 
 
 
Figure 12. Structure of full-length 
PKHD1 and its splicing variants. A, Set of 71 
nonoverlapping exons that spans the entire 
length of PKHD1 (upper row) and 15 
additional overlapping exons that use different 
splice sites (gray boxes, lower row). Exons, 
which are not present in the cDNA that 
encodes the longest ORF, are indicated by 
hatched boxes. The position of important 
protein domains is indicated. B, Approximate 
location of each primer set used to amplify 
various cDNAs, with representative set of 
amplified products (below each schema). 
White boxes indicate noncoding exons in the 
corresponding transcripts while gray boxes 
identify exons with alternative boundaries (A). 
The templates used for each amplification are 
as follows: human adult kidney double-
stranded cDNA for primer sets 1–4, 6, and 8; 
human kidney mRNA and total RNA for 
primer sets 5 and 7; human adult kidney 
cDNA library for primer set 9. “SC” indicates 
approximate location of stop codons, and 
“ORF” indicates that an open reading frame 
extends throughout the length of the fragment. 
C, Longest ORF identified by RT-PCR/cDNA 
amplification. This ORF is the composite 
sequence of products 2.1 and 4.1 of panel B 
and includes a total of 67 exons. Am. J Hum 
Genet. 2002 May;70(5): 1305-17. 
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the alternative exons combination, but also having the unique combination of the 67 ORF-related 
PKHD1 exons (Figure 12C). It has been not described how many of the transcripts are translated into 
protein, but it can be easily imagined that this single gene might encode numerous distinct 
polypeptides.  
Recently, PKHD1 has been describe to have a homologue named PKHDL1, with an identity of 
25.0% and similarity of 41.5%, predicted to function as a receptor with inducible T lymphocyte 
expression (Hogan et al., 2003). 
1.2.3. Polyductin/Fibrocystin-1, expression and location. 
This novel protein of 4,074 amino acids, which Onuchic et al. (2002) have named “polyductin” 
(PD1) and Ward et al. (2002) has called 
“fibrocystin”, is predicted by SMART to be a 
Type I membrane protein with a 3,858 amino 
acid extracellular amino terminus, a single 
transmembrane-spanning domain, and a short 
carboxyl terminus (Figure 13). PD1 contains 
multiple IPT domains, mostly related with a 
number of receptor molecules such as HGFR 
and plexin A3, and PbH1 repeats most 
commonly associated with polysaccharidases. 
Multiple potential N-glycosylation sites and 
three putative cAMP/cGMP phosphorylation 
sites were predicted within the cytoplasmic 
C-terminus. The overall structure suggests 
that PD-1 acts as either a ligand or a receptor (or both) involved in either cell-cell recognition or cell-
Figure 13. Structure of polyductin and related 
proteins. Multiple tandemly repeated IPT domains are 
common features of the group. Polyductin-M shares the 
general structure of the HGFR and plexin A3, in having a 
long extracellular domain, a single TM domain, and a short 
cytoplasmic carboxyl terminus. Am. J Hum Genet. 2002 
May;70(5): 1305-17. 
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matrix interactions. The prediction for the translated alternative splice products classifies the PD-1 
isoforms into two groups:  
• The first group includes the longest continuous ORF which may also contain molecules 
lacking some middle domains, a single TM element, and may be associated with the 
plasma membrane (PD1-M, Figure 13). 
• A second group of isoforms lacking the TM domain, that probably may be secreted 
(PD1-S, Figure 13). 
A possible third group would behave similar to neurexin family of genes (Missler et al., 1998), 
coding shorter fragments with variable number of IPT and PbH1 domains, and different specificities or 
binding affinities for targeting factors. 
Several studies have localized PD-1 in the cilia/basal body and possibly other sub-cellular 
locations like apical membrane and in cytoplasm (Ward et al., 2003; Wang et al., 2004; Zhang et al., 
2004, Menezes et al., 2004). Renal cystic disease has been associated with defects in the function of 
primary cilia, being suggested by many investigators that cilia may hold the key to understanding renal 
tubular structure and function (see review by Watnick T et al., 2003). Interestingly, a recent 
comparative genomic strategy comparing genomes of species with and without flagella/basal bodies 
identified a PKHD1-related gene as a probable component of the Flagellar Apparatus Basal Body 
Proteome (Li et al., 2004).  
Human PD-1 has been shown to be primarily expressed in blood-derived cell-lines and 
upregulated in T cells following activation, biliary and pancreatic duct epithelia, and in cortical and 
medullary collecting ducts and thick ascending limbs of Henle of the kidney. Analyses of mouse 
developing tissues showed specific staining in the ureteric bud branches, intra- and extrahepatic biliary 
ducts, pancreatic ducts, and salivary glands (Menezes et al., 2004).  
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1.2.4. Polyductin-1’s interacting partners and signaling pathways.  
This area is a new land to discover but, recently, Kaimori et al. (oral communication at the ASN, 
2005) suggested that  PD-1 has opposing effects on canonical Wnt signaling and marked effects on 
cellular morphology that depend on cell density. 
1.2.5. PKHD1 animal models. 
Up until now, there are not many animal models described for PKHD1. The PCK rat, used by 
Ward et al to identify human PKHD1, was the first animal model for ARPKD (Lager et al., 2001). 
These rats develop progressive cystic enlargement after one week of age with the cysts arising from 
the thick ascending limb of Henle's loop (TAL), distal tube (DT) and collecting duct (CD) in the 
corticomedullary region and outer medulla. The rats also develop severe polycystic liver disease, with 
bile duct abnormalities present at birth. The biliary tree is markedly distorted, showing multiple 
dilatations of the bile ducts and focal budding. Cholangiocyte cilia in the PCK rat were abnormal with 
bulbous extensions and diminished length. Recently, the kidneys of PCK rats have been shown to have 
dysregulated renal cAMP activity that responded well to treatment with V2 receptor antagonists 
(Gattone et al., 2003) improving the kidney function. 
Unfortunately, many investigators consider the rat as an expensive and limited model for the 
analysis of diseases. Several groups have failed to develop a mouse model that mimics the human 
disease (Moser et al., 2005). This could be related to the complicated splice phenomenons of Pkhd1, 
limiting the possible strategies applicable for the generation of the model. In this thesis, we describe 
the first mouse model for ARPKD mimicking the human disease, by using a floxed system that allows 
tissue and timed  the conditional inactivation of the gene. 
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2. Aims 
2.1. General Aims 
 
One major obstacle to develop a therapy for polycystic kidney disease is the limited 
understanding of the disease into the genetic, molecular and pathogenic level. This thesis introduces 
the first genetic test for clinical diagnosis of ADPKD (PKDX, Athena Diagnostics). The importance of 
the PKDX test is enormous, because it could be used for diagnostic uncertainties, pre-symptomatic 
evaluations, donor testing for living-related transplants, etc. The basis of this test was basically 
developed by scientific investigators from the Germino laboratory, applying their knowledge and 
methods for complete sequencing of the PKD genes. The major goals of this thesis was to help in the 
development of these methods and, together with Athena Diagnostics, test the efficiency and establish 
a classification for the genetic changes found in ADPKD patients. Using the information provided by 
the analysis of the PKD genes (structure, composition, organization, etc) and the genetic changes 
found on the ADPKD patients; it will be establish a statistical method to help in a better knowledge of 
the these genes and the mutagenesis mechanisms involved on them. A parallel aim is to understand 
how mutations result in the disease phenotype and try to get a mechanistic understanding of the disease 
process, which can then be used to guide the rational development of therapies.  
To develop therapies for ADPKD and ARPKD, it is necessary to generate first the tools 
(molecular genetic studies, in vitro culture systems, and genetically faithful mouse models in an 
integrated fashion). As mentioned in the introduction, it has been describe a very useful Pkd1 mouse 
model able to control its inactivation in a temporal and spatial specific manner. A very big goal for this 
thesis is, to generate novel ADPKD (Pkd2flox11-13) and ARPKD (Pkhd1flox3-4) conditional mouse models 
to be applied for a better understanding of the biological consequences caused by their mutations and 
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their application for development of a therapy.  
2.2. Specific Aims. 
2.2.1 SUBPROJECT I: Mutational screening and analysis of the entire PKD1 and PKD2 
genes in 82 unrelated ADPKD families through the clinical /genetic PKDX test. 
• Aim #1: Design of a mutation analysis strategy to help in the develop of a 
clinical/genetic test for the ADPKD genes (PKDX® test). 
• Aim #2: Check the efficiency of PKDX® test in a group of 82 unrelated ADPKD 
families.  
• Aim #3: Analysis and classification of the changes found in PKD1 and PKD2 genes 
• Aim #4: Develop of a statistical method for the analysis of gene behavior. 
• Aim #5: Test of this statistical method in the PKD genes. 
2.2.2 SUBPROJECT II: Conditional Inactivation of Murine PKD2 using a tri-allelic system.  
• Aim #1: Create a murine Pkd2 model using gene targeting techniques. 
• Aim #2: Test whether the neomycin cassette results in a hypomorphic allele.  
• Aim #3: Confirm that the floxed allele is functional.  
• Aim #4: Test whether inactivation of Pkd2 leads to PKD phenotypes. 
2.2.3. SUBPROJECT III: Generation of a conditional murine model of PKHD1 gene.  
• Aim #1: Create a murine Pkhd1 model using gene targeting techniques. 
• Aim #2: Test the hypothesis that inactivation of mouse Pkhd1 can mimic human 
ARPKD. 
• Aim #3: Determine whether PKHD1del3-4 is a null allele. 
• Aim #4: Characterize the complex transcriptional profile in PKHD1. 
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3. Mutational screening and analysis of the entire PKD1 and PKD2 genes in 82 
unrelated ADPKD Families through the PKDX test (SUBPROJECT I). 
3.1. Abstract. 
 
Autosomal dominant polycystic kidney disease (ADPKD) occurs as a result of mutations in 
either of two genes, PKD1 or PKD2. The disease is characterized by age dependent growth of renal 
cysts such as ESRD with typically ensues during mid adulthood. Given the age dependent expression 
of ADPKD, there has been intense interest in developing reliable techniques for presymptomatic DNA 
diagnosis. These tests have potential value in the pre-transplant evaluation of donors and in early 
treatment protocols should they become available.  
The development of PKD gene testing has been hampered by the complicated structure of the 
PKD1 gene. PKD1 is replicated in several highly homologous copies that make it difficult to assay the 
bona fide PKD1 gene. We have overcome these obstacles by developing a long-range PCR technique, 
which now forms the basis for the only available clinical DNA test (PKDx). In order to assay the 
sensitivity of this test we collected DNA samples from 82 individuals who were judged to have PKD 
using standard clinical criteria. Definite disease causing mutations (frameshift, stop codon or splice 
site) were identified in 34 patients (41.46%, PKD1=24, PKD2=10). Eight additional patients (9.9%) 
had in frame deletions or insertions. We observed an extraordinarily high level of variability in the 
PKD1 gene with a mean of 13.2 genetic variants per patient (range 0-60). Many of these variants were 
novel, non-conservative missense changes (36.4% patients). However, the suspected pathogenicity of 
these amino acid substitutions was difficult to confirm based on our current understanding of PKD1 
structure and function. We conclude that clinical interpretation of PKD gene testing will be 
challenging because of the high frequency of amino acid substitutions in PKD1. These limitations need 
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to be understood to develop appropriate algorithms for the use of gene testing in ADPKD. Future 
efforts will focus on developing in vitro systems to evaluate the functional consequences of these 
mutations. 
3.2 Material and Methods. 
3.2.1. Patient recruitment. 
Eighty-two unrelated ADPKD patients were recruited from an outpatient clinic, after obtaining 
informed consent and approval from the Ethic Committee and IRB. Some of the probands in this study 
were subjected to ultrasound criteria for ADPKD diagnosis, linkage equilibrium, and classified 
according to sex, ethnicity, birth date, family history, renal and extrarenal phenotype criteria (liver 
aneurysms, other vascular phenotypes, infertility, ESRD, GFR, and others). A blood sample from each 
proband was then coded and sent to Athena Diagnostics, Inc. for sequence analysis. 
3.2.2. Mutation detection and DNA Sequence Analysis. 
Sequence analysis of patient samples was performed using methods described in detail 
previously (Watnick et al., 1997; Watnick et al.,1999; Phakdeekitcharoen et al., 2001) and optimized in 
collaboration with Athena Diagnostics, Inc. Briefly, genomic DNA was derived from whole blood 
using a Puregene® DNA extraction kit (Gentra Systems, Inc. Minneapolis, MN). The amplified 
product served as template for highly specific long-range PCR amplification of eight segments 
encompassing the entire PKD1 duplicated region. This crucial step prevents the spurious amplification 
of PKD1 homologues that would otherwise confound the analysis. The eight long-range PCR products 
served as template for 43 nested PCR reactions while the unique region of the PKD1 gene (Table 2) 
and the entire PKD2 gene (Table 3) were amplified from genomic DNA as 28 additional gene 
segments.  
All 71 PCR products were then bi-directionally sequenced using ABI Big Dye terminator 
chemistry (versions 3.1 and 1.1 depending upon primer position and/or fragment length) followed by 
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electrophoresis on an ABI 3730 capillary 
sequencer (Applera Corporation, Norwalk, 
CT). The entire coding region of the PKD1 
and PKD2 genes including the highly 
conserved exon/intron splice junctions 
between all 61 exons of both genes were 
analyzed. 
3.2.3. LR PCR. 
Specific details of the primer 
sequences, annealing temperatures, and 
extension times used for each LR template of 
the PKD1 duplicated region are provided in 
Table 4. 300 to 400 ng of genomic DNA was 
used as template for each LR product, except 
that for exon 1. The LR PCR amplification 
was performed in a Perkin Elmer 9600 thermal cycler, with denaturation at 95°C for 3 minutes and 35 
Table 2. Oligonucleotide primers for templates from exons 34 to 46 of the of PKD1 gene (non-replicated 
region).  
Table 3. Oligonucleotide primers for amplifying the exons 
of the PKD2 gene from genomic DNA. 
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cycles of a two-step protocol that included denaturation at 95°C for 20 s followed by annealing and 
extension at a temperature and for a time specific for each primer pair (Table 4). A final extension at 
72°C for 10 min was included in each program. The total PCR volume was 50 µl, with 4 U of rTth 
DNA polymerase XL (Perkin Elmer Cetus, Norwalk, CT) and a final magnesium acetate concentration 
of 0.9 mM. A hot-start protocol, as recommended by the manufacturer, was used for the first 
amplification cycle.  
For the exon 1 LR product (T1), the LR template was generated using 500 ng of genomic DNA. 
The LR PCR amplification protocol was modified to include denaturation at 95°C for 1 min and 35 
two-step cycles of denaturation at 95°C for 30 s followed by annealing and extension at 69°C for 7 
min. The total PCR volume was 50 µl, with 1 µl of Advantage-GC genomic polymerase (Clontech, 
Palo Alto, CA), GC melt of 1.5 M, and a final magnesium acetate concentration of 1.1 mM. 
 
Template  
 
Primers  
 
Sequence (5' 3')  
 
Position (5')  
 
Size (kb)  
 
Tm (°C)  
 
ET (min)  
 
T1 BPF14b CCATCCACCTGCTGTGTGACCTGGTAAAT 2043 2.2 69 7 
 BPR9 CCACCTCATCGCCCCTTCCTAAGCAT 4290    
T2 to T7 BPF9b ATTTTTTGAGATGGAGCTTCACTCTTGCAGG 17907 4.6 68 7 
 BPR4 CGCTCGGCAGGCCCCTAACC 22489    
T8 to T12 BPF12 CCGCCCCCAGGAGCCTAGACG 22218 4.2 68 7 
 BPR5b CATCCTGTTCATCCGCTCCACGGTTAC 26363    
T13 to T15 F13 TGGAGGGAGGGACGCCAATC 26246 4.4 68 7 
 R27b  GTCAACGTGGGCCTCCAAGT 30612    
T15 to T21 F26b AGCGCAACTACTTGGAGGCCC 30603 3.4 70 4.5 
 R2 GCAGGGTGAGCAGGTGGGGCCATCCTAC 33953    
T22 BPF15 GAGGCTGTGGGGGTCCAGTCAAGTGG 36815 0.3 72 1 
 BPR12b,c AGGGAGGCAGAGGAAAGGGCCGAAC 37136    
T23 to T28 BPF6 CCCCGTCCTCCCCGTCCTTTTGTC 37325 4.2 69 7 
 BPR6b AAGCGCAAAAGGGCTGCGTCG 41524    
T29 to T34 BPF13b GGCCCTCCCTGCCTTCTAGGCG 41504 5.8 68 8 
 KG8R25b GTTGCAGCCAAGCCCATGTTA  47316     
Table 4. Oligonucleotide primers for long-range specific templates from exons 1 to 34 of the PKD1 gene . aTm, 
annealing temperature; ET, extension time. bPKD1-specific. cBold type in the BPR12 primer sequence identifies 
intentional replacement of C by A, to enhance discrimination of PKD1 from the homologues primer. J Am Soc 
Nephrol. 2001 May;12(5):955-63. 
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3.2.4. Mutation Detection. 
The LR templates were serially diluted to 1:104 or 1:105, to remove genomic contamination, 
and were then used as templates for nested PCR of 200- to 400-bp exonic fragments (Watnick et al., 
1997; Watnick et al., 1999). The sequences and PCR conditions for each new pair are summarized in 
Table 5. Intron-based primers were positioned approximately 30 to 50 bp away from consensus splice 
sites. Exons larger than approximately 400 bp were split into overlapping fragments of 350 bp. Two 
microliters of diluted LR product was used as template for the amplification of each exon.  
Exon Primer Sequence (5'-3') Fragment Size 
 (bp) 
Tm  
(°C) 
1 1F1: 5'-GGTCGCGCTGTGGCGAAGG-3' 328 67 
  1R1: 5'-CGGCGGGCGGCATCGT-3'     
  1F2: 5'-ACGGCGGGGCCATGCG-3' 348 67 
  1R2: 5'-GCGTCCTGGCCCGCGTCC-3'     
2 2F: 5'-TTGGGGATGCTGGCAATGTG-3' 272 62 
  2R: 5'-GGGATTCGGCAAAGCTGATG-3'     
3 3F: 5'-CCATCAGCTTTGCCGAATCC-3' 171 62 
  3R: 5'-AGGGCAGAAGGGATATTGGG-3'     
4 4F: 5'-AGACCCTTCCCACCAGACCT-3' 299 62 
  4R: 5'-TGAGCCCTGCCCAGTGTCT-3'     
5 5F1: 5'-GAGCCAGGAGGAGCAGAACCC-3' 259 65 
  5R1: 5'-AGAGGGACAGGCAGGCAAAGG-3'     
  5F2: 5'-CCCAGCCCTCCAGTGCCT-3' 284 65 
  5R2: 5'-CCCAGGCAGCACATAGCGAT-3'     
  5F3: 5'-CCGAGGTGGATGCCGCTG-3' 294 65 
  5R3: 5'-GAAGGGGAGTGGGCAGCAGAC-3'     
6 6F: 5'-CACTGACCGTTGACACCCTCG-3' 281 65 
  6R: 5'-TGCCCCAGTGCTTCAGAGATC-3'     
7 7F: 5'-GGAGTGCCCTGAGCCCCCT-3' 311 65 
  7R: 5'-CCCCTAACCACAGCCAGCG-3'     
8 8F: 5'-TCTGTTCGTCCTGGTGTCCTG-3' 215 65 
  8R: 5'-GCAGGAGGGCAGGTTGTAGAA-3'     
9 9F: 5'-GGTAGGGGGAGTCTGGGCTT-3' 253 65 
  9R: 5'-GAGGCCACCCCGAGTCC-3'     
10 10F: 5'-GTTGGGCATCTCTGACGGTG-3' 364 65 
  10R: 5'-GGAAGGTGGCCTGAGGAGAT-3'     
11 11F2: 5'-GGGGTCCACGGGCCATG-3' 311 67 
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  11R2: 5'-AAGCCCAGCAGCACGGTGAG-3'     
  11midF: 5'-GCTTGCAGCCACGGAAC-3' 386 65 
  11midR: 5'-GCAGTGCTACCACTGAGAAC-3'     
  11F1: 5'-TGCCCCTGGGAGACCAACGATAC-3' 303 67 
  11R1: 5'-GGCTGCTGCCCTCACTGGGAAG-3'     
12 12F: 5'-GAGGCGACAGGCTAAGGG-3' 311 64 
  12R: 5'-AAGCCCAGCAGCACGGTGAG-3'     
     13 13F: 5-TGGAGGGAGGGACGCCAATC-3 308 67 
  13R: 5-GAGGCTGGGGCTGGGACAAG-3     
     14 14F: 5-CCCGGTTCACTCACTGCG-3 220 64 
  14R: 5-CCGTGCTCAGAGCCTGAAAG-3     
     15 15F16: 5-CGGGTGGGGAGCAGGTGG-3 280 67 
  15R16: 5-GCTCTGGGTCAGGACAGGGGA-3     
  15F15: 5-CGCCTGGGGGTGTTCTTT-3 270 64 
  15R15: 5-ACGTGATGTTGTCGCCCG-3     
  15F14: 5-GCCCCCGTGGTGGTCAGC-3 250 67 
  15R14: 5-CAGGCTGCGTGGGGATGC-3     
  15F13: 5-CTGGAGGTGCTGCGCGTT-3 256 67 
  15R13: 5-CTGGCTCCACGCAGATGC-3     
  15F12: 5-CGTGAACAGGGCGCATTA-3 270 65 
  15R12: 5-GCAGCAGAGATGTTGTTGGAC-3     
  15F11: 5-CCAGGCTCCTATCTTGTGACA-3 259 60 
  15R11: 5-TGAAGTCACCTGTGCTGTTGT-3     
  15F10: 5'-CTACCTGTGGGATCTGGGG-3' 217 67 
  15R10: 5-TGCTGAAGCTCACGCTCC-3     
  15F9: 5-GGGCTCGTCGTCAATGCAAG-3 267 67 
  15R9: 5-CACCACCTGCAGCCCCTCTA-3     
  15F8: 5-CCGCCCAGGACAGCATCTTC-3 261 64 
  15R8: 5-CGCTGCCCAGCATGTTGG-3     
  15F7: 5-CGGCAAAGGCTTCTCGCTC-3 288 64 
  15R7: 5-CCGGGTGTGGGGAAGCTATG-3     
  15F6: 5-CGAGCCATTTACCACCCATAG-3 231 65 
  15R6: 5-GCCCAGCACCAGCTCACAT-3     
  15F5: 5-CCACGGGCACCAATGTGAG-3 251 64 
  15R5: 5-GGCAGCCAGCAGGATCTGAA-3     
  15F4: 5-CAGCAGCAAGGTGGTGGC-3 333 67 
  15R4: 5-GCGTAGGCGACCCGAGAG-3     
  15F3: 5-ACGGGCACTGAGAGGAACTTC-3 206 64 
  15R3: 5-ACCAGCGTGCGGTTCTCACT-3     
  15F2: 5-GCCGCGACGTCACCTACAC-3 265 67 
  15R2: 5-TCGGCCCTGGGCTCATCT-3     
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  15F1: 5-GTCGCCAGGGCAGGACACAG-3 228 68 
  R27: 5-AGGTCAACGTGGGCCTCCAA-3     
  15F1-1: 5-ACTTGGAGGCCCACGTTGACC-3 276 69 
  15R1-1: 5-TGATGGGCACCAGGCGCTC-3     
  15F1-2: 5-CATCCAGGCCAATGTGACGGT-3 266 64 
  15R1-2: 5-CCTGGTGGCAAGCTGGGTGTT-3     
     16 16F: 5-TAAAACTGGATGGGGCTCTC-3 294 56 
  16R: 5-GGCCTCCACCAGCACTAA-3     
     17 17F: 5-GGGTCCCCCAGTCCTTCCAG-3 244 67 
  17R: 5-TCCCCAGCCCGCCCACA-3     
     18 18F: 5-GCCCCCTCACCACCCCTTCT-3 342 67 
  18R: 5-TCCCGCTGCTCCCCCCAC-3     
     19 19F: 5-GATGCCGTGGGGACCGTC-3 285 67 
  19R: 5-GTGAGCAGGTGGCAGTCTCG-3     
     20 20F: 5-CCACCCCCTCTGCTCGTAGGT-3 232 64 
  20R: 5-GGTCCCAAGCACGCATGCA-3     
     21 21F: 5-TGCCGGCCTCCTGCGCTGCTGA-3 232 67 
  TWR2: 5-GTAGGATGGCCCCACCTGCTCACCCTGC-3     
23a TWF1 5'CTGCACTGACCTCACGCATGT3' 377 62 
  23R1 5'GCCAAAGGGAAAGGGATTGGA3'     
23b 23F2 5'CCGCGGAGCCTGCTGTGCTAT3' 631 56 
  23R2 5'TGCCACGGGCCTGAAAGCATA3'     
24 24F 5'TATGCTTTCAGGCCCGTGGCA3' 382 62 
  24R 5'AGAGCCCATACCCGGTCCAGTCC3'     
25 25F 5'GGACTGGACCGGGTATGGGCTCT3' 392 62 
  25R 5'CACCCAGGCCCTCCTCGACTC3'     
26 26F 5'CTGGGTGGGCTCGGCTCTATC3' 553 65 
  26R 5'TGGTAGCGATGCTCACGTCACTT3'     
27 27F 5'CAGGCCAAAGCTGAGATGACTTG3' 339 62 
  27R 5'AGAGGCGCAGGAGGGAGGTC3'     
28 28F 5'CCCTCTGCCCCCGCATTG3' 380 62 
  28R 5'GGAGAGCCAGATGTGCTTGTCAA3'     
29 29F 5'GGTGCTGGCCGCGAGTAAGG3' 414 62 
  29R 5'CCGTGCTGTGTGGAGGAGAG3'     
30 30F 5'CCTCTTCCTGCCCAGCCCTTC3' 318 62 
  30R 5'CTTCCCGAGCAGCCTTTGGTG3'     
31 31F 5'GTCCCATATATCCAGCATTCT3' 330 56 
  31R 5'ACAGTGTCTTGAGTCCAAGC3'     
32 32F 5'GCCTTGGCGCAGCTTGGACT3' 185 65 
  32R 5'ACACCCAGCAAGGACACGCA3'     
33 33F 5'GGTGTGCGGGCTGCGTGT3' 459 62 
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  33R 5'CTCGGCAAGGACCTGCTGGAT3'     
34 34F 5'GAGAGGAGGGGGCTCTGAAG3' 475 62 
  34R 5'AAAAACCCGCCCATAATTTC3'     
Table 5. Nested primers used for mutation detection. 
3.2.5. Analysis of the Electronic Database Information. 
The following GenBank sequences (accessed at http://www.ncbi.nlm.nih.gov/Web/Genbank) 
were used as reference files for this report: L39891 for PKD1 genomic nucleotide positions, L33234 
for PKD1 cDNA positions, and AC002039 for the sequences of the homologous loci.  
3.2.6. Generation of Polycystin-1 Cleavage Mutant Constructs.  
The wild type construct (AF20, great donation of Dr. Germino) was the base plasmid for the 
generation of the cleavage mutants. AF20 was derived from pCI-PKD1-Flag (Hanaoka et al., 2000) by 
eliminating the BglII site of the vector. The cleavage mutants were generated in a two-step PCR 
procedure by using pfu DNA polymerase and AF20 as template. 5´ and 3´ PCR products with 
compatible ends were generated with the desired mutant nucleotide included in one of the primers, 
digested with the appropriate enzymes, and then cloned into the same sites of the AF20 in a tri-
molecular ligation reaction.  
3.2.7. Cleavage Assay.  
The construct was transfected into various mammalian cells by using Lipofectamine Plus (Life 
Technologies, Rockville, MD). The cells were lysed in buffer [20 mM sodium phosphate, pH 7.2/150 
mM NaCl/1 mM EDTA/10% (vol/vol) glycerol 0.5% Triton X-100] containing complete protease 
inhibitor cocktails (Roche Molecular Biochemicals) for 1 h on ice. The cleared supernatant was 
subjected to immunoprecipitation (IP) by using either agarose-conjugated α-Flag (Sigma) or affinity-
purified α -CT or α -GFP (Roche Molecular Biochemicals). The IP product was resolved on a 4% or 
3–8% SDS gel, electro-blotted to a poly (vinylidene difluoride) membrane, and probed with various 
antibodies. 
.          Polycystic Kidney Disease. From the clinical/genetic test, through in vitro and in vivo analysis, and back to humans 
   38 
3.3. Results: 
3.3.1 PKDX family test. 
A systematic direct sequencing-based analysis of PKD1 and PKD2 mutations and variants has 
been performed in a group of 82 ADPKD patients. Samples were screened for all 46 exons of PKD1 
and for 15 exons of PKD2 and its respective exon-intron junctions comprising the transcript with the 
longest continuous ORF of both genes. It has been detected 34 (41.5%) patients associated with 
definitive mutation (Stop Codon, Frameshift, or Splicing defect): 24 (29.3%) of them to PKD1 (eight 
Stop Codons, 15 Frameshift, and 1 Splicing variant) and 10 (12.2%) to PKD2 (six Stop Codons, 3 
Frameshift, and 1 Splicing variant). In addition, It has been identify eight (9.7%) patients associated to 
an in-frame deletion or insertion alteration (6 PKD1 and 2 PKD2) and 25 (30.5%) to one or more 
missense change (24 PKD1 and 1 PKD2). A novel, recurrent, highly pathogenic mutation was found in 
three families without other possible association to any pathogenic variant. The inclusion of these three 
families would go up the detection rate from 81.7% to 85.2%. No disease causing variants were 
detected in 12 patients (14.6%) (Table 6). 
A) 
 Truncation and Splicing Inframe Mutations 
 Stop 
Codon 
Frameshift Splicing Insertions Deletions 
Amino acid changes No 
mutation 
8 (9.7%) 15 (18.3%) 1 (1.21%) 0 (0%) 6 (7.3%) PKD1 
Total 24 (29.26%) Total 6 (7.4%) 
25 (30.5%) 
6 (7.3%) 3 (3.7%) 1 (1.21%) 0 (0%) 2 (2.4%) PKD2 
Total 10 (12.3%) Total 2 (2.5%) 
1 (1.2%) 
14 (17%) 18 (22%) 2 (2.42%) 0 (0%) 8 (9.75%) 
Total 34 (41.46%) Total 8 (9.9%) 
26 (31.7%)  Total 
68 (82.9%) 
 
 
 
14 (17%) 
B) 
 Truncation and Splicing  Inframe  
insertions and deletions 
Amino acid  
changes 
Silent changes 
PKD1 21 (19 Novel) 6 (6 Novel) 73 (52 Novel) 111 (75 Novel) 
PKD2 6 (3 Novel) 2 (2 Novel) 6 (4 Novel) 6 (5 Novel) 
Table 6. Results of PKDX family test. A) Classification of the different changes associated to the disease for 
ADPKD patients linked to PKD1 or PKD2. B) Total number of individual changes found in each gene. 
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The following criteria has been used to predict whether a sequence variant was pathogenic: 1) 
the potential chain-terminating effect on the longest predicted polypeptide; 2) disruption of a canonical 
splice site or creation of a novel site; 3) alteration in the polarity or change of an amino acid, 4) 
structural disruption of the protein domain and; 5) assessment of the variant frequency in the total 
number of patients.  
The difficulty of classifying the missense changes as pathogenic becomes more complicated in 
families that have one or more missense change associated to a definitive mutation. 47 patients 
(57.3%) were associated to a unique mutation (38 PKD1, 46.3%; 9 PKD2, 11%) and 20 (24.3%) to one 
or more pathogenic changes (16 PKD1, 19.5%; 4 PKD2, 4.9%). The total number of changes per 
patient for both genes is variable from one (JHUJHU605-1; 0 changes in PKD1 and 1 change in 
PKD2), to sixty-one (JHU411; 60 changes in PKD1 and 1 change in PKD2). The minimum total 
number of changes found in a patient associated to a mutation is three (JHU576 and JHUYP109, both 
with 3 changes in PKD1and none in PKD2) (Table 7). 
Pedigree Mutations Disease Associated Other unclassified amino acid changes 
# of Changes 
per patient 
 PKD1 PKD2   PKD1 PKD2 
JHU605 S91X   4 0 
JHU 567 R1436X   24 0 
JHU YP108 Y2265X   5 1 
JHU563 R2430X  R807Q 19 1 
JHU593 Q2556X   3 2 
1539998 Q2686X   5 0 
JHU574 E2810X   4 0 
JHU620 W4011X   22 0 
JHU578  R306X L247F 3 3 
JHU583  R306X P36H 5 1 
JHU607  R742X  21 1 
JHU594  R872X  22 3 
JHU566  R872X  1 3 
JHU608  R872X  4 2 
JHU568 W305 fsX  W305C 4 1 
JHU582 P694 fsX   1 0 
JHU585 A696 fsX   6 2 
JHU508 V1718 fsX   5 2 
JHU613-1 D2152 fsX  E624K 21 0 
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JHU611 P2224 fsX   29 1 
JHU600 P2975 fsX   25 2 
JHU609 I3109 fsX   41 1 
JHU579 I3109 fsX   23 2 
JHUYP116  720ins1 D3494E 3 2 
JHU586  720ins1  22 1 
JHU577 F2834fsX   4 1 
JHUYP111 N116 fsX  S1619F(PKD1) and  M583I(PKD2) 7 1 
JHUMP15 R1672 fsX   5 1 
JHU599 L3343 fsX  R1312Q 20 1 
JHUYP104 G3792 fsX   4 2 
JHUYP115 N101del   20 0 
JHUYP107 V546del  R1142W 25 1 
JHU560 A2894del   21 1 
JHU592 K3232del  A1516T 3 1 
JHU571 L3287del  V2267M and  F4007L 10 0 
JHUYP112 V4129del  S4053F 19 2 
JHU596  103del H201Q and Q2182R 35 1 
JHU416  605del  2 3 
JHU591-2  786del2  4 2 
JHU580 IVS19+?GxT   5 1 
JHU562  IVS7-1GxA  3 2 
JHU559 C47S  M800L in PKD2 24 3 
JHU612-1 A271D   4 0 
JHU602 Y420C  R1351W , W2882R and E2966D 25 1 
JHUYP103 Y528C  R1942H 28 1 
JHU570 P579Q   5 1 
CP001 R611W   6 0 
JHUYP105 T1773I   3 2 
JHUYP100 T1861I and R2166C   8 1 
JHU411 S1047L  Q2182R 60 1 
JHU587 C210F and R2329Q   6 2 
JHU565 T2422K   24 0 
JHU603 R2516C   4 0 
JHU597 R2643C   3 1 
JHUYP101 R2767C   4 2 
JHU589 F2853S   22 2 
JHU601B Q3016R   43 1 
JHU 576 N3295K   3 0 
JHU564 A2302G and G3326R  I3367V 4 1 
JHU617 L3730Q  L1394V 5 1 
JHUYP114 R4149C   22 1 
JHU572  S349P  17 1 
JHU569 L2619P   22 2 
JHUYP109 E2771K   3 0 
JHU575 N1034S   17 1 
JHU614-1   A1516T  and E586D 10 0 
JHU588 L2448P   39 0 
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JHU606   - 5 2 
JHU584   R2200C (JHU 573) 20 1 
JHU595   R2121R, V3408L and IVS24+ G-C  16 2 
JHU 573   IVS24+ G-C, R2200C (JHU584) 5 0 
JHUYP102   V3408L (JHU 595, JHU596) 21 0 
JHU590   G109G  IVS24+G-T  IVS41- C-T 3 1 
JHU178   P1168S (JHU565) 2 1 
JHU610   S196S 40 2 
JHU604   3'UTR G-A    2 0 
JHU616-1     17 0 
JHU615-2    0 1 
JHUYP110    3 0 
JHUYP113    2 1 
JHU598    19 0 
JHUYP106    4 1 
 
Table 7. Summary of Mutation Changes Identified in the 82 families. 
 
It is been found patients having with more than one changes classified as missense changes 
presumably responsible of the disease (for example JHUYP100, JHU587 and JHU564), but only one 
can be really responsible of it. The patient JHU587 has one fully conserved amino acid changed in the 
extracellular region of the PC-1 (C201F) and the other in a highly conserved amino acid of REJ 
domain (R2329). The missense change A1516T is a novel change of a highly conserved amino acid in 
PKD1-R9 of PD1 found in two families, associated to an inframe deletion (K3232del, JHU592) and to 
a highly conserved novel amino acid change (E586D, JHU614-1). Two novel missense mutations and 
unclassified novel amino acid substitutions has been found in JHU602: a fully conserved amino acid 
substitution on the consensus structure of the C-Type-Lectin domain changing the structure of the 
domain (Y420C), a CpG change in a fully conserved amino acid change on PKD-R7 domain 
(R1351W), and a non conserved amino acid change (W2882R), all of which are likely to be highly 
pathogenic. Two novel amino acid substitutions of highly conserved amino acids of PKD1 (A2302G 
and I3367V) were found in JHU564 (Table 7).  
Some patients were associated to a mutation disease associated, but also presented another 
possible change that, following the criteria previously establish by other investigators, could be 
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classified as responsible of the disease. 18 PKD1-patients and 4 PKD2-patients have more than one 
change that could be classified as responsible of the disease (Table 7). 
3.3.2. PKD1 and PKD2 Mutations. 
Among the putative mutant alleles, 22 were predicted to cause chain-termination. 13 frameshift 
variants (deletions, insertions and duplications), eight nonsense mutations and one splice variant where 
found in PKD1, and two frameshift, three nonsense mutations and one splicing in PKD2. N116fsX 
(JHU111 and JHU 577) and I3109fsX (JHU579 and JHU609) were found to be recurrent (Table 8).  
Mutation Mutation Effect Variant Exon 
cDNA Protein Stop 
Codon 
Splice 
Site 
Domain Pedigree Rate Reference 
PKD1 gene 
Frameshift: 
 3 559delTTT
AA 
N116fsX 117  LRR2 JHUYP111  1/164 NOVEL 
 5 1124insCT W305 fsX 334  PKD R1 JHU568  1/164 NOVEL 
 10 2291ins1 P694 fsX 713   JHU582 1/164 NOVEL 
 10 2297ins1 A696 fsX 713   JHU585 1/164 NOVEL 
 15 5225delA
G 
R1672 fsX 1721  PKD R11 JHUMP15 1/164 1 
 15 5365insT V1718 fsX 1770  PKD R12 JHU508 1/164 NOVEL 
 15 6666insG D2152 fsX 2174  REJ JHU613-1  1/164 NOVEL 
 15 6881insA P2224 fsX 2261  REJ JHU611 1/164 NOVEL 
 23 8713delT F2834 fsX 2874   JHU577 1/164 NOVEL 
 24 9134ins1 P2975 fsX 3068   JHU600 1/164 NOVEL 
 26 9536ins5 I3109 fsX 3317   JHU579, JHU609 2/164 NOVEL 
 30 10239delT L3343 fsX 3395  TM3 JHU599  1/164 NOVEL 
 40 11587delG G3792 fsX 3824   JHUYP104 1/164 NOVEL 
Nonsense: 
 2 483 C>A S91X 91  LRR1 JHU605 1/164 NOVEL 
 15 4517 C>T R1436X 1436  PKD R8 JHU 567 1/164 NOVEL 
 15 7006 C>A Y2265X 2265  REJ JHU YP108 1/164 NOVEL 
 18 7499 C>T R2430X 2430  REJ JHU563  1/164 2 
 19 7877 C>T Q2556X 2556  REJ JHU593 1/164 NOVEL 
 22 8267 C>T Q2686X 2686  REJ 1539998 1/164 NOVEL 
 23 8639 G>T E2810X 2810  REJ JHU574 1/164 NOVEL 
 44 12243 
G>A 
W4011X   TM9 JHU620 1/164 NOVEL 
Splicing: 
 19 VS19+1 
G>T. 
VS19+1 
G>T. 
 Loss of 
acceptor 
site 
REJ JHU580 1/164 NOVEL 
PKD2 gene 
Frameshift: 
 11 2226ins1 720 fsX    JHU586, JHUYP116  2/164 NOVEL 
 12 2422delA
G 
786dfsX   COILED COIL JHU591-2 1/164 NOVEL 
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Nonsense: 
 4 982 C>T R306X   TM1 JHU578 , JHU583  2/164 5 
 11 2224 C>T R742X    JHU607 1/164 6 
 14 2680CxT R872X    JHU594 , JHU566, 
JHU608 
3/164  
Splicing: 
       7  IVS7-1GxA  Loss of 
donor 
site 
 JHU562 1/164 NOVEL 
Table 8. Truncating and Splice variants. Ref: N. Novel.; 1 Watnick et al., 1999; 2 Phakdeekitcharoen et al., 2000; 3 
Rossetti et al., 2001; 4 Peral et al., 1997; 5 Veldhuisen et al., 1997; 6 Peral et al., 1998; 7, Peral et al., 1996; 8 Rossetti et 
al., 2002; 9 Thomas et al., 1999; 10 Rossetti et al., 1996; 11 Reiterová y col., 2002; 12   ; 13 Inove et al., 2002; 14 
Perrichot et al., 1999; 15 Bogdanova et al., 2001; 16 Watnick et al., 1998; 17 Perrichot te al., 2000; 19 Aguiarri et al., 
2000; 20 Bateman et al., 1999. 
 
N116fsX was associated in both families to another possible pathogenic change (F2834fsX in 
JHU577 and S1619F in JHU577). D2152fsX (JHU613-1) and L3343fsX (JHU599) were associated to 
another variant (Table 7).  
All frameshift deletions were caused by sequence motifs that possess an axis of internal 
symmetry and vary in length between 5 and 18 bp. Symmetric elements spanning 5 bp or more appear 
to be overrepresented in the vicinity of short human gene deletions. For example, N116fsX is on an 
ATTTAATTTA motif, where a deletion of 5 amino acids was found (559delTTTAA) in PKD1. These 
types of motifs can be found along PKD1 and PKD2. This mechanism of mutagenesis is the 
responsible for all of the PKD1 and PKD2 deletions in our pool of families and 76% of previous 
published deletions. Other mechanisms of deletion such as direct repeats, palindromes and 
quasipalindromes sequences have been shown to be responsible of frameshift and small deletions at 
least in E. coli (de Boer JG et al., 1984), but we could not observe any of these type. 
All inframe deletions (6, PKD1 and 2, PKD2) were novel and fully or highly conserved in our 
group of families, the total published population likely being pathogenic (Table 9). For this type of 
study, where the clinicians want to determine if their patients are or are not ADPKD, it is risky to 
classify inframe and missense as pathogenic. More definite information or other approaches are needed 
to determine the potential implications of these changes. 
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All single nucleotide changes were analyzed for potential splice effects using Splice Site 
Prediction by Neural Network (SSPNN; http:/fuitfly.org/seqtools/splice.html). Splice site scores 
predicted the theoretical impact upon donor and acceptor site strength and the probability that 
sequence variants created novel splice sites. This was very useful to predict the effect of certain 
nucleotide changes on splicing. 3 variants were predicted to alter splicing with alterations, SS scores 
>50%. One variant in PKD1 and another in PKD2 disrupted the canonical GT splice donor or AG 
acceptor and presumably caused exon-skipping. One missense change was predicted to alter splicing in 
a fully conserved residue Q3016R.  
Table 9. Deletions inframe  
 
 
Of the 81 amino acid substitutions, 75 were PKD1 and 6 PKD2. Of the 75 PKD-1 amino acids 
substitutions, 35 residues were fully conserved from Fugu rubripes to Homo sapiens, 30 residues were 
highly conserved in mammalians from Mus musculus to Homo sapiens, and 10 had no conservation. 
To assess the statistical probability of pathogenicity for each amino acid substitution, we applied the 
matrix criteria described by Miller and Kumar. This matrix, developed using disease-associated human 
genetic variations and interspecific comparisons as well as Graham’s chemical difference matrix, 
Mutation Domain Conservation Pedigree Variant 
Detection 
Reference  Exon 
cDNA Protein  Fugu Mouse Level    
PKD1 gene 
3 514-551delCAA N101del LRR2 N N Fully JHUYP115 1/164 NOVEL 
8 1848-1851delTGG V546del  V V Fully JHUYP107  1/164 NOVEL 
 23 8892-
8898delCCAACTCCG 
A2894del  AGA VGS Fully JHU560 1/164 NOVEL 
28 9905-9909delAAG K3232del PLAT I K Highly JHU592  1/164 NOVEL 
29 10070-10074delCTC L3287del TM2 L L Fully JHU571 1/164 NOVEL 
45 12597-12600delTGG V4129del  V V Fully JHUYP112  1/164 NOVEL 
PKD2 gene 
1 374-378delTGG 103del Poly-
Glu 
 V Highly JHU 596  1/164 NOVEL 
8 1879-1882delTTC 605del TM5  F Highly JHU416 1/164 NOVEL 
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defines the relative likelihood that a missense change represents a polymorphism versus a pathogenic 
alteration (Figure 14). 
In this study, of 29 missense 
changes, 20 were predicted to have a 
higher pathogenic potential than 
polymorphic probability, six were 
predicted to be potentially 
pathogenic substitutions with an 
equal provability of being 
pathogenic and polymorphism, and 
three of these missense changes 
were predicted to be polymorphism. 
All these missenses are novel and 
unique in this study and only one 
(E2771K) was described previously 
by Rossetti et al. (2001), indicating 
the high probability to be disease 
associated. In these patients, we 
define as unclassified the variant 
changes that appear only once, not common in the population, and are associated to another change in 
the same patient. 
Of the 25 unclassified variants, 11 were predicted to have the probability to be highly 
pathogenic, 9 equally pathogenic and 5 polymorphisms. 21 amino acid substitutions were predicted to 
be polymorphism with a high prevalence on the population since it appears in homozygosity or is a 
Figure 14. Plots showing the relative frequencies of amino acid 
changes observed in interspecific comparisons (circles) and detected 
in disease patients (squares).  The width of the symbols is 
proportional to the relative frequency of a given amino acid change. 
Diamonds indicate amino acids changes that cannot be observed as a 
result of a single base mutation. Horizontal and vertical lines across 
the graph denote groups of amino acids with relatively similar 
properties, thus, residue changes to an amino acid with similar 
properties are found along diagonal elements of the grid. Human 
Molecular Genetics, 2001, Vol. 10 No. 21. 
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conserved amino acid group change. 5 of 21 were predicted to be polymorphism, 10 having the equal 
probability to be pathogenic or polymorphism, and 6 were predicted to be highly pathogenic (Table 
10). 
Mutation Conservation Exon 
cDNA Protein 
Domain Path./ P. 
Provability Fugu Mouse Level 
Pedigree Variant 
Detection 
Reference 
PKD1 gene: 
Pathogenic Variants. Missense. 
1 351GxC C47S LRR N-
Flank 
P.H. W C Highly JHU559 1/164 NOVEL 
5 840GxT C210F  Equal C C Fully JHU587  1/164 NOVEL 
5 1023CxA A271D WSC Path.H. A A Fully JHU612-1 1/164 NOVEL 
6 1470AxG Y420C C-
TYPE-
LECTIN 
Path.H. F Y Fully JHU602  1/164 NOVEL 
7 1794AxG Y528C C-
TYPE-
LECTIN 
Path.H. Y Y Fully JHUYP103  1/164 NOVEL 
9 1947CxA P579Q  Equal P P Fully JHU570 1/164 NOVEL 
9 2042CxT R611W  Path.H. R R Fully CP001 1/164 NOVEL 
13 3312AxG N1034S PKD R4 P.H. G S Highly JHU575 1/164 NOVEL 
13 3351CxT S1047L PKD R4 Path.H. M S Highly JHU411  1/164 NOVEL 
15 4262CxT R1351W PKD R7 Path.H. R R Fully JHU602   1/164 NOVEL 
15 5529CxT T1773I PKD 
R12 
Path.H. S T Fully JHUYP105 1/164 NOVEL 
15 5793CxT T1861I PKD 
R13 
Path.H. T S Fully JHUYP100  1/164 NOVEL 
15 7116CxG A2302G REJ Equal S A Highly JHU564  1/164 NOVEL 
16 7197GxA R2329Q REJ Equal E R Highly JHU587  1/164 NOVEL 
18 7476CxA T2422K REJ Equal T T Fully JHU565  1/164 NOVEL 
18 7554T>C L2448P REJ Path.H. L L Fully JHU588 1/164 NOVEL 
19 7757CxT R2516C REJ Path.H. R R Fully JHU603 1/164 NOVEL 
20 8067TxC L2619P REJ Path.H. L L Fully JHU569  1/164 NOVEL 
21 8138CxT R2643C REJ Path.H. R R Fully JHU597 1/164 NOVEL 
23 8509CxT R2767C REJ Path.H. R R Fully JHUYP101 1/164 NOVEL 
23 8522GxA E2771K REJ Path.H. E E Fully JHUYP109 1/164 3 
23  TxC F2853S  Path.H. F F Fully JHU589 1/164 NOVEL 
29 10096CxA N3295K TM2 Path.H. N N Fully JHU 576 1/164 NOVEL 
30 10187GxC G3326R TM3 Path.H. G G Fully JHU564  1/164 NOVEL 
39 11040TxA L3730Q  Equal F L Highly JHU617  1/164 NOVEL 
46 12658CxT R4149C  Path.H. R R Fully JHUYP114 1/164 NOVEL 
Pathogenic Variants. Splicing 
25 9258AxG Q3016R  Path.H. Q Q Fully JHU601B 1/164 4 
Unclassified Variants. 
1 318CxA P36H LRR-NF Equal T P Highly JHU583   1/164 NOVEL 
2 485GxA A92Y LRR1 Equal F A Highly  1/164 7 
5 814CxT H201Q  P.H. C C Fully JHU 596   1/164 NOVEL 
10 2081GxA E624K  Path.H. V E Highly JHU613-1  1/164 NOVEL 
15 3637CxT R1142W PKD R5 Path.H. K Q Highly JHUYP107  1/164 NOVEL 
15 4146GxA R1312Q PKD R7 Equal N Q NO JHU599  1/164 NOVEL 
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15 4757GxA A1516T PKD R9 Equal T I Highly JHU592  
JHU614-1   
2/164 NOVEL 
15 5067CxT S1619F  Path.H. A S Highly JHUYP111  1/164 NOVEL 
15 6707CxT R2166C REJ Path.H. P R Highly JHUYP100   1/164 NOVEL 
15 6756AxG Q2182R REJ Path.H. G Q Highly JHU596  
JHU411   
2/164 NOVEL 
15 6809CxT R2200C REJ Path.H. R R Fully - 5/164 NOVEL 
16 7138CxT G2309R REJ Path.H. G H Highly -  4/164 NOVEL 
23 8855TxA W2882R  Path.H. G Q NO JHU602   1/164 NOVEL 
Polymorphisms 
5 950CxT L247F  Equal Q W NO JHU578  1/164 NOVEL 
5 1004CxT T263S(H)  P.H. Q T Highly   2/164 NOVEL 
8 1925CxT P572S(H)  Equal G P Highly   4/164 NOVEL 
9 1973AxC E586D  P.H. A E Highly JHU614-1   1/164 NOVEL 
11 2427AxG Q739R  Path.H. R Q Highly - 11/164 NOVEL 
15 3527CxG L1106V PKD R4 P.H. S V Highly JHU565  1/164 NOVEL 
14 3486TxC M1092T(H) PKD R4 Equal T T NO -  30/164 8 
15 3678GxC G1156A PKD R5 P.H. Y D NO JHUYP107  1/164 NOVEL 
15 3713CxT P1168S PKD R5 Equal - P Highly JHU565 
JHU178 
2/164 NOVEL 
15 4229CxT R1340W PKD R7 Path.H. H H NO JHUYP114  
JHUYP100 
, JHU588  
3/164 NOVEL 
15 4391CxG L1394V PKD R8 P.H. V L Fully JHU617   1/164 NOVEL 
15 4406TxG W1399R(H) PKD R8 Path.H. Q R NO -  22/164 NOVEL 
15 6036GxA R1942H PKD 
R14 
Equal R R Fully JHUYP103   1/164 NOVEL 
15 6038GxA V1943I(H) PKD 
R14 
P.H. V V Fully -  5/164 NOVEL 
15 7010GxA V2267M REJ Path.H. V V Fully JHU571   1/164 NOVEL 
19 7853GxC E2548Q(H) REJ Equal R V NO  - 4/164 NOVEL 
21 8124AxG H2638R(H) REJ Path.H. Y L NO   32/164 NOVEL 
21 8231CxT P2674S REJ Equal V S NO JHU 567 2/164 NOVEL 
22 8334CxT T2708M REJ Equal T T Fully JHU594   1/164 NOVEL 
23 8411CxA P2734T REJ Equal P P Fully JHU569   1/164 NOVEL 
23 8415AxT Q2735L REJ Equal S Q Highly JHU569   1/164 NOVEL 
23 8651GxA G2814R REJ Path.H. A G Fully - 6/164 NOVEL 
23 8924GxA V2905I  P.H. V V Fully  - 1/164 3 
24 9109GxC E2966D  P.H. G E Highly JHU602   1/164 10 
31 10311AxG I3367V  P.H. I V Fully JHU564  1/164 NOVEL 
33 10433GxC V3408L(H)  Equal E V Highly -  5/164 NOVEL 
34 10693CxA D3494E  P.H. - D Highly JHUYP116   1/164 NOVEL 
35 10743CxT A3511V(H)  Equal L I Fully  - 13/164 NOVEL 
42 11835CxT A3875V  Equal S A Highly - 1/164 NOVEL 
44 12230TxC F4007L  Path.H. F F Fully JHU571   1/164 NOVEL 
44 12341AxG I4044V(H) TM10 Equal H I Highly  - 42/164 10 
45 12371CxT S4053F  Path.H. G T Highly JHUYP112   1/164 NOVEL 
45 12386CxT A4058V(H)  Equal T A Highly -  12/164 10 
PKD2 gene: 
Pathogenic Variants. Missense. 
4 1111TxC S349P  Path.H. - S Fully JHU572 1/164 NOVEL 
Unclassified Variants. 
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8 1815GxA M583I  Equal - M Fully JHUYP111  1/164 NOVEL 
13 2486GxA R807Q  Equal - R Highly JHU563  1/164 NOVEL 
Polymorphisms 
1 149CxT R28P  Path.H. - R Highly - 50/164 10 
1 634GxA A190T  Equal - A Highly - 3/164 NOVEL 
13 2464AxC M800L  P.H. - M NO JHU559 1/164 11 
Table 10. Amino Acid Substitutions. Ref: N. Novel.; 1 Watnick et al., 1999; 2 Phakdeekitcharoen et al., 2000; 3 
Rossetti et al., 2001; 4 Peral et al., 1997; 5 Veldhuisen et al., 1997; 6 Peral et al., 1998; 7, Peral et al., 1996; 8 Rossetti et 
al., 2002; 9 Thomas et al., 1999; 10 Rossetti et al., 1996; 11 Reiterová y col., 2002; 12   ; 13 Inove et al., 2002; 14 
Perrichot et al., 1999; 15 Bogdanova et al., 2001; 16 Watnick et al., 1998; 17 Perrichot te al., 2000; 19 Aguiarri et al., 
2000; 20 Bateman et al., 1999 
 
 
R1340W (PKD repeat 7) was previously characterized to be a non-conservative missense 
change demonstrating segregation with the disease (Rosseti et al., 2002). It is very unlikely to be 
responsible of the disease for many reasons, because it is present in 3 patients, all of them were 
associated with another novel missense change fully conserved and predicted to be highly pathogenic. 
On the other hand, it is possible that changes like this could work as modifiers, been responsible of the 
intrafamilial variability. 
3.3.3. PKD1 and PKD2 polymorphisms. 
There was an impressive degree of sequence variability, particularly in the PKD1 gene, among 
patients in the study sample. In addition to the sequence alterations described in previously, we also 
detected a large number of polymorphisms (Table 11). Polymorphisms were defined as 1) sequence 
variants not predicted to alter an amino acid 2) Missense changes found in homozygosity in at least 
one patient and 3) intronic sequences of unknown significance and 4) Changes in the 3’ UTR of 
unknown significance. 
On average, the 82 study participants had 13.1 PKD1 sequence variants per patient with a 
range of 0 to 60. In contrast there was an average of only 1.1 PKD2 variants per patient with a range of 
0-3. A total of 112 Silent and intronic variants were found in PKD1, 4 in the 5´UTR, 33 intronic 
changes, 74 in the coding sequence and 1 in the 3´UTR. In PKD2, 4 were found in the coding 
sequence and 2 in the non-coding region (Table 11). These changes are not only important for a 
.          Polycystic Kidney Disease. From the clinical/genetic test, through in vitro and in vivo analysis, and back to humans 
   49 
clinical perspective (intragenic modifiers), also they have an enormous value in the understanding of 
the structure, behavior and evolution of these genes  
 
# Designation cDNA Change (s) Location Domain Frequency (%) Reference 
PKD1 Polymorphisms.     
1 T263S(H) 1004C>T Exon 5   2/164  NOVEL 
2 P572S(H) 1925C>T Exon 8   4/164  NOVEL 
3 M1092T(H) 3486T>C Exon 14 PKD R4 30/164 8 
4 W1399R(H) 4406T>G Exon 15 PKD R8 22/164 16 
5 V1943I(H) 6038G>A Exon 15 PKD R14 5/164 NOVEL 
6 E2548Q(H) 7853G>C Exon 19 REJ 4/164  NOVEL 
7 H2638R(H) 8124A>G Exon 21 REJ 32/164 NOVEL 
8 P2674S(H) 8231C>T Exon 21 REJ 2/164  3 
9 F3066L (H) 9407T>C Exon 25   38/164 NOVEL 
10 V3408L(H) 10433G>C Exon 33   5/164 NOVEL 
11 A3511V(H) 10743C>T Exon 35   13/164 NOVEL 
12 I4044V(H) 12341A>G Exon 44 TM10 42/164 3, 17, 18, 14,10 
13 A4058V(H) 12386C>T Exon 45   12/164  10 
14   104C>T Exon 1  5´UTR 1/164  Novel 
15   145C>T Exon 1   5´UTR 2/164  Novel 
16   160C>T Exon 1   5´UTR 1/164  Novel 
17   210C>T Exon 1   5´UTR 1/164  Novel 
18 L72L 425C>T Exon 1 LRR1 2/164  Novel 
19 G109G 538A>T Exon 3 LRR2 1/164  Novel 
20 IVS4+1G>A(H)   Intron 4   1/164  Novel 
21 S196S 799C>T Exon 5   2/164  Novel 
22 A341A 1234C>T Exon 5 PKD R1 5/164   3 
23 L373L(H) 1330T>C Exon 5   36/164  3, 15 
24 G441G 1534G>A Exon 6 C-LECTIN 1/164  Novel 
25 H570H 1921C>T Exon 8   1/164  3 
26 IVS9+2del7   Intron 9   12/164  Novel 
27 IVS9+2 T>A   Intron 9   1/164   Novel 
28 IVS9+28del7 (H)   Intron 9   4/164 8 
29 ISV9-44G>C   Intron 9   1/164  8 
30 IVS9-4A>G   Intron 9   42/164  8 
31 IVS10-4 G>A   Intron 10   1/164  Novel 
32 P738P(H) 2425C>G Exon 11   4/164  Novel 
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33 A745A 2448C>G Exon 11   1/164  Novel 
34 A898A 2905A>C Exon 11 PKD R2 4/164  9 
35 P900P 2911G>A Exon 11 PKD R2 10/164  16, 9 
36 D910D 2941C>T Exon 11 PKD R2 10/164  16, 9 
37 IVS11-5C>T   Intron 11   2/164  8 
38 IVS11+23C>T(H)   Intron 11   4/164  Novel 
39 IVS12-15C>T   Intron 12   5/164  Novel 
40 G1021G(H) 3274T>C Exon 13 PKD R4 30/164  16, 9 
41 L1037L 3392A>G Exon 13 PKD R4 15/164   9 
42 E1061E 3394G>A Exon 14 PKD R4 1/164   Novel 
43 P1076P 3439G>A Exon 14 PKD R4 1/164  Novel 
44 A1124A 3583C>T Exon 15 PKD R4 25/164  9 
45 S1125S 3586C>T Exon 15 PKD R5 25/164  9 
46 F1163F 3700C>T Exon 15 PKD R5 1/164  Novel 
47 T1171T 3724C>G Exon 15 PKD R5 1/164  Novel 
48 D1310D 4141C>T Exon 15 PKD R7 1/164  Novel 
49 L1357L 4282G>T Exon 15 PKD R7 1/164  Novel 
50 S1373S 4330C>T Exon 15 PKD R7 1/164  Novel 
51 S1452S 4567T>C Exon 15 PKD R8 1/164  Novel 
52 P1511P 4744G>A Exon 15 PKD R9 1/164   Novel 
53 A1555A(H) 4876A>C Exon 15 Extracellular 42/164   16, 1, 9 
54 T1558T 4885G>A Exon 15 Extracellular 9/164 2 
55 S1603S 5020C>T Exon 15 Extracellular 1/164  Novel 
56 T1724T(H) 5383C>T Exon 15 PKD R12 40/164 9 
57 A1818A(H) 5665G>A Exon 15 PKD R13 5/164  8 
58 G1860G 5791C>A Exon 15 PKD R13 1/164  Novel 
59 A1894A 5893C>T Exon 15 PKD R14 1/164  8 
60 L1921L 5974G>A Exon 15 PKD R14 2/164  9 
61 V2026V 6289C>T Exon 15 PKD R15 1/164  Novel 
62 R2121R 6574C>T Exon 15 PKD R16 1/164  Novel 
63 T2180T 6751C>T Exon 15 REJ 1/164  Novel 
64 A2202A 6817G>A Exon 15 REJ 1/164  Novel 
65 V2257V 6982G>A Exon 15 REJ 1/164  Novel 
66 IVS16+10 G>A   Intron 16 REJ 1/164  Novel 
67 R2359R 7289G>C Exon 17 REJ 3/164  Novel 
68 L2389L(H) 7376T>C Exon 17 REJ 46/164  1, 2, 9. 
69 G2425G 7486C>T Exon 18 REJ 1/164  Novel 
70 L2481L(H) 7652C>T Exon 18 REJ 39/164   1 
71 IVS19+24 C>A   Intron 19 REJ 2/164  Novel 
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72 L2570L(H) 7919T>C Exon 20 REJ 31/164  1, 9 
73 IVS20+ C>A   Intron20 REJ 1/164  Novel 
74 ISV20-16C>G   Intron20 REJ 2/164  Novel 
75 IVS22+8G>A (H)   Intron 22 REJ 1/164  1 
76 S2729S 8398G>A Exon 23 REJ 2/164  Novel 
77 A2749A 8458G>A Exon 23 REJ 1/164  Novel 
78 S2766S 8509C>T Exon 23 REJ 1/164  13 
79 D2789D 8578C>T Exon 23 REJ 2/164  Novel 
80 S2813S 8650C>T Exon 23 REJ 2/164   3 
81 S2893S 8890C>G Exon 23   2/164  3 
82 A2971A(H) 9124T>C Exon 24   2/164  Novel 
83 IVS24-20G>A (H)   Intron 24   3/164  Novel 
84 IVS24-17A>G(H)   Intron 24   6/164   Novel 
85 IVS24+17A>G   Intron 24   32/164  Novel 
86 S3007S 9232C>T Exon 25   1/164  Novel 
87 V3065V(H) 9406G>C Exon 25   38/164  Novel 
88 V3090V 9481C>T Exon 26 TM1 3/164  Novel 
89 P3110P(H) 9543T>C Exon 26   37/164   6 
90 IVS26+76C>A   Intron26   1/164  Novel 
91 IVS27-13T>C(H)   Intron27   15/164   8 
92 T3223T 9880G>A Exon 28 PLAT 2/164  6 
93 S3265S 10006C>T Exon 29   1/164  Novel 
94 IVS29-4 C>T   Intron29   1/164  Novel 
95 A3455A 10576C>T Exon 34   1/164  Novel 
96 L3589L 10976C>T Exon 36 TM5 5/164  Novel 
97 IVS37-4 C>T   Intron 37   1/164  Novel 
98 IVS37-10 C>A   Intron 37   1/164  Novel 
99 IVS38+11G>A   Intron 38   4/164  Novel 
100 R3752R 11385C>A Exon 39 Polycystin motif 1/164  Novel 
101 L3753L 11465G>C Exon 39 Polycystin motif 1/164  Novel 
102 IVS39- 72   Intron 39   1/164   Novel 
103 IVS41+ C>T   Intron 41   1/164  Novel 
104 IVS41+5insGGG   Intron 41   2/164  Novel 
105 IVS41-11C>T C>T Intron 41   2/164   Novel 
106 S3893S(H) 11890C>T Exon 42   3/164  8 
107 IVS43+42C>A   Intron 43   6/164  Novel 
108 R3971R 12124C>T Exon 43   3/164  Novel 
109 L4025L 12286C>T Exon 44   1/164  Novel 
110 L4035L 12316C>T Exon 44 TM10 1/164  Novel 
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111 IVS44+22delG   Intron44   4/164  Novel 
PKD2 Polymorphisms.     
1 R28P 149CxT Exon 1  50/176 (28.40) 10 
2 R60R 246GxA Exon 1  1/176 (0.56) Novel 
3 G140G 486GxA Exon 1  22/176 (12.5) Novel 
4 IVS6-4 C-T  Intron 6  1/176 (0.56) Novel 
5 L539L 1683GxC Exon 7  1/176 (0.56) Novel 
6 IVS8+5 G-A  Intron 8  1/176 (0.56) Novel 
Table 11. Amino Acid Substitutions. Ref: N. Novel.; 1 Watnick et al., 1999; 2 Phakdeekitcharoen et al., 2000; 3 
Rossetti et al., 2001; 4 Peral et al., 1997; 5 Veldhuisen et al., 1997; 6 Peral et al., 1998; 7, Peral et al., 1996; 8 Rossetti et 
al., 2002; 9 Thomas et al., 1999; 10 Rossetti et al., 1996; 11 Reiterová y col., 2002; 12   ; 13 Inove et al., 2002; 14 
Perrichot et al., 1999; 15 Bogdanova et al., 2001; 16 Watnick et al., 1998; 17 Perrichot te al., 2000; 19 Aguiarri et al., 
2000; 20 Bateman et al., 1999 
 
3.3.4. Mutational analysis using in vitro systems.  
This aim was not initially proposed in this thesis. For a clinical point of view, it was imperative 
that missense changes and deletions inframe with uncertainty significance were subjected to further 
screening. Based on our analysis of pathogenicity, we knew which of the missense changes almost 
certainly had to be pathogenic. Nonetheless, in many cases it was unclear how the substitutions might 
alter function. In vitro systems not only can be used as a complementary study to test protein function, 
also can determine how this is altered by mutations (Qian et al., 2002).  
We propose this tool as a complement to distinguish between polymorphism and mutations, as 
well as to assess the effects of various sequence variants like missense and deletion inframe. One 
example it is, if cleavage of polycystin-1 is important for its function, then one might predict that 
pathologic mutations affecting the sequence at or near the GPS would disrupt this process and (Figure 
19A). A few mutations have been localized within the REJ domain (Figure 19B). Included in this set 
are nine germline missense mutations (Q3016R, L2993P, and E2771K), a de novo missense mutation 
(H2921P), an acquired somatic missense mutation (F2853S), an inframe deletion (6868-5aaDel), a 
nonsense stop codon (E3020X), and two generated mutations predicted to affect the cleavage (L3048F 
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and LT3048-9FS). Each of the 
residues was conserved, relative to its 
position amongst various species and 
they were characterized as highly 
pathogenic changes.  
Therefore, we generated a 
series of expression constructs 
bearing the mutations and tested for 
the effect of each substitution on 
cleavage. We found that Q3016R, 
L2993P, H2921P, F2853S, and 
E2771K mutations almost completely 
inhibited cleavage (Qian et al., 
2002). 6868-5aaDel, L3048F and 
LT3048-9FS partially inhibited 
cleavage, and E3020X did not 
generate a stable protein (Fig. 19C). 
As expected, four polymorphisms 
(F3064L, E2996D, R2791Q and 
R2985) in the same region  were did 
not affect the cleavage pattern. 
3.3.5. Intra- and intergenic analysis. 
A total number of 224 different changes in PKD1 and 21 in PKD2 have been found along both 
genes by the PKDX test (Figure 15). We observed an extraordinarily high level of variability in the 
Figure 15. In vitro system for characterization of human  
mutations. A) A schematic diagram of the domain organization of 
polycystin-1. SP, signal peptide; R1 and R2–16, PKD repeats; 
CLD, C-type lectin domain. The cleavage site with the adjacent 
sequence is represented at right. A black bar indicates epitopes 
recognized by the antibodies used in this study. The positions of 
Flag-epitope and the GFP-tag are indicated. WT encodes FL 
polycystin-1 with a Flag-epitope, whereas GFP-WT has both a 
GFP-tag and a Flag-tag (Qian et al., 2002). B) Schematic 
structures of nine disease-associated mutant forms of polycystin-1 
and four normal variants. An arrowhead marks the relative 
position of the substitution in each protein. ‘‘MUT’’ identifies 
disease-associated mutations and ‘‘POLY’’ identifies 
polymorphic variants. C) Immunoblots probed with antisera that 
recognize C-terminus (top) and N-terminus (bottom). FL=full 
length product, CTF=160KDa cleavage product, NTF= 400KDa 
cleavage product. The asterisk indicates an additional band of 
uncertain nature. 
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PKD1 gene, with a mean of 13.04 genetic variants per patient for PKD1 (range 0-60) and 0.92 genetic 
variants per patient for PKD2 (range 0-3) (Table 7).  
One of our aims was to understand the mechanisms involved in PKD1 and PKD2 mutagenesis. 
In order to study the mutagenesis rate in both genes, it has been generated a table assigning specific 
codes to the different categories according to the type of change, pathogenicity, and conservation. 
Using this code classification (Table 12), each 4302 amino acids of PKD1 and 969 of PKD2 for every 
single patient of all 82 included in this study was categorized with a code number, generating a table of 
Figure 16.  Diagram showing the mutations detected in the screening of the PKD1 (A) and PKD1 
genes (B). Red color shows the definitive mutations, green the missense changes and the numbers represent the 
polymorphisms shown in table 11.  
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432,333 independent amino acid codes We performed several analyses using this table arranging the 
study into three main parts: We performed several analyses arranging the study into three main parts: 
• Intragenic analysis of PKD1. 
• Intragenic analysis of PKD2 
• Mutagenesis rate of PKD1 and PKD2. 
Change Type Pathogenicity Conservation Heterozygous Homomozigous 
None       0 0 
Definitive Mutation Stop Codon     11 110 
Definitive Mutation Insertion      12 120 
Definitive Mutation Deletion     13 130 
Deletion inframe     Fully 21 210 
Deletion inframe     Highly 22 220 
Deletion inframe     No 23 230 
Amino acid change Missense Patogenic higher Fully 311 3110 
Amino acid change Missense Patogenic higher Highly 312 3120 
Amino acid change Missense Patogenic higher No 313 3130 
Amino acid change Missense Equal Fully 321 3210 
Amino acid change Missense Equal Highly 322 3220 
Amino acid change Missense Equal No 323 3230 
Amino acid change Missense Polymorphism Higher Fully 331 3310 
Amino acid change Missense Polymorphism Higher Highly 332 3320 
Amino acid change Missense Polymorphism Higher No 333 3330 
Amino acid change Unclassified Patogenic higher Fully 341 3410 
Amino acid change Unclassified Patogenic higher Highly 342 3420 
Amino acid change Unclassified Patogenic higher No 343 3430 
Amino acid change Unclassified Equal Fully 351 3510 
Amino acid change Unclassified Equal Highly 352 3520 
Amino acid change Unclassified Equal No 353 3530 
Amino acid change Unclassified Polymorphism Higher Fully 361 3610 
Amino acid change Unclassified Polymorphism Higher Highly 362 3620 
Amino acid change Unclassified Polymorphism Higher No 363 3630 
Amino acid change Polymorphism Patogenic higher Fully 371 3710 
Amino acid change Polymorphism Patogenic higher Highly 372 3720 
Amino acid change Polymorphism Patogenic higher No 373 3730 
Amino acid change Polymorphism Equal Fully 381 3810 
Amino acid change Polymorphism Equal Highly 382 3820 
Amino acid change Polymorphism Equal No 383 3830 
Amino acid change Polymorphism Polymorphism Higher Fully 391 3910 
Amino acid change Polymorphism Polymorphism Higher Highly 392 3920 
Amino acid change Polymorphism Polymorphism Higher No 393 3930 
Polymorphism       4 40 
Table 12. Codes assigned to the different type of mutations. 
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3.3.5.A. Intragenic analysis of PKD1  
For this purpose, the rate of 
mutagenesis in each exon of PKD1 
was calculated for changes 
grouped in two categories: 
• A first group that includes 
definitive mutations, deletions 
in frame and missense and 
highly pathogenic changes 
(Figure 16A). 
• And a second group which 
includes all changes (Figure 
16B). 
Exons were arranged along 
the x-axis and the rate of 
mutagenesis per 100 amino acids 
on the y-axis. For each exon, the 
rate is estimated with a 95% 
confidence interval. There is a 
“reference” line showing the 
‘median’ rate. That is, if there were 
no association between exon and mutagenesis, based on the overall rate of the mutagenesis, the 
reference rate is what we would expect to see. Therefore, exons that have high rates with 95% 
Figure 17.  Mutability behavior of PKD1. A) Mutational rate for 
mutations (stop codons, frameshift and splicing, deletions inframe and 
highly pathogenic missense) and for all type of changes (B). 
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confidence intervals that do not overlap the reference line are associated with statistically significantly 
increased rates of mutagenesis. Using this information, we could determine the rate of mutagenesis per 
exon in each gene and find possible mutagenic patterns. 
Figure 16A shows a cluster of amino acid changes: definitive mutations (frameshift mutation, 
stop codons and splicing variants), mutations probably associated to the disease (deletions inframe and 
missense changes) and any changes consider highly pathogenic in the replicated region of PKD1 
(exons 1-32). It also indicates an extremely high rate of mutagenesis for disease associated changes in 
exon 21, suggesting a mutagenic effect of the polypirimidine tract located in intron 21 into the 
surrounded areas. When we consider every single type of change in this analysis, high rate mutability 
appears to be also in an area surrounding exon 21, approximately between exon 13 to exon 26, 
supporting the previous hypothesis (Figure 16B).  
A substantial fraction of the variants present in PKD1 were also found in the homologues, 
suggesting the possibility of gene conversion between the homologues and the replicated region of 
PKD1 (Watnick et al., 1998). To verify that this mechanism of mutagenesis is involved, we compared 
the rates of mutagenesis of the replicated region (exons 1 to 32) versus the non-replicated region 
(exons 33 to 46). The IRRs represent the incidence rate in exons 1 to 32 divided by the incidence rate 
in exons 33 to 46. Therefore, IRRs greater than one suggest that exons 1 to 32 have increased 
mutagenesis as compared to exons 33 to 46, and IRRs less than one suggest that exons 33 to 46 have 
increased mutagenesis as compared to exons 1 to 32. There does not appear to be a difference in the 
rate of mutagenesis comparing exons 1-32 and 33-46 for all changes. The interesting thing is the 
comparison of a) definitive mutations only; b) definitive mutations, deletions in frame, and missense; 
c) and definitive mutations, deletions in frame, missense and highly pathogenic changes show clear 
evidence that the replicated region (exons 1-32) has a higher rate of mutagenesis than the non-
replicated region (Table 13). 
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When only definitive mutations were analyzed, the IRR is somewhat higher than when we 
compare definitive mutations, deletions in frame, missense; definitive mutations, deletions in frame, 
missense and highly pathogenic (missense and unclassified), but it does not achieve statistical 
significance probably because the mutagenesis thought gene conversion is not the only phenomenon 
implicated in the highly mutagenic rate of PKD1. 
Type of amino acid change IRR 95% confidence 
interval 
p-value 
Definitive mutations only 2.76 0.64, 12.0 0.17 
Definitive mutations, deletions in frame, and missense 2.50 1.09, 5.74 0.03 
Definitive mutations, deletions in frame and missense and higher pathogenic (missense and 
unclassified) 
2.52 1.06, 5.99 0.04 
Definitive mutations, deletions in frame and missense and higher pathogenic (missense, 
unclassified, and polymorphisms) 
5.07 2.15, 12.0 <0.001 
All changes 0.97 0.80, 1.19 0.79 
Table 13. Mutagenesis of the non-replicated vs. replicated region of PKD1. 
 
As we mention in the introduction of this Thesis, there are three possible hypothetic 
mechanisms involved in the high mutagenic rate of the PKD1 gene: 
• Gene conversion between homologues and the replicated region of PKD1. 
• Its highly GC-rich content with a large number of CpG dinucleotides, known as hot 
spots for C-T transitions. 
• Influence of the Polypyrimidine tract present in intron 21. 
This data shows the first strong statistical evidence that PKD1 homologues (Figure 16A) and 
the polypyrimidine tract (Figure 16A-B) are the major phenomenons responsible of the high mutagenic 
rate in the PKD1 gene. To test whether GC-rich regions and CpG dinucleotides are involved in PKD1 
mutagenesis, a depth analysis of the gene structure also has been developed. 
Table 14 compares the nucleotide content of the human and mouse PKD1 gene and cDNA, 
showing that the human PKD1 gene and cDNA have 10% more of the GC content (GC%) and a higher 
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CpG dinucleotides content than the mouse genomic and cDNA. On the other hand, PKD2 does not 
show this difference between human and mouse (Table 14). It has been shown that only 8-10% of the 
Pkd1 knockout mice develop renal cyst. The difference in the mice Pkd1 gene structure (with only one 
small polypyrimidine tract and the absence of homologues), in the CG% and in the CpG dinucleotides 
content could explain why humans have higher mutation rate and greater “second hits” in comparison 
to mice. 
However, a deep analysis of the gene structure has been develop to investigate whether the 
GC% or the large number of CpG dinucleotides are directly associated to the high mutation rate of 
PKD1. In the mutation database of the 82 families, CxT changes (PKD1, 40.2% and PKD2, 46.1%) 
and GxA changes (PKD1, 16.7 % and PKD2, 38.4%) were the most abundant (Table 15A). 52 of the 
211 individual changes were located in CpG dinucleotides, but only three of these were mutations 
associated to the disease (Table 15B).  
The analysis of GC% and CpG content in the full length PKD1 coding sequence was also done 
(Figure 17), to determine if there is a mutational pattern associated to any of these mutagenic 
mechanisms. It was observed an increase of the GC% in the coding sequence of PKD1. Surprisingly, 
exon 3 has the lowest GC% but it has one of the highest mutagenic rates (Figure 15A).  
 PKD1 PKD2 
 gDNA cDNA cDNA 
 Human Mouse Human Mouse Human Mouse 
C 17664 11942 4828 4078 1075 1132 
G 15766 11721 4643 3947 1193 1350 
A 8486 12675 2148 2830 1398 1306 
T 11606 10302 2520 3286 1407 1346 
%GC 62.5 50.7 66.9 56-7 44.7 48.3 
CpG 2114 594 908 300 155 167 
Table 14. GC% and CpG content of Human and mouse PKD1 gene and cDNA. 
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B) A) 
On the other hand, exons 1 and 42 have the highest GC% and CpG content in addition to the 
lowest mutational rate. To determine if CpG dinucleotides are surrounded by rich CG% areas and if 
 
 
 
 
 
Table 15. Nature of the PKD1 and PKD2 
changes. A) CxT and GxA are the most 
common type of change found in ADPKD 
genes. B) 52 changes where linked to CpG 
dinucleotides.  
Figure 18. GC% and CpG content of human PKD1 gene. A) GC% rate per exon B) CpG dinucleotides 
content per exon. C) CpG dinucleotides in GC, normalized by exon. 
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they are associated with highly mutagenic rate exons, the ratio of CpG to GC% was taken. 
Unfortunately, we did not find any significant evidence that these two mechanisms are directly 
implicated into the highly mutagenic rate of PKD1 gene. We cannot exclude that probably are 
responsible of some mutations. 
3.3.5.B. Intragenic analysis of PKD2  
The PKD2 gene has a lower mutagenic 
rate per exon. This is especially evident in 
exon 21 of PKD1 which has the highest 
mutagenic rate of 0.7, while the highest 
mutagenic rate of PKD2 is only 0.23 in exon 
1. The majority of the exons for PKD2 also 
have rate of 0. This results in the 
improvement of the overall mutagenic rate of 
exons that have a rate grater than 0 based on 
the standard normalization (Figure 18). In 
addition, unlike PKD1, PKD2 presents 
recurrent definitive mutations in exons 4, 11, 
and 14 with recurrent polymorphisms in exon 
1. This recurrence evolutionally conserved 
could explain the higher mutagenic rate of 
these exons compare to the ones with rates 
equal to zero. However when the founder 
effect is taken into account and the recurrent 
Figure 19. Mutability behavior of PKD2. A) Mutational 
rate per exon (stop codons, frameshift and splicing, 
deletions inframe and highly pathogenic missense) and for 
all type of changes (B). 
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mutation is actually considered to be unique, then the mutagenic rate would more accurately be closer 
to the base line.  
3.3.4.C. Mutagenesis rate of PKD1 and PKD2. 
The quantity that is used to evaluate the rate of mutagenesis is the “incidence rate ratio” (IRR), 
which is a ratio of the mutagenic rate in PKD1 to PKD2 (Table 16). An IRR greater than one indicates 
that the rate of mutagenesis in PKD1 is higher than in PKD2, an IRR less than one indicates that the 
rate of mutagenesis in PKD2 is higher than in PKD1, and an IRR of exactly 1 indicates that the rate of 
mutagenesis in PKD1 and PKD2 are equal.  The table 16 provides the IRR for each group of changes 
and their 95% confidence intervals (i.e. a range of values, which we are 95% certain, contains the 
“true” IRR).  The p-value tests the hypothesis that the true IRR is equal to 1.  Observation of “all the 
changes” result in a p-value of <0.001. This means that if the IRR comparing mutagenesis in PKD1 to 
PKD2 truly is equal to 1, then the chance of observing a result as extreme as we observed (i.e. an IRR 
of 5.89) is less than 1 in 1000. Therefore, it is highly unlikely that the true IRR is equal to 1. 
Group of changes IRR 95% confidence 
interval 
p-
value 
Definitive mutations only 1.36 0.62, 2.97 0.45 
Definitive mutations, deletions in frame, and missense 2.79 1.47, 5.27 0.002 
Definitive mutations, deletions in frame and missense and higher pathogenic (missense and 
unclassified) 
3.27 1.74, 6.15 <0.001 
Definitive mutations, deletions in frame and missense and higher pathogenic (missense, 
unclassified, and polymorphisms) 
1.57 1.16, 2.13 0.004 
All changes 5.89 4.60, 7.53 <0.001 
Table 16. Mutagenic rate of PKD1 vs. PKD2 
 
The IRR was, for all types of variant groups, greater that 1, indicating that PKD1 is suitable to 
more mutation phenomenons than PKD2. One interesting phenomenon is that PKD2 shows similar 
provability to get a definitive mutation than PKD1, but significant less probability to get other type of 
mutation. That suggest than PKD2 has less plasticity than PKD1, and for this reason PKD1 needs more 
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hits to affect its function. As table 16 shows, PKD1 is approximately six times (IRR= 5.89) more 
mutable than PKD2.  
3.4. Discussion. 
Given the age dependent manifestation, the potential for genotype/phenotype correlations and 
pre-symptomatic testing, there has been much interest in developing reliable techniques for DNA 
diagnosis in ADPKD (Hannig VL et al, 1991, Phakdeekitcharoen B et al., 2001). Pre-symptomatic 
testing, for example, may be relevant in a variety of clinical circumstances including the evaluation of 
living donors from ADPKD families, younger individuals or for those from PKD2 families who have a 
milder disease. Moreover, unilateral nephrectomy in an individual at 50% risk of inheriting ADPKD 
may demand a higher level of certainty with respect to diagnosis since the consequence of 
uninephrectomy in an individual with ADPKD could lead to more rapid disease progression. 
Genetic testing for ADPKD has posed a unique set of challenges in terms of DNA diagnostics. 
PKD1 analysis in particular has been complicated because the 5’ portion of the gene (exons 1-34) is 
replicated in at least five highly homologous copies (<2% divergence) on chromosome 16. Several 
groups were finally able to analyze the PKD1 sequence by using gene-specific primers to amplify 
large products that can then be screened via nested PCR (Watnick et al., 1997, Peral et al., 1996, 
Roelfsema et al., 1997 Badenas et al., 1999, Thomas et al., 1999, Watnick et al., 1999 Rossetti et al., 
2001 Rossetti et al., 2002) Although some investigators have reported the use of denaturing high-
performance liquid chromatography (DHPLC) to screen nested PCR products for mutations, 
unfortunately this strategy was not cost effective for clinical sample analysis (Rossetti., 2002). The 
main reason for this is that PKD1 has a high rate of DNA variants, genetic and allelic heterogeneity, 
large gene size, and an absence of mutational hot spots at both genes, which has complicated the use of 
this method as a definitive test for mutational identification and potential genotype/phenotype 
correlations. 
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The establishment of a rational strategy to screen the entire coding region for both genes based 
on directed sequencing will reduce the efforts and costs in the study of ADPKD families. Watnick et 
al. have developed methods that could be broadly applied to the community for both research and 
clinical diagnostic purposes exploiting our knowledge about the sequence of PKD1, its homologues, 
and our experience in the use of long-range (LR) PCR. We applied the LR technology to the PKD1 
study and then progressively refined the primer pair combinations/anchor points so that “less-optimal” 
sources of DNA could also be use for testing. Our approach has since been widely embraced and has 
now formed the basis for the only PKD DNA test used in clinical practice (PKDX). We have worked 
closely with Athena Diagnostics to help translate our research-based methods into a useful clinical 
tool. This is the first transfer of gene discovery results to clinical practice for this disorder. There are a 
number of circumstances where it can be potentially very helpful (diagnostic uncertainties, pre-
symptomatic evaluations in at-risk young adults, donor testing for living-related transplants, etc). The 
currently available DNA test offered by Athena Diagnostics (PKDX) involves direct-DNA sequencing 
of the entire coding regions of both PKD1 and PKD2.  
In order to test the sensitivity of PKDX, we submitted blood samples from 82 patients with 
clinical ADPKD to Athena Diagnostics for DNA testing. It has been found mutations distributed along 
the PKD1 and PKD2 genes with a detection rate around 83%, the highest until now. Using strict 
criteria, we were able to identify pathogenic mutations, defined as truncating mutations, splice site 
mutations, inframe insertions and deletions, in 51.3% of the patients tested. A substantial fraction of 
PKD mutations (31.7%) were missense changes that may be difficult to interpret in isolated samples or 
in the absence of a more refined understanding of the domain architecture of PKD proteins. In 
addition, we found a remarkably high rate of sequence variability in the PKD1 gene with an average of 
13 genetic variants per patient (range 0-60), suggesting that PKDX is indeed highly sensitive, as 
predicted. Direct sequencing is the most sensitive method showed up to now of detecting DNA 
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variability in PKD1 and PKD2, but the need for strict interpretation of the results is essential if they 
are to be used for clinical decision-making. Complete analysis of both genes is especially important 
because there have been no mutational hot spots identified in either PKD1 or PKD2. For this purpose, 
a criteria have been established to predict the pathogenicity of amino acid substitutions and potential 
splice site alterations for each proband. 
The PKDX test has revealed a number of important observations: 
• Of all the mutations found in PKD1, many of them were consider truncating (54.6%) but 
a significant fraction appears to result in missense changes (45.4%).  
• On the other hand, almost all PKD2 mutations resulted in truncation of the protein 
(92.5%) many localized in 5´segments and thus unlikely to yield a stable PC2.  
• The majority of the PKD1 mutations are unique to the family in which they were found. 
In contrast, 2 novel mutations were recurrent in more than one PKD2 family (R306X in 
two families and R872X in three). 
• 75% of the changes implicating the alteration of an amino acid (truncating, splicing, in 
frame mutations and amino acid changes) found in both genes were novel. Interestingly, 
only a small fraction of silent changes (31.6%) were not described previously. The entire 
in frame mutations were novel. 
• While interfamilial variability may be explained in part by the position or nature of the 
germline mutation, intrafamilial variability is likely to be due to other genetic, 
environmental and stochastic factors. Several missense that were classified as “normal” 
or “undetermined” could play a important role in the variability found within the families 
linked to a unique mutation.  
.          Polycystic Kidney Disease. From the clinical/genetic test, through in vitro and in vivo analysis, and back to humans 
   66 
• We have identified a number of individuals with multiple missense changes but no 
definitive pathogenic mutation associated to the disease. It may be the case that, 
accumulation of this type of changes can compromise the plasticity shown by PKD1, 
resulting in a hypomorphic allele. 
• These data highlight the challenges of distinguishing between “normal” missense variants 
and those that are likely to be disease-associated. Many of the missense changes found 
were unique to the family in which they were discovered. In some of the cases, they could 
be excluded as mutations because they did not segregate with the disease. Frequently, 
however, we found that the variant either segregated with disease or could not be further 
tested because of insufficient family material. As an example, it has been found ADPKD 
families with one novel missense change that was not detected in more than 164 
chromosomes, but did not follow our criteria of classification of missense disease 
associated. This has several important implications: 1) DNA testing alone may not be 
able to provide definitive diagnosis in the setting of “private missense changes”; 2) 
further investigation and better tools are needed to evaluate the functional consequences 
of such missense changed.  
• To solve this inconvenience, in vitro systems have been proposed to both study PC1 
function and to determine how it is altered by disease-associated variants. While this part 
of the thesis was not originally proposed in the initial set of aims, the large number of 
missense changes with uncertain significance that have been identified, made it 
imperative that we tackle this problem. We knew that some of the missense changes 
almost certainly had to be pathogenic since they were discovered as either de novo or 
acquired mutations. In vitro system was used to evaluate putative mutations and 
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polymorphisms of the REJ domain. These results have several important implications: 1) 
we have shown that in vitro tools can be used to distinguish between polymorphisms and 
mutations; 2) We can use these systems to asses the effects of various PKD1 sequence 
variants. 
The data given by the direct sequencing of the entire PKD1 and PKD2 coding region has been 
proved to be a very powerful for a better understanding of both genes. After a comprehensive analysis 
of all changes through strict criteria, it has been established different approaches to analyze the 
different phenomenons implicated in the mutagenesis of both genes. It has been develop a statistical 
method based on a specific code classification for each amino acid of both genes per each individual. 
This code classification differentiates the unchanged amino acids from the ones that have suffer a 
change, taking in consideration the type of change (truncation, inframe, missense, polymorphism,…) 
and its zygote status (homozygous or heterozygous). Using this method, it has been tested different 
hypothesis proposed previously by other authors: 
• Watnick et al. (1998) proposed the gene conversion between duplicated region of PKD1 
(exons 1 to 34) and its homologues as a mechanism in the mutagenesis of this gene. They 
found that a substantial fraction of the variants were present in PKD1 are also found in 
the homologues. It has been found changes all along of PKD1. The application of his 
statistical method proved that the duplicated region of PKD1 is 5.07 times more suitable 
to changes disease associated than the non-duplicated region, suggesting the influence of 
a none random mechanism of mutagenesis in this region. Combining the application of 
this method and Watnick et al. findings, it can be concluded that the high rate of disease 
associated changes located in the duplicated region of PKD1 is due to the gene 
conversion with its homologues. 
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• The American PKD1 consortium (1995) and Qian et al., (1996) reported an extremely 
unusual 2.5 kb polypyrimidine tract within intron 21 that may be responsible for the 
PKD1 increased rate of mutation. It has been suggested that this 2.5 Kb polypyrimidine 
tract, the longest found in humans, can form intramolecular triplex structures, 
predisposing to mutation and loss of function (Blaszak et al., 1999). These hypotheses 
have been tested through a systematic analysis of all type of variants along both genes, 
founding a highly mutagenic area in the surrounded region of intron 21, near the 
polypyrimidine tract. Interestingly, we also observed the highest mutagenic rate of PKD1 
in exon 21. 
• Two other mutation mechanisms hypothetically related to the high mutation rated of 
PKD1 are the influence of the GC% and CpG sites. It has not been found robust date that 
supports these hypotheses with the statistical method, but, it suggested the possible 
association of the CG% to areas of high mutational rate. The implication of mutational 
mechanism associated to the CpG site was less obvious, with 3 disease associated 
mutations found in a CpG site. No definitive data was found for definitively confirm 
these hypotheses. 
• A new mutation mechanism has been associated with the high mutation rate of PKD1. It 
has been proved that symmetric elements along the genomic sequence of PKD1 were hot 
spots for all frameshift mutations (deletions and insertions) found in the 82 individuals, 
and in 76% of the frameshift mutations previously reported. This phenomenon has been 
related with mutagenesis in other genes, but it is the first time that has been related to the 
mutagenesis of a PKD gene. Deletion breakpoint junction regions were found to be non-
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random both at the nucleotide sequence levels, an observation consistent with an 
endogenous sequence-directed mechanism of mutagenesis (Krawczak et al., 1991). 
Also, it has been provided experimental evidence that PKD1 is highly mutable. Comparing 
PKD1 and PKD2 genes through statistical method, it has been shown that PKD1 is ~6 times more 
mutable than PKD2. In one striking example, we found one individual who had 60 PKD1 variants and 
only 1 PKD2 polymorphism. Another observation is that while PKD1 did not show major recurrent 
mutations, PKD2 showed recurrence in some individuals. We also have observed that there are 
individuals who tend to have many changes while there are others who have very few. One potential 
explanation is that certain haplotypes might be more mutable. Given the high mutability of PKD1, we 
suggest that the prevalence of individual mutations in evolution will increase, resulting in a greater 
frequency of more than one mutational event directly associated with disease severity per patient. 
When PKD2 suffer a mutational event, in most of the cases, result in a change disease associated. On 
other hand, PKD1 need more hits to really cause a disease associated mutation, showing the high 
plasticity of this gene 
In this part of the thesis, it has been introduce the only clinical test (PKDX, Athena 
Diagnostics) offered for diagnosis of ADPKD patients. It has been proved to be the most effective test 
describe up to now, with 83 % of detection rate. It has been established a critic criteria for 
classification of the changes found in the ADPKD genes. Also, it has been presented a novel approach 
for analysis of mutagenesis for the ADPKD genes based on statistical analysis, which can be applied 
for the analysis of other genes. Based on this method, it has been proved the implication of different 
mutagenic mechanisms involved in the PKD genes. 
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4 Conditional Inactivation of Murine PKD2 using a tri-allelic system (SUBPROJECT II). 
4.1. Abstract 
Homozygous inactivation of either murine Pkd1 or Pkd2 results in embryonic lethality, limiting 
the use of these models to study adult phenotypes. Several groups have made floxed alleles of Pkd1 
but since the function of Pkd1 and Pkd2 may not be entirely overlapping, a floxed allele of Pkd2 
would be a valuable tool. We generated mice with a loxP site in Pkd2 intron 10 and a loxP-FRT-
PGKneo-FRT cassette in intron 13 (Pkd2flox11-13). Cre-mediated recombination between the loxP sites 
was predicted to result in loss of the C-terminal tail of the protein, which mimics many disease-
associated mutations. We found that Pkd2cond behaved as a hypomorphic allele. Matings of Pkd2flox11-
13/+ heterozygotes yielded only 3/57 live homozygotes. However, when the neomycin cassette was 
deleted mice that were homozygous for the resulting Pkd2delneo allele were fully viable and fertile. 
Next, we bred Pkd2delneo mice with a Cre deleter strain to produce mice that carried a germ line 
deletion of exons 11-13 and we found that this allele (Pkd2Ko11-13) functioned as a true null. In order to 
determine whether Pkd2delNeo could be inactivated in vivo, we generated mice that were heterozygous 
for Pkd2Kol11-13 and Pkd2DelNeo in combination with a Meox-2 directed Cre recombinase. Since Meox-2 
Cre results in greater than 95% (somatic) deletion of floxed DNA segments, these mice die shortly 
after birth and have all the features of the classic Pkd2 null phenotype, including severe edema, renal 
cysts, pancreatic cysts, and randomization of left/right axis. This system has provided three new Pkd2 
alleles: a hypomorphic allele, a new knock-out allele that is predicted to lack the Pkd2 C-terminus, and 
a conditional allele that can be used to selectively inactivate Pkd2 in vivo. These models will provide a 
rich source of cells for in vitro inactivation of Pkd2. 
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4.2. Matherial and Methods. 
4.2.1 Generation of Pkd2cond targeting construct. 
The goal in this project was to develop a line of animals in which we could regulate the timing 
and location of a Pkd2 mutation. It has been engineered a targeting construct with two lox P sites 
flanking exons 11-13 along with an FRT-flanked neomycin cassette (gift of Dr. Gail Martin) inserted 
into intron 13 (Fig. 20A-C). Cre-mediated recombination between the lox P sites should result in the 
loss of exons 11-13 generating a frameshift with a premature termination codon early in exon 14. This 
change is similar to several truncating mutations that have been associated with the human disease. 
The targeting construct was entirely sequenced and then electroporated into 129SV/J stem cells.  
~230 clones were screened by Southern blot analysis and 21 legitimate targeting events were 
identified. Since the two lox P sites were separated by ~1.5 kb, it has been predicted that the proximal 
site would be lost in a subset of the clones after the homologous recombination. This was assayed by 
PCR and as expected, all but three clones had lost the lox P site located in exon 11. Of these clones, 
one was injected into C57BL/6 blastocysts and obtained six highly chimeric (>95%, assayed by coat 
color) animals (four females and two males). The two male chimeras were bred to C57BL/6 females 
and the agouti animals were tested for germ line transmission of the floxed allele by Southern blot as 
demonstrated in Fig 20D. The blot demonstrates that four of the pups in this particular litter have germ 
line transmission of the floxed allele. PCR analysis confirmed the presence of both lox P sites  
4.2.2. Functional inactivation of the Pkd2cond allele. 
To test whether the deletion of exons 11-13 would result in a functional null allele (Pkd2Ko11-
13), heterozygous Pkd2cond (also called Pkd2flox11-13) F1 mice were bred with Meox-Cre transgenic mice 
to produce Pkd2flox11-13/+ male offspring that were also positive for the Meox-Cre transgene. Expression 
of the latter results in deletion of floxed DNA segments in >95% of the carrier’s germline (Tallquist et 
al., 2000). Thus, the majority of its offspring should have either the Pkd2+ or Pkd2del11-13 allele. Given 
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that the homozygous state for null mutations of Pkd1 results in embryonic lethality, we reasoned that 
Pkd2Ko11-13/ Ko11-13 heterozygotes also were unlikely to be viable. We tested this hypothesis by setting 
up a series of 10 crosses between Pkd2flox11-13/+; Meox2Cre/+ males and females to evaluate the 
pregnancies. 
Figure 20. Pkd2 Genomic map and Targeting contruct. A) Targeting construct is 11Kb in length and 
contains Lox P sites and a FRT-flanked neomycin cassette. B) Wild-type allele. C) Predicted restriction 
map after homologous recombination. Probes used to analyze stem cells and mice are shown. Arrows 
denote primers designed to assay Flp mediated detection of Pgk.Neo cassette and Cre mediated deletion 
of exons 11-13. D) Southern blots from offspring o chimeric animals. Tail DNA was digested with two 
restriction enzymes and probed with a 5´external probe (AfkII) or a 3´internal probe (BglII). Four pups 
(asterisks) have germ line transmission of the targeting construct. 
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4.2.3. Genotyping. 
Genomic DNA from mouse-tails was obtained as follows. In short, ~5mm long piece of the 
tails were digested in Proteinase K buffer (50 mM Tris pH 8.5, 1 mM EDTA, .5% Tween 20) at 60°C 
for about 2h with shaking. After inactivation of the enzyme at 99°C for 15min, 1µl of the solution was 
used for PCR genotyping with primer locations shown in Figure 21, and whose sequences are as 
follows:  
Primer a (MG-Pkd2loxp-F): CCT TTC CTC TGT GTT CTG GGG AG. 
Primer b (MG-Pkd2loxp-R): GTT TGA TGC TTA GCA GAT GAT GGC. 
Primer c (MG-Pkd2Pgk-F): GGG GTT TCC TAT GAA GAG TTC CAA G. 
Primer d (MG-Pkd2Pgk-R): CTG ACA GGC ACC TAC AGA ACA GTG. 
Primer e (MG-Pkd2PGKR2): GCC AGA GGC CAC TTG TGT AG. 
 
Figure 21. Pkd2 genotypes derived from the Pkd2Cond allele (Pkd2flox11-13). Schematic illustration of 
the Pkd1cond(PKD2flox11-13), Pkd2delNeo and Pkd2ko11-13 alleles and the positions of the primer pairs for 
the genotyping strategy. The predicted sizes for the various products are illustrated into the schematic 
gel drawing on the right. Different genotypes are shown as an example of PCR-based genotyping 
strategy. 
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4.2.4. Preparation for Histology. 
Kidney, liver, and pancreas specimens from adult animals were collected and immediately 
fixed in 10% buffered formalin at 4°C overnight. Embryos at different ages were fixed with ice-cold 
4% paraformaldehyde in PBS via cardiac perfusion of the mother and then kept in 4% 
paraformaldehyde overnight at 4°C. Following rehydration in water for 2h, all samples were 
dehydrated in a graded alcohol series and embedded in paraffin for histological analysis. 
4.2.5. Immunofluorescent staining. 
For immunolabeling, tissues were fixed, sectioned and stained as previously described (Esni et 
al., 2004 ). The following antibodies were used at the indicated dilutions for immunofluorescence 
analysis; rat monoclonal anti-E-cadherin (Zymed Laboratories, 1:200), rabbit polyclonal anti-Pdx1 
(gift from Christopher Wright, 1:500), goat polyclonal anti-amylase (Santa Cruz Biotechnology, 
1:500), and guinea pig polyclonal anti-insulin and anti-glucagon (Linco Research, 1:1000). The 
following reagents were purchased from Jackson ImmunoResearch Laboratories: Biotin-conjugated 
anti-rat (1:500), anti-guinea pig (1:500) and anti-goat IgG (1:500). Cy3- and Cy2-conjugated 
streptavidin (1:1000, 1:300), Cy3-conjugated anti-rabbit (1:300), and Cy5-conjugated anti-rat (1:300). 
For each antibody, specificity was confirmed using negative control slides omitting primary antibody. 
Fluorescence confocal microscopy was performed with a confocal laser scanning microscope 
(410LSM, Zeiss) using a 40x (NA 1.5) C-apochromat objective, and image analysis was performed 
using MetaMorph series 5.0 software (Universal Imaging).  
4.2.6. Reverse Transcription–PCR. 
Total RNA was extracted from fetal tissues using the Qiagen RNA extraction kit according to 
the manufacturer’s protocol. First-strand cDNA was synthesized using Superscript II (Invitrogen) from 
100 ng of total RNA and then used as template for PCR amplification of Pkd1 transcripts (Platinum 
Taq; Invitrogen). Primers; (a) MGcPkd2-10F: CAGCAGAAAGCAGAAATGG; (b) MGcPkd2-14R: 
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CGTCCTAACACCTCTCGTCT; (c) MGcPkd2-15F: GGAAGTGGAAATGGAAGTGCTAAC; (d) 
MGcPkd2-15F: CTTATCATTGTCGTACTGGACAGCC; were used to amplify the different products 
of the entire mouse Pkd2 cDNA (Figure 27C), with a common Tm of 55.5 ºC. 
4.3. Results.  
It is anticipated that the gene modifications described above will result in animals with four 
different Pkd2 alleles (Figure 21), with which three of them would be use for its characterization. The 
first will have the correctly targeted allele with both lox P sites and the FRT-flanked neo gene 
(PKD2flox11-13, Figure 21). It is very possible that the neomycin gene, which is within 400 base pairs of 
exon 13, will impair the transcriptional efficiency of Pkd2, thereby yielding a loss-of-function type 
allele with variable penetrance. The second allele will be created by FLP-mediated deletion of the 
neomycin gene (Pkd2delNeo, Figure 21). It is expected that this allele will function completely normally. 
The third allele will be a true mutant after Cre-mediated excision of exons 11-13 (Pkd2ko11-13, Figure 
21). The goal of the first two aims is to test each of these alleles. 
4.3.1. Confirm that the floxed allele is functional  
It has been generated a floxed allele with the possibility of generating three functional 
conditional alleles (Figure 22). First one, the Pkd2flox11-13 with two loxP sites flanking exons 11, 12 and 
13 and a neomycine selection marker flanked with two FRT sites in intron 13. It would be tested the 
possibility that this allele function as hypomorphic, due o the presence of three stop codons in three 
different frames causing transcription termination. A second Pkd2del11-13 allele has been generated by 
using the Cre/lox system into the Pkd2flox11-13 to delete the exons 11-13 in presence of the neomycine 
cassette. The Pkd2del11-13allele is predicted to be null, same as the Pkd2Ko11-13 allele. In order to 
generate a fully viable conditional allele (Pkd2delNeo allele), the neomycin cassette has been deleted 
through recombination between the two FRT sites mediated by FLP recombinase expression 
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(FLP/FRT system). A forth allele, Pkd2Ko11-13, can been generated through loxP site recombination by 
crossing the Pkd2delNeo allele with a murine line expressing Cre recombinase (Cre/lox system using a 
Meox2-Cre expressing mice). This allele is predicted to delete an important region of the C-terminal 
portion of PC2, causing the disruption of this protein. Both the FRT sites, flanking the neomycin 
cassette, and the Lox-P sites have been proved to be functional in vivo through a PCR-based strategy 
(Figure 21). Figure 22 shows that the PCR from primer pairs 2/3 amplify bands of 2.4 kb or 385 bp in 
Pkd2flox11-13 or wild type alleles, respectively. Therefore heterozygous mice (Pkd2flox11-13/+; Figure 22, 
lane 1) have both bands. Pkd2flox11-13/flox11-13 homozygotes (Lane 2) have only the 2.4 kb band while 
Pkd2+/+ wild type mice (Figure 22, lane 5) have only the 385bp band. When the FRT sites are activated 
using FLPase, the Neomycin gene is deleted (Pkd2delNeo) such that primers 2/3 amplify a PCR product 
of 473 base pairs. Therefore, Pkd2delNeo/+ mice (Figure 22, lane 4) have both the 473 and 385 bp. bands. 
When a broadly expressed Cre activates the LoxP sites, primer 2 is deleted along with exons 11-13.    
Figure 22. FRT and LoxP sites are functional in vivo. Pkd2cond (Pkd2flox11-13) mice were bred to mice carrying 
broadly expressed FLPase or Cre enzymes. (A) PCR genotyping of the progeny using two primer pairs as 
demonstrated schematically (B). Lanes 1 &7: Pkd2flox11-13/+, Lane 2: Pkd2flox11-13/flox11-13, Lanes 3 & 6: Pkd2del11-
13/+ Primer #2 is deleted by deletion of exons11-13, Lane 4: PKD2delNeo/+, Lane 5 &8: PKD2+/+ (wild-type). M=1 
Kb plus ladder, PKD2flox11-13 is the targeted, floxed allele. PKD2del11-13 results after activation of LoxP sites 
(deleting exons 11-13) while PKD2delNeo is generated after activation of FRT sites, deleting the Neomycin gene. 
Primers 1,2,3 are designated by labeled arrows. LoxP sites: red arrows, FRT sites: purple arrows, Neomycin 
gene: Green box, Exons: Grey boxes.  
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Therefore, Pkd2del11-13/+ mice have only the wild type band (385 bp). Functionality of the LoxP 
sites is confirmed by PCR using primers 1/3. Primers 1/3 amplify a product of 4.1 kb or 2.2 kb in 
Pkd2cond or wild type alleles, respectively (Figure 22, lane 7: Pkd2flox11-13/+, lane 8: Pkd2+/+ wild type 
mice). Activation of LoxP sites results in a band of 2.8 kb.  As expected PCR 1/3 in Pkd2∆11-13/+ mice 
yields bands of 2.8 and 2.2 kb (Figure 24, lane 6).  
Since the neomycin cassette may have an effect on Pkd2 expression, we removed this element 
from a subset of mice at the outset. Pkd2cond mice were crossed to mice expressing the Flp recombinase 
to generate mice with only loxP sites flanking exons 11-13 (Pkd2delneo/+). Deletion of the neomycin 
gene was confirmed using PCR. Once the neomycin cassette is removed, this allele should behave in a 
wild-type fashion. In order to document this, males and females with the Pkd2flox11-13/delneo allele were 
crossed and homozygotes should be born in the expected Mendelian ratio. As expected, once the 
neomycin cassette was deleted, mice that were homozygous for Pkd2delNeo/delNeo were viable, fertile, 
and born in the expected Mendelian ratios.  
4.3.2. Neomycin cassette results in a hypomorphic allele. 
If the neomycin gene significantly impairs transcription of Pkd2, we would expect that 
homozygosity for Pkd2flox11-13 would lead to a lethal phenotype as above. If there is some functional 
polycystin-2 made, however, then we may wind up with a hypomorphic allele represented by a milder 
phenotype. In order to establish a breeding colony for these experiments, it has been crossed Pkd2flox11-
13 mice with NIH Black Swiss mice. The highly chimeric male was also being crossed to 129SV/J 
(wild type) mice yielding offspring with germ line transmission of the Pkd2flox11-13 allele in an inbred 
129SV/J background. We first examined a small number of adult heterozygotes (N=5) for 
abnormalities associated with the heterozygous state. The literature suggests that adult PKD2 null 
heterozygotes will have occasional kidney cysts and asymptomatic liver cysts.  
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The Pkd2flox11-13 allele was 
bred to homozygosity. As expected, 
the Pkd2flox11-13 allele has reduced 
viability due to the presence of the 
neomycin cassette, which is known 
to have a variable effect on splicing. 
From several Pkd2flox11-13/+ matings, 
only 3/57 were homozygous for the 
Pkd2flox11-13 allele (expected 1/4 or 
~14), suggesting that around 80% of 
the Pkd2flox11-13/flox11-13 offspring died 
in utero. It has been found three 
different manifestations these 
Pkd2flox11-13/flox11-13 mice that 
survived to birth: a) those without 
any major observed phenotype, b) with a severe vascular phenotype and aneurisms, and c) those with a 
sonic hedgehog protein like-phenotype (Helms et at., 1997) with cleft palette and a central eye never 
associated previously to loss of Pkd2 (Figure 23A). The Pkd2flox11-13/flox11-13 embryos which died in 
utero have been associated with a very severe vascular phenotype, with a general dilatation of the 
vascular tree (Figure 21B). None of the Pkd2flox11-13/flox11-13, the ones that survived to birth and the ones 
that died in utero, manifested the classic features associated with total loss of Pkd2 (edema, cystic 
renal disease, cardiac abnormalities, and situs inversus) except the vascular phenotype. 
However, if pregnancies of Pkd2flox11-13/+ vs. Pkd2Ko11-13/+ were harvested at E17.5, the 
compound heterozygotes (Pkd2Ko11-13/flox11-13) display a vascular phenotype similar to that described for 
Figure 23. Pkd2 flox11-13 phenotypes. (A) A representative example of 
Pkd2flox11-13/flox11-13 mice at the first day of live that survived 
manifesting no obvious phenotype (pup #2), vascular phenotype and 
aneurisms (red arrow, pup #1), or a rare phenotype with an central 
eye (black arrow, pup #3) and cleft palette (green arrow, pup #3). (B) 
The Pkd2flox11-13/flox11-13 embryos of developmental day E16.5 showed 
a severe dilatation of the vascular tree. (C) The Pkd2Ko11-13/flox11-13 
dead at E17.5 had the typical edema and hemorrhage similar to that 
previously reported for Pkd1 and Pkd2 null embryos, but without 
polycystic kidney and pancreas disease. 
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both Pkd2 and Pkd1 null alleles with gross edema and hemorrhage (Figure 23C). These studies suggest 
that the Pkd2flox11-13 allele is hypomorphic targeting the Pkd2 locus. 
4.3.3. Inactivation of Pkd2 leads to PKD phenotypes. 
In order to test whether deletion of 
exons 11-13 would result in a null phenotype, 
we bred PKD2delNeo mice with Meox2-Cre 
transgenic mice. Since the Meox-2 Cre results 
in >95% deletion of floxed DNA segments in 
the germline of the carrier, we were able to 
generate mice that were heterozygous for 
Pkd2KO11-13 (Tallquist et al., 2000). The 
embryos that were homozygous for this 
“knock out” allele exhibited the classic 
features of the “Pkd” null state with 
polyhydramnios, hemorrhage and edema 
(Figure 24).  
With the goal of determining 
whether Pkd2delNeo could be inactivated in 
vivo, we used a breeding strategy to generate mice heterozygous for one Pkd2KO11-13 allele in 
combination with Pkd2delNeo and Meox-2 Cre. In this series of experiments, we used a Meox-2 Cre 
(B6.129S4-Meox2tm1(Cre)Sor, Jackson Laboratories) to test if the floxed allele (Pkd2delNeo) functions 
as expected (i.e. results in deletion of Pkd2 exons 11-13). In this line, the Cre recombinase has been 
“knocked in” to the Meox2 locus (mesenchyme homeobox 2 gene) and is thus expressed under control 
of the Meox-2 promoter. Since Meox-2 is broadly expressed in the early epiblast (not placenta), this 
Figure 24. Pkd2KO11-13 functions as a null allele. We used a 
Meox-2 Cre transgenic line to generate mice with a germ 
line Pkd2KO11-13. We crossed heterozygotes and harvested the 
pregnancy at E15.5. A subset of the embryos (1-4) is shown 
with their corresponding PCR genotypes. Embryos 3 and 4 
are Pkd2KO11-13/+ and look normal, while 1 and 2 (close-up in 
panel 5) are homozygotes (Pkd2KO11-13/KO11-13). Both 
homozygous embryos exhibit polyhydramnios and edema 
(arrow). Location of PCR primers for WT and Pkd2KO11-13 
alleles are mapped. All four primers are used in the 
genotyping reaction. The “E” primer is lost upon Cre 
mediated deletion so only a smaller band is amplified. 
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results in the Cre-mediated deletion of floxed DNA segments in greater than 90-95% of embryonic 
tissues including the germ line. The Meox-2 Cre has been bred to Pkd2delNeo homozygotes (generated 
above). Both PCR (primers flanking the deletion) and PCR analysis have been used to detect Cre 
mediated deletion of Pkd2. Only offspring inheriting the Meox-2 Cre should demonstrate the presence 
of the Pkd2del11-13 allele. The Pkd2+/delNeo-Meox-2Cre+ males have been “back-crossed” to Pkd2flox11-
13/delNeo homozygous females. Since the Meox-2 Cre has greater than 95% activity in the male germ 
line, approximately half of the offspring carried a constitutive Pkd2 deletion (Pkd2KO11-13) and 50% had 
the Pkd2delNeo allele in combination with Meox-2 Cre. Therefore 1/4 (1/2X1/2) will be PKD2∆neo/Ko11-13-
Meox-2Cre+, a combination that should result in perinatal lethality.  
In order to establish perinatal lethality, it has been allow pregnancies to come to term. 
Figure 25. LoxP sites flanking PKD2 exons 11-13 recombine 
in vivo to yield a mutant phenotype. A-D: Product of a 
PKD2d∆neo/∆neo, and PKD2KO11-13 Meox2Cre+ mating. This 
animal died shortly after birth with genotype PKD2KO11-
13/PKD2delneo, Meox2Cre+. The animal had profound edema (A, 
red arrow) and both renal cysts (B, C and F black arrows) and 
pancreatic cysts (D and E) on histopathology. L=liver, 
K=kidney, P=pancreas, C=cyst.  
Figure 26. Situs inversus defined by 
rightside organs in Pkd2Ko11-
13/delNeo;Meox2-Cre mouse. Lower left 
image represents high magnification 
view of hearth (H) pointing to the left. 
The lower right shows cystic pancreas 
(P), spleen, stomach (St) and spleen 
(Sp). K (Kidney); L (Lungs). 
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PKD2delNeo/KO11-13-Meox-2Cre+ animals died shortly after birth or with the typical Pkd loss of function 
phenotype including polyhydramnios, total body edema, hemorrhage, pancreatic and renal cysts.  
The reason that the animals survive to birth is that the Meox-2 Cre is not active in placental 
tissues and data from our group suggests that embryonic lethality is due to a failure in placentation, 
same as shown for Pkd1 conditional mouse (Piontek et al., 2004). All other genotypes should be 
phenotypically normal. The advantage of this breeding strategy is that there is no need to sacrifice 
pregnancies prior to birth, which limits the numbers animals needed. In addition to gross inspection, 
we performed a complete histopathologic survey, including 5 animals of each genotype. In Figure 25, 
we show a representative example of the phenotype, including severe edema, renal cystic disease, and 
pancreatic cysts. In addition, several of these animals exhibited situs inversus, which has been reported 
in two other PKD2 targeted murine lines (Figure 26).  
In summary, it has been generated a functional floxed allele that can be used to conditionally 
inactivate PKD2 using Cre recombinases to control temporal and spatial gene inactivation. In addition, 
it has been created a new PKD2 mutant allele (PKD2KO11-13) that behaves as a functional null.  
4.3.4. Pkd2Ko11-13 is a null allele. 
As predicted, the RT-PCR studies confirmed that the Pkd2Ko11-13 allele is transcribed into a null 
pattern on the RNA level. Figure 27 shows 4 embryos from a pregnancy of embryonic development 
day e16.5. Two of the embryos were heterozigous (E2 and E3), one wild type (E1) and one 
homozygous for Pkd2Ko11-13 allele. Embryo E4 showed a severe hemorrhage with severe edema, while 
the others did not show any phenotype (Figure 27A). As expected, E4 also manifested a severe 
polycystic pancreas and kidney disease, confirming the entire PKD phenotype spectrum associated 
with the complete loss of Pkd2 (Figure 27B). In order to verify if the loss of exons 11, 12 and 13 could 
cause the disruption of the Pkd2 reading frame, a RT-PCR strategy has been design based on 3 
different primer pair combination. The first includes amplification of a 572 bp fragment from exon 10 
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to 14 for the wild type allele and a small 
fragment of approximately 168 bp for the 
Pkd2KO11-13 allele, indicating the loss of 
exons 11-12-13 and the disruption of the 
Pkd2 reading frame. Based on this, the 
RT-PCR indicated that embryo E1 is wild 
type Embryo, embryos E2 and E3 RNA 
are heterozygous, and embryo E4 
homozygous for the Pkd2Ko11-13 allele. 
Same result was found when the RT-PCR 
primers were located in exons 10 and 15 
(wild type band of 900 bp and a mutant 
band of approximately 496 bp). When a 
RT-PCR was developed with primers 
located into exon 15, similar ratio of 
amplification was found in Pkd2+/+, 
Pkd2ko11-13/+ and Pkd2Ko11-13/Ko11-13.   
Pkd2Ko11-13 allele works as a 
complete null, where the removal of exons 
11, 12 and 13 result in a truncated protein 
causing all the phenotypes associated with 
the loss of Pkd2. 
Figure 27. Pkd2Ko11-13 allele is a true null. A) E16.5 
pregnancy. E4 showed a severe edema and hemorrhage. B) 
E1 (E2 and E3 -data not shown-) did not any microscopic 
phenotype. E4 manifested a severe polycystic pancreas and 
kidney disease. C) Representation of the primer location for 
RT-PCR in the Ko11-13 and wild type alleles of Pkd2. RT-
PCRs indicate that E2 and E3 were heterozygous for the 
Ko11-14 allele, E4 homozygous and E1 wild type. Primer 
combination a-b and a-d showed the total removal of exons 
11, 12 and 13, causing a complete null allele. 
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4.3.5. Explant culture of E10.5 mouse foreguts allows in vitro modeling of pancreatic cyst 
formation.  
In collaboration with the Dr. 
Leach’s group, it has been pursued the 
development of an in vitro model of cyst 
formation that can be used to clarify 
mechanisms of cyst initiation in PKD 
pancreas or kidney. Such a model would 
allow the observation of cyst formation 
in real time, and also provide a platform 
for pharmacologic and genetic 
manipulation of PKD pancreas and 
kidney. To achieve this model, we have 
taken advantage of cyst formation 
occurring in embryonic PKD pancreas, 
and capitalized on Dr. Leach´s group 
extensive experience with explant 
cultures of both intact E10.5 mouse 
foregut, as well as isolated E10.5 dorsal 
pancreatic buds. On E10.5, the dorsal and ventral pancreas are comprised of distinct buds of 
homogeneous, undifferentiated epithelium (Figure 28A, B). These can either be explanted in the 
context of an intact foregut (Figure 28B), or the dorsal bud and its surrounding mesenchyme can be 
explanted in isolation (Figure 28C). When associated mesenchymal elements were included in the 
explant, E10.5 pancreas undergoes to progressive growth and extensive branching morphogenesis, as 
Figure 28. Explant cultures of E10.5 foregut structures. A, 
E10.5 embryo with dorsal and ventral pancreatic epithelium 
marked by pdx1 expression (brown). B, isolated foregut 
comprised of stomach, proximal intestine, variable portions of 
liver, and dorsal and ventral pancreatic buds. Isolated foreguts 
can be cultured intact, or further isolation of dorsal bud 
epithelium can be performed. C, Lentiviral gene delivery to 
isolated dorsal bud epithelium, followed by recombination with 
isochoric mesenchyme and placement in explant culture. GFP 
fluorescence confirms efficient transgene delivery. D-F, 
isolated foreguts following seven day culture period. D, gastric, 
hepatic, intestinal and pancreatic epithelium marked by E-
cadherin expression. Note extensive branching morphogenesis 
of pancreatic epithelium compared to E10.5 starting material in 
(B). E, amylase expression in dorsal and ventral pancreas. F, 
glucagons expression. St, stomach; liv, liver; vp, ventral 
pancreas; dp, ventral pancreas. Picture donated by Dr.Leach´s 
group. 
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well as differentiation of both endocrine and 
exocrine lineages over a 7-day culture 
period (Figure 7D-F). In contrast, dorsal bud 
epithelium in isolation from mesenchymal 
elements fails to undergo growth or 
differentiation. As a further refinement of 
the explant system, Dr. Leach  laboratory 
had developed unique methodology for 
transgene delivery to E10.5 dorsal bud 
epithelium. This technique involves 
enzymatic separation of the dorsal bud from 
its associated mesenchyme, and 
transduction with either adenoviral or 
lentiviral vectors. 
Following 24 hours of exposure to 
viral particles, the isolated epithelium is 
recombined with isochronic mesenchyme 
and placed on Millipore transwell filters. As 
demonstrated by GFP fluorescence in Figure 
28C, this methodology allows for relatively 
efficient gene delivery, allowing us to 
effectively express a variety of transgenes in dorsal bud epithelium. 
Applying these techniques to PKD pancreas, it has been explanted intact E10.5 mouse foreguts 
harvested from litters established by crosses between Pkd2KO11-13/+ heterozygotes (Figure 29). No gross 
Figure 29. In vitro pancreatic cyst formation in explanted 
E10.5 Pkd2-/- isolated foregut. A and B, bright field images 
of Pkd2+/+ and PKD2KO11-13/ KO11-13 foreguts 
following 7 days in culture. Note large translucent cyst in 
Pkd2-/- explant, outlined by yellow dashed line. C and D, 
Immunofluorescent staining of in vitro cyst epithelium for 
E-cadherin (red) and amylase (green) with DAPI nuclear 
counterstain. E, unmerged and merged images 
demonstrating amylase-positive acinar units immediately 
adjacent to E-cadherin-positive, amylasenegative cyst 
epithelium. Data done in collaboration with Dr. Leach´s group. 
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differences in foregut morphology were observed between Pkd2+/+, Pkd2KO11-13/+ and Pkd2KO11-13/ KO11-
13 embryos at the time of tissue harvest. However, when explanted onto Millipore transwell filters, 
dramatic differences emerged. Pkd2+/+ and Pkd2KO11-13/+ explants underwent normal growth and 
branching morphogenesis, with typical expansion of dorsal and ventral pancreatic buds. In contrast, by 
the fifth day in culture, Pkd2KO11-13/ Ko11-13 pancreas demonstrated the dramatic formation of coalescing 
cystic structures. Of note, these cysts were much more prominent in the dorsal bud than in the ventral 
bud. As in the case of in vivo cysts, in vitro cyst epithelium was E-cadherin positive, but amylase 
negative, except for isolated amylasepositive cells participating in cyst formation (Figure 29).  
4.4 Discussion. 
Autosomal dominant polycystic kidney disease (ADPKD) is the most common form of 
(monogenic) inherited renal failure in the United States. The disorder is characterized by progressive 
renal cystic disease that results in end stage kidney disease in ~50% of the cases (Gabow, P.A., 1993). 
ADPKD is caused by mutations in either of two genes, PKD1 or PKD2 (protein products are called 
polycystins) (Calvet; 1998). 
Since we still understand relatively little about PKD signaling pathways, much effort has been 
devoted to developing faithful animal models of ADPKD that could be used to better understand the 
biology of polycystin proteins. To this end, a number of laboratories have generated mice carrying 
targeted alleles of either Pkd1 (Pkd1-/-) or Pkd2 (Pkd2-/-) (Wu et al., 1998, Wu et al 2001, Boulter et al 
2001, Lu et al 1997), but only for Pkd1 has been develop an conditional knockout that could allow the 
timing and spatial inactivation (Piontek et al., 2004). Since cysts are thought to form via a “two hit” 
mechanism, it is no surprise that heterozygotes are uniformly viable with only rare renal and hepatic 
cysts (Qian F et al., 1996). In contrast, the homozygous state results in mid-late embryonic lethality, 
depending on the model. At the time of demise, animals have diffuse renal cystic disease but most 
groups also describe a variety of other associated abnormalities including gross edema, spontaneous 
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hemorrhage and polyhydramnios (Wu G et al., 2000). Cardiac abnormalities have been associated with 
edema in some but not all of the targeted alleles (Boulter et al., 2000; Muto et al., 2002). Interestingly, 
Pkd2 knock-out mice, although similar to Pkd1 mutants, are not identical. Pkd2-/- mice display 
abnormalities in left/right axis determination (right pulmonary isomerism, randomization of embryonic 
turning, heart looping, and abdominal situs) which have not been described in Pkd1-/- mice 
(Pennekamp et al., 2002). This suggests that the function of the Pkd1 and Pkd2 may not overlap in 
every cell type. The early lethality of the homozygous state has limited the types of questions that can 
be answered with these models. Wu et al. generated an unstable allele of Pkd2 with a local duplication 
that undergoes random somatic mutations (Wu et al., 1998). This is the only model that comes close to 
imitating human disease but it does not allow regulated gene loss. An important limitation of the 
currently available lines of mice with targeted mutations of Pkd2 is that heterozygous animals rarely 
have cystic disease below six months of age. 
Dr. Germino’s group has developed a floxed Pkd1 allele that can be used to control the timing 
and location of the Pkd1 mutation (Piontek et al; 2004) but there is no such model for PKD2. Given 
that the role PKD1 and PKD2 may differ, we believe that both models are necessary to gain a full 
understanding of polycystin biology. In order to study the consequences of polycystin-2 loss in both a 
tissue and stage-specific fashion, we have generated mice with a floxed allele of Pkd2 (Pkd2cond).  
The goal of this Thesis subproject was to generate and characterize this new murine allele. 
These studies will set the foundation for subsequent use of this model to test a range of Pkd2 
associated phenotypes. In this part, it has been described the first line of mice with a floxed allele of 
the Pkd2 gene (Pkd2flox11-13) that functions as a hypomorphic in the undeleted state and as a complete 
null after Cre-mediated deletion. After deletion of the Pgk-Neomycine cassette through the FLP/FRT 
system, it has been shown that mice homozygous for the Pkd2delNeo allele are viable, fertile and born at 
expected Mendelian ratio. By breeding PKD2delNeo/+ mice, to PKD2∆11-13/+ heterozygotes that also were 
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positive for a Cre-recombinase, it could be quickly evaluated the functional impact of Cre-mediated 
loss of PKD2 exons 11-13. As expected, embryos with the PKD2del11-13/del11-13 genotype were present 
in normal Mendelian ratios and recapitulated the range of phenotypes (polycystic kidney and pancreas 
disease, edema, polyhydramnios, hemorrhage and lateralization defect) with homozygous loss of 
PKD2. These results conclusively show that the floxed allele functions as a null allele after Cre-
mediated deletion. Similar results were obtained using mice from different strains, excluding strain 
differences as a trivial explanation for our findings.  
This is the first conditional knockout model described up the moment. This system has 
provided three new Pkd2 alleles: a hypomorphic allele (Pkd2flox11-13 allele) associated to a severe 
vascular phenotype, a new knock-out allele that is predicted to lack the Pkd2 C-terminus (Pkd2ko11-13 
allele), and a conditional allele that can be used to selectively inactivate Pkd2 in vivo (Pkd2delNeo 
allele). These models will provide a rich source of cells and organ culture for testing of in vitro 
inactivation and therapy consequences. 
Pkd2flox11-13 is a hypomorphic allele.  It has been show that the presence of the neomycine 
cassette in intron 13 disrupts normal behavior of Pkd2, playing an important role in vascular phenotype 
development. Pkd2flox11-13 allele could be established for a better understanding of the vascular 
phenotype in ADPKD patients. Several reports describe the vascular phenotype as a major cause of 
dead and disability in ADPKD (Rossetti et al., 2003). It has also been described that lower levels of 
Pkd1 is sufficient to cause PKD (Inma et al., 2004). This is not the case for Pkd2 because as it has been 
shown, homozygous mice for the Pkd2flox11-13 allele that dye in utero by a very severe vascular 
phenotype and as in those that survived to birth, never manifest PKD. Since Pkd2flox11-13/flox11-13 
developed a major vascular phenotype accompanied by intramural bleedings, it seems that reducing 
levels of Pkd2 result in structural weakness of arterial wall. Given that, Pkd2flox11-13/flox11-13 can be 
proposed as an interesting model in the study of the vascular phenotype and the effects of therapy.  
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Cre-mediated deletion of Pkd2  in  tissues. The floxed allele of Pkd2 described in this report 
(Pkd2delNeo) can be used to distinguish between different possibilities. It has been shown in this report 
that in utero expression of Cre recombinase (Meox2-Cre) in Pkd2delNeo/Ko11-13 mice results in a null 
allele and cyst formation. As expected, embryos Pkd2delNeo/ko11-13-Meox2-Cre+ recapitulated the range 
of phenotypes (edema, polyhydramnios, hemorrhage and lateralization defects) observed for Pkd2ko11-
13/ko11-13 embryos. This demonstrates the functional similarity of the Cre-mediated recombination to a 
true knock-out allele.  Also, it can be used to examine the consequences of temporally and spatially 
regulated inactivation of Pkd2. For example, it can be examined what other factors affect the relative 
rate of cyst growth in the kidney and liver by fixing the time and location of gene inactivation. 
Equally, this model offers a uniquely powerful way of testing various interventions on the rate of cyst 
growth by removing the unpredictability of the timing of somatic mutation.  
This new line of animals also is an invaluable tool in the study of different biological aspects of 
PKD2.  It can be used for test if PKD2 is important for both formation and maintenance of tubules 
(controlling the PKD1 inactivation timing), to determine the cause of fetal demise, assess the role of 
PC2 in the development of various other tissues that are altered in PKD1 nulls (by selective 
inactivation of bypassing the embryonic lethality), to screen for post-developmental functions of 
PKD2 that are not manifest in humans because of the two-hit nature of disease and not observed in 
mice because of the early lethality associated with its homozygous loss.  
Pkd2ko11-13, a new knock-out allele lacking the Pkd2 C-terminus. The present knock-out 
mouse derived from the conditional allele after Cre recombinase has, like other gene-targeted alleles 
for Pkd2, an embryonic lethal phenotype in the homozygous stage and recapitulates the range of 
phenotypes observed for Pkd2ko11-13/ko11-13 embryos with polycystic kidney and pancreas disease, 
edema, polyhydramnios, hemorrhage and lateralization defects.  
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In vitro modeling of the pancreas cyst formation associated to the loss of Pkd2. Explant 
culture data demonstrate that Pkd2KO11-13/ KO11-13 embryonic pancreas undergoes rapid in vitro cyst 
formation, providing a novel platform for the study of PKD cyst pathogenesis. Specifically, the ability 
to culture multiple synchronous explants will allow precise temporal analysis of initiating events in 
cyst formation. This type of analysis will be critical in the accurate identification of cyst precursor 
lesions. In addition, the in vitro model opens the door to relatively high-throughput analysis of 
pharmacologic and/or genetic modifiers of the PKD phenotype, providing significant advantage over 
traditional in vivo work.  
Together, these preliminary data define cyst formation in PKD mouse pancreas as a consistent 
and tractable event, and further suggest the likely participation of epithelial progenitors in cyst 
initiation. Whether progenitor cells are recruited to cyst formation by selective expansion or by acinar 
cell dedifferentiation remains to be determined. In this regard, it is notable that in vitro cyst formation 
is evident following only 5 days in explant culture, while acinar cell differentiation typically requires a 
full 6-7 days. The generation of new information regarding cyst formation in PKD pancreas, including 
the identification of pharmacologic and genetic modifiers of this event is very important. In addition to 
clarifying mechanisms of pancreatic cyst formation, these studies are also likely to generate new 
information regarding epithelial progenitor cells in adult and embryonic pancreas. Finally, by 
characterizing and manipulating pancreatic cyst formation in adult and embryonic pancreas, it can be 
anticipated that significant insights will also be generated regarding PKD associated cysts in other 
tissues, including liver and kidney.  
This model concluded several important keys for understanding the biology of ADPKD. 
Polycystin-2 is essential for normal embryonic development, maintenance of the normal elongating 
nephron, pancreatic ductal structure and vascular tree. The develop of useful tool that help for a better 
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understanding of  the cellular and molecular underpinnings of these findings will provide the discovery 
of possible targets for therapeutic intervention in ADPKD.   
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5. Generation of a conditional murine model of PKHD1 gene (SUBPROJECT III). 
5.1 Abstract. 
Mutations of human PKHD1 result in ARPKD. A number of groups have tried to model the disease in 
mice by disrupting murine PKHD1 by gene targeting but none have produced mice with PKD. Based 
on the gene’s pattern of expression and its pattern of mutations in humans, we suspected that 
homozygous inactivation of mouse Pkhd1 could be lethal. We thus developed a novel floxed allele of 
Pkhd1 (Pkhd1flox3-4) that has an FRT-flanked neomycin cassette inserted into intron 4 and loxP sites 
flanking exons 3-4. The floxed allele is fully functional and homozygotes are viable and healthy. We 
have shown that Cre-mediated recombination induces deletion of the exon 3-4 fragment as intended to 
produce a novel mutant allele (Pkhd1del3-4). Matings of Pkhd1del3-4/+ yielded only ~20% of the expected 
number of liveborn Pkhd1ko3-4/del3-4(18/252; 63 expected) with a substantial fraction subsequently 
succumbing to respiratory failure. One Pkhd1del3-4/del3-4 neonate died with an intracerebral hemorrhage. 
Among the survivors, all had a variety of hepatobiliary abnormalities including congenital hepatic 
fibrosis, choledochal cysts and ascending cholangitis. Most also had severe pancreatic cystic disease 
manifest by four weeks of age. Many were growth retarded and a subset had severe hindlimb 
abnormalities. Interestingly, mice that lacked gross pancreatic abnormalities had polycystic kidney 
disease that histopathologically resembles that of humans. Long-range RT-PCR of kidney and liver 
specimens from normal and Pkhd1 mutant mice confirmed that the mutant allele is transcribed but it 
encodes a different pattern of transcripts. This new line of mice, which allows inactivation of Pkhd1 in 
a spatio-temporally controlled manner, presents a complete spectrum of ARPKD phenotypes and will 
be a powerful tool in the study of PKHD1 biology and the pathogenesis of human ARPKD. 
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5.2. Material and methods. 
5.2.1. Generation of a conditionally activated Pkhd1 flox3-4 targeting construct. 
A floxed allele was generated to allow regulated removal of exons 3 and 4 (Figure 30A).  It has 
been avoided exons 1 and 2 since it can be concerned, based on our human studies, that the gene might 
use alternative upstream exons.  After examination of human data, it has been noted that exon 3 was an 
apparent hotspot for mutations in humans and that its removal with exon 4 should delete essential 
exons, remove an alternative translation start site42 and disrupt the reading frame.  
 ~400 clones had been screened, identifying only one that was properly targeted and retained 
Figure 30: Gene-targeting of Pkhd1 to produce a floxed allele. A) Schematic of targeting construct (TC), wild 
type allele (WT) and Pkhd1flox3-4 (Flox3-4). “Int” and “Ext” identify position of probes used in C. B) Same as in 
A except includes map of all possible alleles derived from Pkhd1flox3-4: Cre-mediated deletion (Pkhd1Del3-4), 
FLP-mediated deletion (Pkhd1delNeo)  and both (Pkhd1del3-4Neo. Pkhd1del5 allele was gently donated by Dr. 
Somlo. “a-h” identifies position of primers used to identify genotypes in D. C) Southern blot of ES cells, 
marker sizes in red identify properly targeted band sizes. D) PCR results showing that the allele deletes 
properly (Del3-4). E) Offspring Genotyping from a Pkhd1del5/flox3-4 vs Pkhd1del5/ lox3-4 mating. 
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both lox P sites as verified by multiple hybridizations and PCRs (Figure 30C and 30D).  The clone was 
expanded and used to generate highly chimeric animals that transmitted the targeted allele (Pkhd1flox3-
4) with high frequency.  
It has been verified that the allele can be transmitted through the germline, that PKHD1flox3-
4/flox3-4 are viable and thus far appear healthy, and we have also shown that Cre recombinase induces 
deletion of the exon 3-4 fragment as intended (Figure 30D). 
5.2.2. Genotyping. 
Genomic DNA from mouse-tails was obtained as follows. In short, ~5mm long piece of the 
tails were digested in Proteinase K buffer (50 mM Tris pH 8.5, 1 mM EDTA, .5% Tween 20) at 60°C 
for about 2h with shaking. After inactivation of the enzyme at 99°C for 15min, 1µl of the solution was 
used for PCR genotyping with primer locations shown in Figure 30B, and whose sequences are as 
follows: (a) M/loxP-F: GGG AAG CAG AAA TTC AGG; (b) C2R: AGA TGA AGC ACG GAT 
CAG TGG G; (c) KoPKHD1-F: CTT TAC CCC AAC AAT GGC; (d) koPKHD1-R: GTG TAC CTC 
GTC TGG CAT GTC; (f) M/Pgk-R: AAA GCT AAA AGT GGG AGA GAC G;  (g) PgkNEO-R1: 
GCT CAT TCC TCC CAC TCA T; (h) PGKR2: GCCAGAGGCCACTTGTGTAG; For detection of 
Cre + animals we used: CRE-F (200bp): ATT GCT GTC ACT TGG TCG TGG C; CRE-R (200bp): 
GGA AAA TGC TTC TGT CCG TTT GC. 
5.2.3. Preparation for Histology. 
Kidney, liver, and pancreas specimens from adult animals were collected and immediately 
fixed in 10% buffered formalin at 4°C overnight. Embryos at different ages were fixed with ice-cold 
4% paraformaldehyde in PBS via cardiac perfusion of the mother and then kept in 4% 
paraformaldehyde overnight at 4°C. Following rehydration in water for 2h, all samples were 
dehydrated in a graded alcohol series and embedded in paraffin for histological analysis. 
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5.2.4. Immunofluorescent staining. 
For immunolabeling, tissues were fixed, sectioned and stained as previously described (Esni et 
al., 2004). The following antibodies were used at the indicated dilutions for immunofluorescence 
analysis; rat monoclonal anti-E-cadherin (Zymed Laboratories, 1:200), rabbit polyclonal anti-Pdx1 
(gift from Christopher Wright, 1:500), goat polyclonal anti-amylase (Santa Cruz Biotechnology, 
1:500), and guinea pig polyclonal anti-insulin and anti-glucagon (Linco Research, 1:1000). The 
following reagents were purchased from Jackson ImmunoResearch Laboratories: Biotin-conjugated 
anti-rat (1:500), anti-guinea pig (1:500) and anti-goat IgG (1:500). Cy3- and Cy2-conjugated 
streptavidin (1:1000, 1:300), Cy3-conjugated anti-rabbit (1:300), and Cy5-conjugated anti-rat (1:300). 
For each antibody, specificity was confirmed using negative control slides omitting primary antibody. 
Fluorescence confocal microscopy was performed with a confocal laser scanning microscope 
(410LSM, Zeiss) using a 40x (NA 1.5) C-apochromat objective, and image analysis was performed 
using MetaMorph series 5.0 software (Universal Imaging). 
5.2.5. Reverse Transcription–PCR. 
Total RNA was extracted from fetal tissues using the Qiagen RNA extraction kit according to 
the manufacturer’s protocol. First-strand cDNA was synthesized using Superscript II (Invitrogen) from 
100 ng of total RNA and then used as template for PCR amplification of Pkhd1 transcripts (Platinum 
Taq; Invitrogen). Primers; (a) MFL-F1: GTGAGTTCCAGTCCAACAGG; (b) MFL-R1: 
GAGCAGTTACAGTGGGATTCA; (c) MFL-R2: GGGTGAAGATGCTGCTGTAATC; (d) MFL-R3: 
CCAGGGACAATCTGACTGAAG; (e) MFL-R4: TCTATTCCCACTTCTCCATCAG; (f) MFL-RF2: 
GAATGTGGTGGAGTCAGTATCG; (g) MFL-F3: GCAGGCTTGTCTAACAGTGAAC; (h) MFL-
F4: ATCAAGAGACCTACTCGCTGC were used to amplify the different products of the entire 
mouse PKHD1 cDNA (figure 44), with a common Tm of 55.5 ºC. 
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Figure 32.  H & E staining of kidney (b), liver (c and e) and
pancreas (d and f) from 16 week old animals. Pkhd1del5/del5
(a-d); wild type (e-f). 
5.3. Results 
5.3.1. Test the hypothesis that inactivation of Pkhd1 can mimic the human disease. 
The characterization of Pkhd1 models created by other collaborators has been developed 
previously to the Pkhd1flox3-4 allele.  
Dr. Somlo’s laboratory has developed a Pkhd1 allele with the insertion of a Neomycine 
cassette in the end of exon 4, generating a splice donor skipping the exon 5 into the RNA level 
(Pkhd1del5, ASN 2004). Pkhd1del5 homozygotes mice are born at expected Mendelian rates and are 
fertile. By 12 weeks, large pancreatic cyst formation with adjacent acinar destruction and chronic 
pancreatitis was noted in 10% of the homozygous mice (Figure 31-2). A mild abnormal growth was 
Figure 31. Characterization of 12 weeks old 
Pkhd1del5/del5. Homozygous Pkhd1del5 can 
show polycystic pancreas (2), eventually 
growth retardation (3), or do not show any 
phenotype at all (1).  
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seen in more than 1 % of the animals compared to their own littermates (Figure 31-3). Histologic 
examination of kidneys revealed normal glomerular and tubular development, with no cysts apparent 
at 16 weeks of age (Figure 32B). Intrahepatic bile duct proliferation, with features reminiscent of von 
Meyenburg complexes/ductal plate malformation, was noted as early as two weeks.  By 16 weeks, 
microscopic liver cysts were present (Figure 32C). Pancreatic ductal ectasia was found in all null 
animals (Figure 32D).   
Our results for the PKHD1del5/del5 mice are similar to what has been described by other groups, 
for example, Ward et al. (ASN, 2004) targeted exon 2 of mouse Pkhd1 showing a similar liver and 
pancreatic disease manifestation. Interestingly, other two Pkhd1 mouse model with truncated exons 
from the 5´of the gene where associated with only the liver phenotype. When Moser et al. (2005) 
targeted exon 42, the homozygous mice only developed the liver phenotype similar to the Pkhd1del5 
mouse model, but no evidence of polycystic kidney disease, polycystic pancreas disease, perinatal 
demise or other ARPKD associated phenotypes. The same happen with the Pkdhd1cl mouse, where a 
cystic liver (cl) associated mutation arose spontaneously in a congenic strain generated by 
introgressing a segment of distal chromosome 4 from C57BL/6J (B6) onto the DBA/2J strain (Jackson 
Laboratories).  Dr. Guay-Woodford’s group mapped the cl 
locus to the PKHD1 interval and identified a frameshift 
mutation, c.7589delGGinsT, in Pkhd1 exon 49. Pkdhd1cl 
mutants develop massive cystic liver disease by four months 
of age and histopathological analysis demonstrated a biliary 
dysgenesis lesion that resembles human ARPKD (Figure 
33).Curiously, none of the mouse models thus far described 
has a renal phenotype.  This thesis follows up on these 
Figure 33: Biliary lesion in cl mutant. 4 
months Pkhd1 cl/cl liver with irregularly 
shaped & dilated bile ducts (BD). PV portal 
vein, 100X. 
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observations and seeks to test the hypothesis that the lack of a renal phenotype is due to the 
complicated pattern of splicing.  
As explained previously, a new conditional Pkhd1 allele (Pkhd1flox3-4) has been generated 
though the insertion of a Pgk-Neomycin cassette in intron 4 with exons 3 and 4 flanked by loxP sites. 
Using the Cre/loxP system, exons 3 and 4 can be deleted through recombination between the two loxP 
sites when Cre-recombinase is 
expressed. Offspring from 
mice where deletion of these 
exons was induced in the 
epiblast using a Cre-
recombinase driven by the 
Meox2 promoter, will carry out 
a germline allele (Pkhd1del3-4) 
predicted to delete the exons 3, 
4 and 5 at the RNA level. 
Crosses of Pkhd1del3-4 with the 
PKHD1del5 allele have shown 
that PKHD1del5/del3-4 has a more 
severe manifestation that PKHD1del5/del5. Compound PKHD1del5/del3-4 mice were born at expected 
Mendelian rates. It has been found animals with severe polycystic pancreas disease and liver fibrosis.  
By 5-6 weeks, large pancreatic cyst formation with adjacent acinar destruction and chronic pancreatitis 
was noted in 23% of the homozygous mice (Figure 34D). A mild abnormal growth was seen in 4% of 
the animals. Histologic examination of kidneys revealed normal glomerular and tubular development 
Figure 34. Phenotypes of Pkhd1del3-4/del5. Panel A: Gross external 
appearance of 5-6 wk old mice with a dilated gallbladder. Panel B-D: 
Gross internal appearance and histopathology of same mice in A. Inset 
shows low power image and position from where specimen was selected. 
K: Kidney, L: Liver, CBD, common bile duct, Cy: cyst. Arrow shows mild 
dilatation into the collecting ducts. 
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(we can observe a mild dilatation in the collecting ducts), with no cysts apparent at this age.  
Intrahepatic bile duct proliferation, with features reminiscent of von Meyenburg complexes/ductal 
plate malformation, was noted as early as two weeks.  Microscopic liver cysts were present (Figure 
34C).  
5.3.2. Pkhd1del3-4/del3-4 model mimics the human disease. 
Breeding studies were developed to test whether Pkhd1del3-4 homozygotes have more severe 
disease than Pkhd1del5/del5, Pkhd1del5/del3-4compound heterozygous, Pkhd1cl/cl allele or any other publicly 
described Pkhd1 mutant alleles.  
Pkhd1del3-4/+ x Pkhd1del3-4/+ crosses have produced 84 offspring, of which only six of 21 
expected have the Pkhd1flox3-4/flox3-4 genotype.  The viable homozygote mutants have a range of 
phenotypes: three are smaller than their littermates (~P28) and two have obvious bony abnormalities 
(Figure 35A).  Two have been harvested at five to six weeks of live to test for PKHD1 expression and 
were found to have small kidney, liver and pancreatic cysts.  
Also, it has been produced a number of other crosses, founding the following:  
a) PKHD1del3-4/flox3-4;Meox2cre/+. These mice have a germline mutation in one allele and the 
deletion of the other allele in 95% of the cells after Cre-mediated deletion in the epiblast through the 
Meox2-Cre. 16 mice of 18 expected with this combination presented a range of phenotypes that 
includes some mice that appear grossly normal (N=7, two of them developed pancreatic cyst and liver 
fibrosis at five to six weeks), multiple newborns that died by respiratory failure in the perinatal period 
(N=7, gastrointestinal tract filled with air, Figure 35B), and a set that was significantly smaller than its 
littermates (N=2, Figure 35C);  
b) PKHD1flox3-4/del5;Meox2cre/. It has been characterized a total number of 18 mice with this 
genotype (of 19 expected) with a range of phenotypes including one that died of respiratory failure, 
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one that apparently died of intracerebral hemorrhage shortly after birth (Figure 35D), 11 that were 
growth retarded, and 5 that appeared grossly normal;  
c) PKHD1del3-4/del5. These mice carry two different germline mutations. Six mice were born 
while 12 were expected based on the genotypes of the parents; three of six have had massive 
pancreatic disease by four weeks of age with hepatic fibrosis (Figure 35E). This is in contrast to only 
8/173 PKHD1del5/del5 that develops this feature between 6-16 wks.  
Because human ARPKD patients suffer from cystic biliary dysgenesis and polycystic kidneys, 
detailed histological analyses of all internal organs with special emphasis on liver and kidneys were 
performed. 
- Pkhd1del3-4/del3-4  renal phenotype. 
Comparison of kidneys from Pkhd1 del5/del5, Pkhd1del3-4/del5, and Pkhd1del3-4/del3-4 at five to six 
weeks of age showed a severe cystic disease in the Pkhd1del3-4/del3-4 mice and a very mild kidney 
Figure 35: Pkhd1 mutant phenotypes. a) Pkhd1del3-4/del3-4 three week old with abnormal limb structure and 
function and eye abnormalities; b) Pkhd1del3-4/flox3-4;Meox2cre/+ that died shortly after birth due to respiratory 
failure. The stomach and intestines are filled with air (arrows); c) Pkhd1flox3-4/del5; Meox2cre/+ three week old 
(bottom) and its normal (Pkhd1del5/+) littermate (top). d) Pkhd1flox3-4/del5;Meox2cre/+:Newborn that died shortly 
after birth with multiple hemorrhages/vascular abnormalities (arrows); e)Pkhd1del3-4/del5:a four week old with 
massive abdominal distension due to pancreatic cysts; f) Pkhd1del3-4/del5:a three week old with very large cysts of 
the bile duct (arrow). 
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disease with focal areas of dilated ducts in the Pkhd1del3-4/del5 (Figure 36). ~ 10% of Pkhd1del3-4/del3-4 
showed a very severe polycystic kidney disease at 3 months of live, increasing up to 80% at 6 months 
of age. No obvious changes have been found in kidneys for the Pkhd1del5/del5 mice at any stage. 
Figure 37 shows Pkhd1del3-4/del3-4 kidneys at five to six weeks, three months, and six months of 
age. Not only the disease progression is enhanced, also the penetrance with an increase from ~ 10% at 
three months of age to almost all at six months.  
In order to ensure that the kidney phenotype originates from the collecting ducts, it has been 
used a specific marker for collecting duct epithelial cells (Aquaporin-2, Figure 38). As in humans, the 
majority of the cysts have a collecting duct origin, being the Pkhd1del3-4 model the only one that 
completely mimics human ARPKD.  
Figure 36. Pkhd1del3-4/del3-4 shows a severe kidney phenotype. Focal duct dilatation was found 
in Pkhd1del3-4/del5 kidneys. Massive Polycystic disease has been found in kidneys from Pkhd1del3-
4/del3-4 . No alterations were found in Pkhd1del5/del5.kidneys. 
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Figure 37. Polycystic Kidney disease progression in Pkhd1del3-4/del3-4 mouse. 
Figure 38. Cysts from ARPKD model (Pkhd1del3-4/del3-4) have a dilated collecting duct origin.  
Aquaporin-2 staining (red) of the dilated collecting ducts in adult mouse kidneys (5-6 weeks). DAPI-
stained nuclei appear in blue. 
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- PKHD1del3-4/del3-4  hepatic phenotype. 
Severe congenital hepatic fibrosis is been found in homozygous PKHD1del3-4/del3-4 mice. The 
size of cystic liver degeneration was slightly variable, differing from multiple small cysts to huge liver 
cysts (Figure 39). Liver histology of PKHD1del3-4/del3-4 mice at five to six weeks of age showed 
maximal polycystic liver transformation. The liver changes were confined to abnormal bile duct 
architecture, fibrosis in the portal tracts and the lobular hepatic parenchyma.  
As in humans, defects in PKHD1/Polyductin lead to abnormal and/or arrested development of 
the biliary and portal systems. The classical pathological findings in ARPKD is the ductal plate 
malformation, in which there is an increased numbers of dilated and irregular or tortuous bile ducts 
present in an interrupted ring around the periphery of a portal tract which frequently lacks a centrally 
located bile duct. These biliary findings recapitulate the ductal plate, a stage of normal bile duct 
development, and persistence of this stage is evidence for developmental arrest as part of the 
physiopathology of ARPKD. The portal tracts are expanded by mature collagenous tissue, which 
eventually forms interportal bridges that initially do not disrupt the acinar architecture (a pattern that 
Figure 39. Macroscopic and histological liver sections of a 6 weeks old Pkhd1del3-4/del3-4 mouse.
Degenerated hepatic lobules between cystic bile ducts (H&E) surrounded by fibrosis (Blue staining 
of the Tricome). 
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has been termed congenital hepatic fibrosis -CHF-).  
- PKHD1del3-4/del3-4  Pancreatic Phenotype. 
Since the pancreatic phenotype is not one of the most common manifestations of human 
ARPKD and has a very high penetrance in all of the described models, we decided to define an in 
depth characterization of this phenomenon. 
As in the liver, we found massive pancreatic cyst formation as early as P0 in PKHD1del3-4/del3-4 
mice that initiate in a centroacinar position, implying that pancreatic cysts may arise from an 
undifferentiated pancreatic progenitor cell (Figure 40C and 40D). PKHD1del3-4/del3-4 shows cystic 
dilatation of the central duct, with peripheral displacement of the acini. The expansion of the 
parenquima was associated to the large progression of the ductal cysts, with periductal fibrosis, chronic 
inflammation and progression of cystic acini associated to the destruction of the normal acini (Figure 
Figure 40. Candidate cyst precursor lesions arising in adult Pkhd1 del3-4/del3-4 mice. A, wild-type adult pancreas 
demonstrating lack of dilated epithelium immediately adjacent to acinar units; arrowhead indicates centroacinar 
zone comprised of the most terminal branches of the ductal epithelial tree. B-D, candidate cyst precursor 
lesions. Arrowheads in B-D indicate zones of apparent acinar cell participation in early cyst formation. Note 
occasional gradual transition between columnar, highly eosinophilic acinar cells and cuboidal cystic epithelium, 
as indicated by arrowhead in (D). Asterisk in (B)  indicates lumen of non-dilated inter-lobular duct. Asterisk in 
C indicates lumen of adjacent large cystic structure. 
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40A and 40B).  In adult mice, sometimes the weight of the cystic pancreas was similar to the total 
body weight of the mouse (Figure 40). All this suggests the need for further evaluation at various 
embryonic time points, as well as the role of Polyductin in normal pancreatic development. 
As an initial step towards clarifying mechanisms of pancreatic cyst formation in ARPKD, we 
have examined H&E-stained sections of tissues harvested from P0 as well as adult PKHD1del3-4/del3-4 
mice. While large pancreatic cysts are apparent in each of these conditions, we have further identified 
candidate cyst precursor lesions delineated by an initially subtle expansion of the “centroacinar” zone, 
defined by the most terminal elements of the ductal epithelial tree immediately adjacent to the acinar 
units.  
In order to rigorously resolve the question of “selective expansion” vs. “dedifferentiation”, 
Cre/lox-based lineage tracing was developed. Pancreatic cyst epithelium shares common features with 
undifferentiated embryonic epithelium. To further characterize pancreatic cell types participating in 
cyst formation, it has been compared epithelial gene expression patterns between wild-type and 
PKHD1del3-4/del3-4 adult mice through immunofluorescent staining of pancreatic epithelial markers 
(Figure 41), including  E-cadherin as general epithelial marker, as well as amylase, insulin, and pdx1. 
It is well known that, while pdx1 is ubiquitously expressed in embryonic pancreatic epithelium and 
restricted to mature β-cells in the adult mice. In the wild-type pancreas (Figure 41, left column), β-cells 
that are clustered in the endocrine islet are pdx1-positive, while the ductal epithelium is negative for 
pdx1 (indicated by arrowheads). In contrast, cyst epithelium arising in the setting of PKHD1 
deficiency (Figure 41, right column) shows strong ongoing pdx1 expression, suggesting a much closer 
analogy to embryonic pancreatic epithelium than to normal ductal epithelium. Assessment of amylase 
and insulin expression underscores this analogy, with insulin-positive endocrine cells arising and 
budding from cyst epithelium (Figure 42). Insulin positive cells are almost never seen in the normal 
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ductal epithelium of the adult pancreas, but instead 
recall the mechanism underlying normal generation of islet cells during embryonic development. 
These observations call into question the traditional characterization of PKD pancreatic cysts as 
“ductal cysts”, and further support the hypothesis that these cysts represent an expansion of 
undifferentiated progenitor cells, similar to those present in embryonic pancreas.  
5.3.3. Determine whether Pkhd1del3-4 is a null allele. 
RT-PCR studies confirmed that the Pkhd1del3-4 allele is transcribed and not a complete null 
on an RNA level. Until now, it could not be possible to determine whether the observed phenotypic 
Figure 41. Epithelial gene expression in wild-type 
and Pkhd1del3-4/del3-4 adult pancreas. Images show 
single-channel and merged images following 
immunostaining for E-cadherin (green) and pdx1 
(red), with DAPI nuclear counterstain. In wild-type 
adult pancreas (left column), pdx1 expression is 
restricted to mature β-cells in islet cluster, and absent 
from ductal epithelium, marked by arrowheads. In 
contrast, Pkhd1del3-4/del3-4 adult pancreas shows strong 
pdx1 expression in cyst epithelium, suggesting 
analogy to embryonic pancreas. 
Figure 42. Amylase, insulin, and pdx1 expression in 
Pkhd1del3-4/del3-4 adult pancreas. Images represent 
merged images following Immunostaining for E-
cadherin, amylase and insulin. Note that acinar cells 
with apical amylase expression in punctate zymogen 
granules are located immediately adjacent to cuboidal 
cyst epithelium, with isolated amylasepositive cell 
also identified within cyst epithelium itself (arrow). 
Staining for insulin and pdx1 reveals that while the 
vast majority of pdx1-positive cyst epithelial cells 
remain undifferentiated, isolated cells undergo β-cells 
differentiation, marked by insulin expression. A 
similar appearance of isolated endocrine cells is 
observed in embryonic pancreas. 
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variability results from variants at modifying loci that encode pathway components or splicing variants 
encoded by the mutant Pkhd1 alleles. RT-PCR amplification of two different wild type mice using 
primers located in exons 2 and 6 showed a unique band of 416pb including a small fragment of the 
exon 2 and 6 exon 3, exon 4, exon 5 and small fragment of the exon 6. RT-PCRs from three different 
Pkhd1del3-4/del3-4 mice showed the absence of the 416bp band, indicating the deletion of exons 3 and 4, 
and the amplification of four fragments of ~650bp, ~600bp, 196bp and 87bp. These correspond to 
aberrant splicing as the result of the deletion of exons 3 and 4. Sequencing of the ~650bp and ~600bp 
fragments indicated splicing events from exon 2 into the Pgk-Neomycin cassette which contains three 
different frame stops codons,  resulting in the loss of the full-length transcript. Splicing events from 
exon 2 to 5 generate a 196bp-fragment, lacking exons 3 and 4 and disrupting also the frame of the 
protein. A small fragment of 87 bp represents the splice event between exons 2 to 6, recovering the 
frame of the protein (Figure 43A).  
When RT-PCR amplification was develop in cystic kidneys, it has been noticed a very low 
amplification of the different fragments, suggesting the possibility of an instable RNA due provably to 
Figure 43. RT-PCR amplification using 
primers from exon 2 to exon 6 in wild 
type and  Pkhd1del3-4/del3-kidneys. (A) Wt, 
Lines 1&2; Pkhd1del3-4/del3-4 Lines 3&4; 
cystic Pkhd1del3-4/del3-4, Line 5. (B) RT-PCR 
products after the deletion of the exons 3 
and 4.  
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a non sense mediated decay mechanism (Figure 43A, line 5). Figure 44B resumes schematically all 
these splicing events derived from the deletion of exons 3 and 4 in the Pkhd1del3-4 allele. 
In a parallel experiment, liver tissue from wild type, Pkhd1del5/del3-4, and two different Pkhd1del3-
4/del3-4 mice have been harvest to test splicing differences of the 
Pkhd1 alleles associated to polycystic liver disease. Long range 
RT-PCRs have been performed using a primers pair located in 
exons 1 and 25 (Figure 44). The expected 2.8 Kb product, as 
well as other smaller products due to the splice variants, were 
observed in the wt mice.  PKHD1del5/del3-4 and PKHD1del3-4/del3-4 
mice have an altered splice pattern predicted to disrupt the full 
length product of Polyductin-1. In addition, several new large 
products were observed in the Pkhd1del3-4/del3-4 resulting of the 
splice into the intronic sequence, and demonstrating that the 
splice pattern is completely altered.  
It has been interpreted positive RT-PCR products as 
evidence that our allele is not a complete null into the 
transcriptional level, but it can not be said that the “new” splice 
variants result in functional products. Comparing the relative 
level of expression between mutants and “controls” can not be 
definitive concluded the impact of a reduced expression, since we do not know how much 
mRNA/protein is required for normal function.  
5.3.4. Characterization the complex transcriptional profile in Pkhd1. 
We performed RT-PCR using primers spaced along the entire gene’s length. Long-range RT-
Figure 44. RT-PCR using Ex1F and 
Ex25R primer set and liver total RNA 
as source. Lane 1: wild type litter 
mate control. Lane 2: Pkhd1del5/del3-4; 
Lanes 3 & 4: Pkhd1del3-4/del3-4; M: 1 kb 
marker. The expected 2.8kb product is 
present in lane 1 (as well as a smaller 
1.7kb product). The predominant 
product in the mutant samples is 
slightly smaller, consistent with 
splicing around the deleted segment. 
Several larger novel products are also 
present in the Pkhd1del3-4/del3-4 
specimens. 
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PCR of kidney and liver specimens from normal and PKHD1 mutant mice supports previous 
impression that the gene is subject to a complex pattern of splicing.  
Figure 45 shows the pattern of RT-PCR products that are attained from normal kidney and liver 
in comparison with the kidney and liver PKHD1del3-4/del3-4 using a panel of forward primers in 
combination with different reverse primers. By using these forward/reverse primer pair combinations, 
we found as even more complex pattern varying between the liver and the kidney (eg. a product of 
~6.4kb amplified using an ex32 and ex62 primer pair that is present in liver and absent in kidney). The 
PKHD1 mutant splicing pattern of laddering differs between tissues of normal. This figure is a 
Figure 45. Characterization of 
the Pkhd1 transcriptional profile 
by RT-PCR  Kidney and liver 
transcriptional profile of 
Pkhd1+/+ vs. Pkhd1del3-4/del3-4. a-h 
are the primers used to amplify the 
different  PKHD1 products  
(Forward primers in red, and 
reverse primers in blue) 1 to 10 
(biggest product sizes are 
indicated for each primer pair). In 
the Pkhd1 full length are indicated 
the exons were the different 
primers bind. ORF: Open Reading 
Frame;  SC: Stop Codon. 
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representative picture of the complicated splice pattern followed by the Pkhd1 gene. This could 
explain why none of the previous mouse models did not mimicked the entire spectrum of ARPKD.  
5.4. Discussion. 
Several lines of mice have thus far been described with mutations of Pkhd1 involving exons 2, 
4, 42, and 49 (Moser et al., 2005, Ward et al., ASN2004, Somlo et al., 2004 and Guay-Woodford, 
personal communication).  Curiously, none of the homozygous mutants manifest any signs of kidney 
disease.  Remarkably, all develop liver disease of variable severity and a subset also develops 
pancreatic cysts.  This is a completely unanticipated result since the gene is most abundantly expressed 
in kidney and its mutation results in kidney disease in both humans and rats. It has been proposed by 
several groups that the lack of a renal phenotype in this mouse models suggests two possibilities: 1) 
Pkhd1 is not essential for kidney development in this species, having different or partially redundant 
functions replaced by one or more other molecules.  This possibility has precedence in the functional 
overlap between mouse Inpp5b and Ocrl1, which may explain why Ocrl1 deficiency does not cause 
Lowe syndrome in mice (Suchy et al., 2002).  2) The mutations thus far have not disrupted transcripts 
essential for the kidney.  In this Thesis, It has been proposed the latter explanation for the following 
reasons: a) the gene is predominantly expressed in mouse kidney, as it is in humans and rats; b) other 
rodents develop renal disease when PKHD1 is mutated; c) the mutant PKHD1 allele still encodes 
transcripts in each of the mutant mouse lines thus far described.  The complicated splicing pattern of 
the gene, coupled with the possibility of multiple transcriptional start sites, accounts for the lack of a 
mutant renal phenotype in the mouse models produced to date.  Human, rat and mouse have been 
predicted to require a PKHD1-encoded gene product for proper kidney formation/function but that 
each species may have different requirements as to what features the protein must have.  The species 
may also differ in their pattern of splicing and thus each may have a different ability to respond to 
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mutations altering specific exons. Therefore, it can be possible that none of the PKHD1 mutant alleles 
thus far described is a true null, and this likely explains the lack of a renal phenotype.  
The goal of this subproject of the Thesis is test the hypothesis that appropriated exon targeting 
and complete inactivation of PKHD1 in mice can mimic the human ARPKD, including renal disease 
and other manifestations.  A second hypothesis, related to the first, is that inactivation of Pkhd1 will 
result in abnormalities in organ systems besides those that have been described. Several lines of 
evidence support this hypothesis: 1) Germino’s group found widespread expression of PKHD1 in 
numerous tissues, with cell-type specific patterns of hybridization for some exons (Nagasawa et al., 
2002), 2) there are reports of an association of aneurysms and ARPKD1 (Neumann et al., 1999 and 
Lilova et al 2001) consistent with the gene’s high level of expression in vascular tissue (Nagasawa et 
al., 2002). 3) PKHD1 mutant mice can, depending on the exon targeted, develop pancreatic cysts. This 
observation suggests that the range of phenotypes that will result from mutation of PKHD1 will 
depend on the nature of mutation that is introduced.  The recent description of a human family with 
ARPKD and cystic pancreas disease suggests that findings in mice may equally apply to humans 
(Guay-Woodford, personal communication).  
Pkhd1flox3-4 is a functional allele . It has been generated the first Pkhd1 conditional knockout 
flanking the exons 3 and 4 by loxP sites and introducing a cassette of Neomycin with three stop 
codons. Exons 3 and 4 are two of the exon with higher homology between mouse and humans, the 
deletion of this exons disrupt the reading frame of the protein, exon 3 has an alternative start site, exon 
4 is been described as a hot spot for human mutation and the Neomycin cassette introduce alterations 
in the gene transcriptional pattern (for example, the Pkd2flox3-4 model described in this thesis). These 
were the major considerations taken in order to cause as much gene damage as possible, seeing the 
difficulty to generate a model that complete mimics the human ARPKD. As mentioned preciously for 
the conditional Pkd2 mouse, this model offers a powerful tool to examine the consequences of 
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temporally and tissue specific regulated inactivation of Pkhd1. This system can be used to establish an 
unambiguous relationship between PKHD1 inactivation and disease manifestations. It can be 
examined which factors are involved in the progression of the disease in each particular tissue.  
After Cre-mediated recombination, it has been proven that the Pkhd1flox3-4 is totally functional. 
Using a Meox2-Cre system, it has been generated a new allele (Pkhd1flox3-4) which mimic a germline 
mutation deleting exons 3 and 4. In the Meox2-cre line, Cre recombinase has been “knocked-in” to the 
Meox2 gene (mesenchyme homeobox-2 gene). Heterozygotes for Cre are phenotypically normal. The 
native promoter of Meox2 restricts Cre expression to epiblast-derived tissues and thus induces deletion 
in 90-95% of somatic cells including germ cells but spares placental trophoblasts. The Meox-2 Cre+ 
mice transmitted the deleted allele to nearly 50% of offspring, and these were crossed to produce 
homozygotes for Pkhd1flox3-4/del3-4. 
Another important tool for the study of PKHD1 biology that can be derived from model is the 
establishment of immortalized cell lines from the PKHD1flox3-4/flox3-4 after crossing to the 
Immortamouse116.  It can be generated genetically null cell lines and their uninduced floxed controls 
as tools for exploring PD1 function and functional characteristics of PKHD1 splicing.  
Pkhd1del3-4/del3-4 mouse model mimics the human ARPKD, including the renal phenotype . 
After performing series of PKHD1del3-4/+ crosses it has been determined that homozygous mutants 
mimic all the phenotypes related to ARPKD. It has been proved that appropriated exon targeting of 
PKHD1 in mice can reproduce ARPKD, including renal disease and other manifestations. The 
Pkhd1del3-4/del3-4 is the only model described up to the moment manifesting perinatal demise, polycystic 
kidney, liver and pancreas disease, growth retardation and vascular phenotype.  
Perinatal demise was a very common phenomenon in the offspring of inbred line 129SV. Mice 
dye with obvious symptoms of respiratory failure, but none of this mice ever have polycystic kidney 
disease. It has been describe that pressure given by the massive kidney from the abdominal cavity is 
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the direct responsible of the dead by respiratory insufficiency. This model would suggest that the 
respiratory insufficiency is a phenomenon independent of the size of the kidneys. It has been found 
several mice dead a couple hours after birth with partially inflated lungs and pulmonary hypertension 
in absence polycystic kidneys. This has very important implications in the understanding of the 
disease.  
Another phenomenon independently of kidney manifestation in this model is the growth 
retardation. Pkhd1del3-4/del3-4 and Pkhd1del5/del5 have a very high penetrance of growth retardation. 
Pkhd1del5/del5 is characterized by the absence of polycystic kidney disease. Also, it has been found 
growth retardation in absence of renal phenotype in the Pkhd1del3-4/del3-4 model. It can be concluded that 
growth retardation and respiratory insufficiency are two manifestations independent of the kidney 
phenotype. 
A very common phenotype found ether in Pkhd1del3-4/del3-4 or Pkhd1del5/del5, but not very 
common in human ARPKD is the severe polycystic pancreas disease (Neuhaus et al., 1996). It has 
been found impressive polycystic pancreas disease where the size of the pancreas was bigger than the 
total size of a mouse. This is the major responsible of spontaneous dead in these models. When the size 
of the polycystic pancreas became very prominent, mice start to have difficulties eating and drinking 
by limited movement. Striking, mice did not died by limited intake. Most of spontaneous dead has 
been associated with rupture of the polycystic pancreas. These mice are the unique ARPKD models 
with this phenotype, what makes them an invaluable tool in the study of this phenotype. 
The vascular phenotype found in the Pkhd1del3-4/del3-4 model was consider from the beginning 
based on the in situ hybridization results that Germino’s group obtained using probes for exons 5 and 
41 (Nagasawa et al., 2002). This result suggests that homozygous mutations of exon 5 would be 
expected to result in a vascular phenotype. It can be predicted that the ARPKD families with 
aneurysms or pancreatic disease likely are examples of situations where biallelic mutations affected 
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exons essential for the integrity of these other organs. 
As in humans, Pkhd1del3-4/del3-4 kidney phenotype manifestation is wild variable. It has been 
classified this phenotype in three major categories based on the severity presentation: milder, 
intermediate and severe renal phenotype. The mild phenotype is been found in mouse as early as three 
months of age, characterized by asymptomatic mild dilatation of the collecting ducts. The intermediate 
phenotype it has been found sporadically at three months, becoming more common in mouse of six 
months of age. This phenotype was characterized by the presence of sporadic cyst and dilated 
collecting ducts, considering a cyst when the lumen was 3 times bigger than normal and accompanied 
by change in the morphological change of the epithelia and glomerulosclerosis. It has been found 
severe kidney phenotype in a variable timing form 5 months up to a year, easy identifiable by the 
sickness of the mouse. Severe cyst formation with a lumen more than three times than normal, fibrotic 
areas associated to renal injury as well as glomerulosclerosis, has been found associated the alteration 
of renal morphology, compromising the mouse survival by renal dysfunction. As in humans, increased 
of the renal volume has been associated with progression of the cystic disease.  
Liver phenotype is the only phenotype common for all the mouse models described until now, 
been found in variable severity and time manifestation for those models. Pkhd1del3-4/del3-4 homozygous 
mice develop a more severe manifestation than previously describe for other mice knockouts. 
Enlargement and fibrosis of portal areas, aberrant proliferation of the bile ducts, hypoplasia of the 
portal vein leading to portal hypertension and splenomegalia, massive common bile dilatation 
sometimes associated with gallstones are very common findings in early time points. Ductal plate 
malformation starts in embryonic development, and fibrotic associated alterations have been found in 
the first day of live.  
Pkhd1del3-4/del3-4is not a complete null, but disrupts the normal gene expression pattern.   It 
has been concluded that the PKHD1flox3-4 is not true null on the RNA level but mimics the human 
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phenotype showing a severe presentation, by the disruption of the polyductin full length and important 
splice variants. The PKHD1del3-4allele is not a true null into the transcriptional level (ie. defined as 
encoding transcripts containing 3’ exons) but results in a severe phenotype with multiple organ 
dysfunction associated (principally with pancreas, liver and kidney abnormalities). This outcome 
indicates that the allele, despite producing transcripts with 3’exons, still functions as a complete null. 
These transcripts are functionally important because additional abnormalities have been found as the 
result from their complete loss. Mice with mutations of exons 42 or 49 only develop liver disease 
while those with mutations of exons 2 or 4 develop both liver and pancreatic disease. In addition to 
these phenotypes, it has been proven that deletion of exons 3, 4, and 5 can mimic the human disease, 
including kidney, pancreas disease, growth retardation and vascular phenotype.  
Pkhd1 undergoes to a complicated splice pattern.. It has been shown that the gene is widely 
expressed, though its transcripts are most abundant in kidney, that it undergoes a complicated pattern 
of splicing and that not all exons are expressed in all tissues. It can be concluded that the reason other 
models failed to mimic the ARPKD was that alternative splicing produces transcripts “skipped” over 
PKHD1 mutations and produced functional products that preserve renal, and possibly other organ, 
function.  Different cell types have distinct requirements for specific classes of transcripts. Differences 
in patterns of splicing may modify disease expression.  
The innovation of this model opens a spectrum of possible testing hypothesis in future 
directions. Using various Cre-recombinases, this system is going to be a powerful model to define the 
spectrum of abnormalities that result from the selective removal of exons 3 and 4 (and 5 into the RNA 
level). This information will ultimately be helpful in determining the types of transcripts that are 
essential for proper formation of each organ. It can be test the hypothesis that PKHD1 has essential 
functions in post-developmental tissues. Since PKHD1 is required for kidney development in mice, we 
predict that it is required for maintenance of tubular morphology and that its loss will either result in 
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cell death (with increased fibrosis) or renal cysts. This hypothesis can be tested producing a mice 
Pkhd1flox3-4/flox3-4 positive for either the taMeoxifen- or interferon-inducible Cre recombinase and 
determine the short and long-term effects of post-natal inactivation in target organs. The mice also 
could carry a reporter gene (Z/AP) that can be used to track Cre recombinase activity.  
Three major conclusions can be done. Mutation of PKHD1 in mice can result in renal disease if 
a suitable segment of the gene is selected for targeting. PKHD1 is essential for maintenance of normal 
renal and biliary tubular morphology. Complete inactivation of the gene can result in a severe 
phenotype, involving additional organ systems (lung, vasculature and pancreas), fetal/perinatal demise 
and growth retardation.   
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6. Conclusiones. 
1. En el primer capítulo de esta tesis ha sido desarrollada una estrategia de búsqueda de 
mutaciones mediante secuenciación directa de los exones y sus regiones colindantes de los 
genes PKD1 y PKD2, causantes de la enfermedad poliquística renal autosómica dominante 
(ADPKD).El establecimiento de una estrategia racional  en el análisis de la totalidad de la 
región codificadora de ambos genes basada en secuenciación directa ha reducido el esfuerzo y 
los costes en el estudio de familias con ADPKD. 
 
2. Para garantizar la eficacia de dicha estrategia, un grupo de 82 pacientes pertenecientes a 
familias con ADPKD fueron sometidos a estudio. De las 82 familias, 55 poseían mutaciones 
causantes de la enfermedad en el gen PKD1 y 13 en el gen PKD2. Esto indica un nivel de 
detección del 83%, el más alto descrito hasta el momento. 
 
3. Se ha trabajado de una manera muy cercana con Athena Diagnostics para ayudar en el traslado 
de los métodos de investigación en una herramienta clínica útil. La estrategia ha demostrado 
ser la más eficiente descrita hasta el momento y ahora forma la base del único test de DNA de 
ADPKD utilizado en práctica clínica (PKDX). 
 
4. El análisis completo de ambos genes es esencialmente importante puesto que no han sido 
identificados lugares calientes o “hot spots” en PKD1 o PKD2. Se ha observado un nivel 
extraordinariamente elevado de variabilidad en el gen PKD1, con una media de 13.2 variantes 
genéticas y un rango entre 0 a 60 variantes por paciente. 
 
5. Hasta 17 SNPs han sido localizados en PKD1 y 2 en PKD2, hablando de la alta flexibilidad de 
PKD1 y proporcionando una “huella dactilar” para cada uno de los genes ADPKD. 
 
6. La secuenciación directa es un método de detección sensitivo de variables del DNA en PKD1 y 
PKD2, pero es necesaria una interpretación estricta de los resultados esencialmente si han de 
ser utilizados en la toma de decisiones clínicas. Para ello se ha establecido un criterio estricto 
de calificación de las variantes basado en tres principios: conservación del cambio, su 
patogenicidad y la probabilidad de generar un splice site.  
 
7. Se demuestra que los sistemas in vitro no solo pueden ser una herramienta muy útil para 
distinguir entre polimorfismos y mutaciones, sino que también pueden ser utilizados para 
demostrar los efectos de las distintas variantes encontradas en PKD1. 
 
8. Se ha establecido un método de estudio del comportamiento génico, basado en la información 
de los cambios encontrados mediante las completa secuenciación de los genes. Así pues, se ha 
analizado sistemáticamente todas las variantes a lo largo de ambos genes, concluyéndose que el 
gen PKD1 es casi 6 veces más mutable que PKD2. Esto se debe principalmente a la presencia 
de un tracto de polipirimidina en el exón 21 del gen PKD1, a  la conversión génica con sus 
homólogos y al alto GC. Éste método puede ser aplicado a otros genes para un mejor 
conocimiento de su comportamiento. 
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9. Los estudios in sílico e in vitro han sentado las bases del primer modelo condicional trialélico 
de ratón del gen Pkd2, un alelo condicionado hipomórfico (Pkd2cond), un alelo condicionado de 
función normal Pkd2delneo que puede ser inactivado in vivo, y un alelo de función nula o 
knockout  (Pkd2del11-13) cuya predicción presenta una disrupción del C-terminal de Pkd2. 
 
10. Se ha demostrado que se puede inactivar in vivo el alelo Pkd2delneo, a través de una deleción en 
un 95% de los segmentos de DNA floxeados, mediada por la recombinasa-Cre de una forma 
somática y regulada por el promotor Meox-2. Estos ratones mueren inmediatamente después 
del nacimiento con todas las manifestaciones de un fenotipo defectivo de Pkd2, incluyendo 
edema severo, quistes renales, quistes pancreáticos y alteración al azar eje axial 
derecha/izquierda. 
 
11. Se exhiben las bases de un modelo in vitro de formación quística basado en el cultivo de cortes 
tangenciales embrionarios, que no solo proporciona el seguimiento en tiempo real de la 
formación quística, sino que también proporciona una plataforma de manipulación 
farmacológica y génica de la poliquistosis pancreática y renal. 
 
12. En esta tesis se presenta el primer modelo de ratón de la PKD recesiva (ARPKD) que muestra 
todas las manifestaciones fenotípicas de la enfermedad. Se desarrolló un alelo funcional 
floxeado de Pkhd1 (Pkhd1flox3-4) que produce la deleción mediada por la recombinasa-Cre de 
los exones 3 y 4. 
 
13. Los ratones Pkhd1D3-4/D3-4 manifiestan los mismos fenotipos de la enfermedad en humanos con 
muerte en fase perinatal, los sobrevivientes desarrollan una variedad de malformaciones 
hepatobiliares con fibrosis hepática congénita, quistes codelocales y colangitis ascendente. 
También presenta una severa poliquistosis pancreática, manifestación variable de la 
poliquistosis renal y retraso en el crecimiento 
 
14. Estas nuevas líneas de ratón permiten la inactivación espacio-temporal de Pkhd1 y Pkd2 de una 
manera controlada, presentan un espectro completo de fenotipos ARPKD y ADPKD, y serán 
una herramienta poderosa en el estudio de la biología y la patogénesis de PKHD1 y PKD2. A 
su vez, de estos modelos se derivará un novedoso sistema celular de inactivación in vitro de los 
genes Pkd2 y Pkhd1.  
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